

CITATION REPORT

List of articles citing

National Institute on Aging-Alzheimer's Association
guidelines for the neuropathologic assessment of
Alzheimer's disease

DOI: 10.1016/j.jalz.2011.10.007
Alzheimer's and Dementia, 2012, 8, 1-13.

Source: <https://exaly.com/paper-pdf/53249470/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
1688	Where, when, and in what form does sporadic Alzheimer's disease begin?. 2012 , 25, 708-14		150
1687	Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. 2012 , 4, 343-357		10
1686	Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. 2012 , 71, 266-73		563
1685	The diagnosis and evaluation of dementia and mild cognitive impairment with emphasis on SPECT perfusion neuroimaging. 2012 , 17, 176-206		24
1684	Presence of Striatal Amyloid Plaques in Parkinson's Disease Dementia Predicts Concomitant Alzheimer's Disease: Usefulness for Amyloid Imaging. 2012 , 2, 57-65		31
1683	Neurobiology of cognitive impairment in Parkinson's disease. 2012 , 12, 1451-66		44
1682	TDP-43: a new player on the AD field?. 2012 , 237, 90-5		19
1681	Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- β plaques: a prospective cohort study. 2012 , 11, 669-78		532
1680	Relation of neuropathology to cognition in persons without cognitive impairment. 2012 , 72, 599-609		153
1679	Proteomic analysis of mice expressing human ApoE demonstrates no differences in global protein solubility between APOE 3 and APOE 4 young mice. 2012 , 33, 3745-55		2
1678	Transcriptional and post-transcriptional regulation of β secretase. 2012 , 64, 943-50		25
1677	The MAPT H1 haplotype is associated with tangle-predominant dementia. 2012 , 124, 693-704		54
1676	The role of astrocytes in amyloid β protein toxicity and clearance. 2012 , 236, 1-5		97
1675	The need to unify neuropathological assessments of vascular alterations in the ageing brain: multicentre survey by the BrainNet Europe consortium. 2012 , 47, 825-33		50
1674	The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. 2012 , 33, 2231.e7-2231.e14		57
1673	Alzheimer's disease markers from structural MRI and FDG-PET brain images. 2012 , 127, 1		13
1672	Vascular dementia: different forms of vessel disorders contribute to the development of dementia in the elderly brain. 2012 , 47, 816-24		134

1671	Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort. 2012 , 4, 34	78
1670	Frontotemporal lobar degeneration with TDP-43 proteinopathy and chromosome 9p repeat expansion in C9ORF72: clinicopathologic correlation. 2013 , 33, 122-33	38
1669	Influence of comorbidities in idiopathic normal pressure hydrocephalus - research and clinical care. A report of the ISHCSF task force on comorbidities in INPH. 2013 , 10, 22	132
1668	Amyloid- β may be released from non-junctional varicosities of axons generated from abnormal tau-containing brainstem nuclei in sporadic Alzheimer's disease: a hypothesis. 2013 , 126, 303-6	31
1667	Amyloid or tau: the chicken or the egg?. 2013 , 126, 609-13	30
1666	3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. 2013 , 28, 1653-60	91
1665	The pathogenesis of cingulate atrophy in behavioral variant frontotemporal dementia and Alzheimer's disease. 2013 , 1, 30	12
1664	Emerging biomarkers in cognition. 2013 , 29, 809-28	11
1663	Pathology of clinical and preclinical Alzheimer's disease. 2013 , 263 Suppl 2, S137-45	39
1662	Amyloid imaging in atypical presentations of Alzheimer's disease. 2013 , 13, 412	29
1661	2013 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2013 , 9, 208-45	1.2 947
1660	Personalized medicine in Alzheimer's disease and depression. 2013 , 36, 616-23	14
1659	Cerebral amyloid PET imaging in Alzheimer's disease. 2013 , 126, 643-57	79
1658	Structural Magnetic Resonance Imaging as a Biomarker for the Diagnosis, Progression, and Treatment of Alzheimer Disease. 2013 , 87-129	1
1657	Amyloid PET Imaging: MCI and AD. 2013 , 8, 431-45	2
1656	Biomarker modeling of Alzheimer's disease. 2013 , 80, 1347-58	586
1655	Clinical and multimodal biomarker correlates of ADNI neuropathological findings. 2013 , 1, 65	110
1654	Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database. 2013 , 13, 137	44

1653	Clinical applications of neuroimaging in patients with Alzheimer's disease: a review from the Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012. 2013 , 5, S3		20
1652	Extracellular matrix modulator lysyl oxidase colocalizes with amyloid-beta pathology in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis--Dutch type. 2013 , 48, 109-14		12
1651	Revisiting the framework of the National Institute on Aging-Alzheimer's Association diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2013 , 9, 594-601	1.2	35
1650	TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT. 2013 , 34, 2889.e5-9		33
1649	Leveraging global resources to end the Alzheimer's pandemic. <i>Alzheimer's and Dementia</i> , 2013 , 9, 363-5	1.2	6
1648	Amyloid PET in clinical practice: Its place in the multidimensional space of Alzheimer's disease. 2013 , 2, 497-511		74
1647	A preliminary study of the whole-genome expression profile of sporadic and monogenic early-onset Alzheimer's disease. 2013 , 34, 1772-8		59
1646	Epigenetic changes in the progression of Alzheimer's disease. 2013 , 134, 486-95		129
1645	Imaging tau deposits in vivo: progress in viewing more of the proteopathy picture. 2013 , 79, 1035-7		11
1644	Neuroinflammatory phenotype in early Alzheimer's disease. 2013 , 34, 1051-9		135
1643	Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. 2013 , 12, 443-53		472
1642	Changes in properties of serine 129 phosphorylated β synuclein with progression of Lewy-type histopathology in human brains. 2013 , 240, 190-204		95
1641	Curcumin-conjugated nanoliposomes with high affinity for A β deposits: possible applications to Alzheimer disease. 2013 , 9, 712-21		112
1640	Progressive supranuclear palsy phenotype mimicking synucleinopathies. 2013 , 329, 34-7		4
1639	Molecular Pathology of the Central Nervous System. 2013 , 357-405		3
1638	Alzheimer's therapeutics: continued clinical failures question the validity of the amyloid hypothesis-but what lies beyond?. 2013 , 85, 289-305		159
1637	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- β changes occur before increases of tau in cerebrospinal fluid. 2013 , 126, 631-41		103
1636	Natural compounds may open new routes to treatment of amyloid diseases. 2013 , 10, 429-39		55

1635	Dementia in the oldest old. 2013 , 9, 382-93	50
1634	Vulnerable neural systems and the borderland of brain aging and neurodegeneration. 2013 , 77, 219-34	222
1633	MicroRNA in Alzheimer's disease: an exploratory study in brain, cerebrospinal fluid and plasma. 2013 , 18, 455-66	86
1632	Amyloid- β positron emission tomography imaging probes: a critical review. 2013 , 36, 613-31	56
1631	Progressive amnesic dementia, hippocampal sclerosis, and mutation in C9ORF72. 2013 , 126, 545-54	22
1630	Ask the Expert: How should vascular dementia be managed?. 2013 , 3, 109-113	1
1629	The Arctic A β P mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated A β . 2013 , 1, 60	27
1628	In vivo characterization of the early states of the amyloid-beta network. 2013 , 136, 2239-52	84
1627	Neuroimaging and the search for a cure for Alzheimer disease. 2013 , 269, 671-91	37
1626	Comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. 2013 , 80, 2121-9	37
1625	Making the diagnosis of frontotemporal lobar degeneration. 2013 , 137, 314-25	22
1624	Proteolytic cleavage of apolipoprotein E4 as the keystone for the heightened risk associated with Alzheimer's disease. 2013 , 14, 14908-22	42
1623	The interest of amyloid PET imaging in the diagnosis of Alzheimer's disease. 2013 , 26, 646-55	16
1622	Examination of the clinicopathologic continuum of Alzheimer disease in the autopsy cohort of the National Alzheimer Coordinating Center. 2013 , 72, 1182-92	72
1621	Impact of brain aging and neurodegeneration on cognition: evidence from MRI. 2013 , 26, 640-5	21
1620	Circulating microRNAs in Alzheimer's disease: the search for novel biomarkers. 2013 , 6, 24	60
1619	Pathology and pathogenesis of vascular cognitive impairment-a critical update. 2013 , 5, 17	208
1618	Renovating Alzheimer's: "constructive" reflections on the new clinical and research diagnostic guidelines. 2013 , 53, 378-87	14

1617	Novel natural structure corrector of ApoE4 for checking Alzheimer's disease: benefits from high throughput screening and molecular dynamics simulations. 2013 , 2013, 620793	13
1616	Alzheimer's disease diagnosis by detecting exogenous fluorescent signal of ligand bound to Beta amyloid in the lens of human eye: an exploratory study. 2013 , 4, 62	29
1615	Intracranial injection of Gammagard, a human IVIg, modulates the inflammatory response of the brain and lowers A β in APP/PS1 mice along a different time course than anti-A β antibodies. 2013 , 33, 9684-92	53
1614	Dementia and mild cognitive impairment in adults with intellectual disability: issues of diagnosis. 2013 , 18, 31-42	62
1613	C9ORF72 expansion in a family with bipolar disorder. 2013 , 15, 326-32	50
1612	Laminar distribution of the pathological changes in sporadic frontotemporal lobar degeneration with transactive response (TAR) DNA-binding protein of 43 kDa (TDP-43) proteinopathy: a quantitative study using polynomial curve fitting. 2013 , 39, 335-47	8
1611	Sensitivity and specificity of diagnostic accuracy in Alzheimer's disease: a synthesis of existing evidence. 2013 , 28, 337-47	20
1610	Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues. 2013 , 3, 219-229	39
1609	Neuropathologic correlates of cognition in a population-based sample. 2013 , 36, 699-709	37
1608	The S-Connect study: results from a randomized, controlled trial of Souvenaid in mild-to-moderate Alzheimer's disease. 2013 , 5, 59	63
1607	Postmortem 3-D brain hemisphere cortical tau and amyloid- β pathology mapping and quantification as a validation method of neuropathology imaging. 2013 , 36, 261-74	26
1606	A Luminex assay detects amyloid β oligomers in Alzheimer's disease cerebrospinal fluid. 2013 , 8, e67898	43
1605	Absence of chronic traumatic encephalopathy in retired football players with multiple concussions and neurological symptomatology. 2013 , 7, 222	103
1604	Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. 2013 , 2013, 589308	7
1603	Immunolocalization of Kisspeptin Associated with Amyloid- β Deposits in the Pons of an Alzheimer's Disease Patient. 2013 , 2013, 879710	3
1602	Oxidative Stress and Its Clinical Applications in Dementia. 2013 , 2013, 319898	25
1601	Soluble beta-amyloid peptides, but not insoluble fibrils, have specific effect on neuronal microRNA expression. 2014 , 9, e90770	40
1600	Clinicotherapeutic Potential of Leptin in Alzheimer's Disease and Parkinson's Disease. 2014 , 2014, 1-9	2

1599	Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions. 2014 , 42, 813-21	20
1598	An evaluation of MSDC-0160, a prototype mTOT modulating insulin sensitizer, in patients with mild Alzheimer's disease. 2014 , 11, 564-73	34
1597	Nicotinic Acetylcholine Receptors in Alzheimer's and Parkinson's Disease. 2014 , 383-415	
1596	Quantitative neuropathological assessment to investigate cerebral multi-morbidity. 2014 , 6, 85	22
1595	Neuropsychological changes in asymptomatic persons with Alzheimer disease neuropathology. 2014 , 83, 434-40	51
1594	Proof-of-Concept Randomized Controlled Study of Cognition Effects of the Proprietary Extract Scelletium tortuosum (Zembrin) Targeting Phosphodiesterase-4 in Cognitively Healthy Subjects: Implications for Alzheimer's Dementia. 2014 , 2014, 682014	20
1593	Invited commentary: how exposure to air pollution may shape dementia risk, and what epidemiology can say about it. 2014 , 180, 367-71	19
1592	Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. 2014 , 4, e005122	24
1591	Phosphatidylinositol-4,5-bisphosphate is enriched in granulovacuolar degeneration bodies and neurofibrillary tangles. 2014 , 40, 489-501	19
1590	Neuropathologic assessment of dementia markers in identical and fraternal twins. 2014 , 24, 317-33	9
1589	PTU-induced hypothyroidism in rats leads to several early neuropathological signs of Alzheimer's disease in the hippocampus and spatial memory impairments. 2014 , 24, 1381-93	25
1588	Synaptic change in the posterior cingulate gyrus in the progression of Alzheimer's disease. 2015 , 43, 1073-90	85
1587	Capillary electrophoresis for the analysis of the effect of sample preparation on early stages of A β -40 aggregation. 2014 , 35, 1814-20	8
1586	Altered CpG methylation in sporadic Alzheimer's disease is associated with APP and MAPT dysregulation. 2014 , 23, 648-56	96
1585	Pathogenesis and treatment of vascular cognitive impairment. 2014 , 4, 471-90	23
1584	Journal Club: comparison of symptomatic and asymptomatic persons with Alzheimer disease neuropathology. 2014 , 82, e76-8	4
1583	PART and SNAP. 2014 , 128, 773-6	68
1582	Prevalence of mixed pathologies in the aging brain. 2014 , 6, 82	158

1581	Theoretical impact of Florbetapir (18F) amyloid imaging on diagnosis of Alzheimer dementia and detection of preclinical cortical amyloid. 2014 , 73, 948-53		25
1580	Alzheimer disease cerebrospinal fluid biomarkers predict cognitive decline in healthy elderly over 2 years. 2014 , 28, 234-8		5
1579	Occludin deficiency with BACE1 elevation in cerebral amyloid angiopathy. 2014 , 82, 1707-15		18
1578	Alzheimer's Disease. 2014 , 122-127		5
1577	Alzheimer's disease-related plaques in nondemented subjects. <i>Alzheimer's and Dementia</i> , 2014 , 10, 522-9.2		6
1576	Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. 2014 , 137, 1176-92		225
1575	Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease. 2014 , 88, 617-30		32
1574	Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer's disease pathogenesis. 2014 , 2, 9		103
1573	Mild to moderate Alzheimer dementia with insufficient neuropathological changes. 2014 , 75, 597-601		63
1572	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. 2014 , 88, 508-16		153
1571	Multifunctional nanoliposomes with curcumin-lipid derivative and brain targeting functionality with potential applications for Alzheimer disease. 2014 , 80, 175-83		156
1570	2014 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2014 , 10, e47-92	1.2	674
1569	A 2-process model for neuropathology of Alzheimer's disease. 2014 , 35, 301-8		44
1568	Integrating the molecular and the population approaches to dementia research to help guide the future development of appropriate therapeutics. 2014 , 88, 652-60		4
1567	Synaptic gene dysregulation within hippocampal CA1 pyramidal neurons in mild cognitive impairment. 2014 , 79, 172-9		80
1566	Advances in the prevention of Alzheimer's disease and dementia. 2014 , 275, 229-50		182
1565	The evolution of preclinical Alzheimer's disease: implications for prevention trials. 2014 , 84, 608-22		429
1564	Multiple mechanisms of iron-induced amyloid beta-peptide accumulation in SHSY5Y cells: protective action of negletein. 2014 , 16, 787-98		28

1563	Primary age-related tauopathy (PART): a common pathology associated with human aging. 2014 , 128, 755-66	776
1562	Self-reported memory complaints: implications from a longitudinal cohort with autopsies. 2014 , 83, 1359-65	129
1561	Recommendations of the Alzheimer's disease-related dementias conference. 2014 , 83, 851-60	80
1560	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimer's and Dementia</i> , 2014 , 10, 808-17	1.2 132
1559	New criteria for frontotemporal dementia syndromes: clinical and pathological diagnostic implications. 2014 , 85, 865-70	155
1558	Patterns of microglial cell activation in frontotemporal lobar degeneration. 2014 , 40, 686-96	50
1557	Hippocampal Lewy pathology and cholinergic dysfunction are associated with dementia in Parkinson's disease. 2014 , 137, 2493-508	173
1556	Flow cytometry analysis of synaptosomes from post-mortem human brain reveals changes specific to Lewy body and Alzheimer's disease. 2014 , 94, 1161-72	24
1555	Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. 2014 , 44 Suppl 4, 1-80	342
1554	Synthesis and evaluation of (13)N-labelled azo compounds for amyloid imaging in mice. 2014 , 16, 538-49	14
1553	Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementias. 2014 , 6, 1	110
1552	Moving beyond anti-amyloid therapy for the prevention and treatment of Alzheimer's disease. 2014 , 14, 169	50
1551	Soluble amyloid beta levels are elevated in the white matter of Alzheimer's patients, independent of cortical plaque severity. 2014 , 2, 83	29
1550	Rapid-onset dystonia-parkinsonism associated with the I758S mutation of the ATP1A3 gene: a neuropathologic and neuroanatomical study of four siblings. 2014 , 128, 81-98	29
1549	Diagnostic effectiveness of quantitative [¹⁸ F]flutemetamol PET imaging for detection of fibrillar amyloid using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. 2014 , 2, 46	16
1548	Biochemical stages of amyloid- β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease. 2014 , 137, 887-903	109
1547	Nucleic acid oxidation: an early feature of Alzheimer's disease. 2014 , 128, 294-304	64
1546	Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. 2014 , 35, 819-26	58

1545	Proteopathic tau seeding predicts tauopathy in vivo. 2014 , 111, E4376-85		307
1544	Is synaptic loss a unique hallmark of Alzheimer's disease?. 2014 , 88, 517-28		74
1543	A platform for discovery: The University of Pennsylvania Integrated Neurodegenerative Disease Biobank. <i>Alzheimer's and Dementia</i> , 2014 , 10, 477-484.e1	1.2	118
1542	Immunolocalization of Smurf1 in Hirano bodies. 2014 , 336, 24-8		6
1541	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020. 2014 , 88, 426-49		84
1540	A comparison of A β amyloid pathology staging systems and correlation with clinical diagnosis. 2014 , 128, 543-50		18
1539	Flexible modulation of network connectivity related to cognition in Alzheimer's disease. 2014 , 100, 544-57		17
1538	The critical need for defining preclinical biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014 , 10, S196-212	1.2	89
1537	Patterns of cerebral amyloid angiopathy define histopathological phenotypes in Alzheimer's disease. 2014 , 40, 136-48		34
1536	Using mice to model Alzheimer's dementia: an overview of the clinical disease and the preclinical behavioral changes in 10 mouse models. 2014 , 5, 88		413
1535	Synaptophysin and synaptojanin-1 in Down syndrome are differentially affected by Alzheimer's disease. 2014 , 42, 767-75		32
1534	Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition. 2015 , 21, 841-50		37
1533	Neuropsychological Markers of Cognitive Decline in Persons With Alzheimer Disease Neuropathology. 2015 , 74, 1086-92		19
1532	Chronic effects of mild neurotrauma: putting the cart before the horse?. 2015 , 74, 493-9		25
1531	Neuropathologic features of suicide victims who presented with acute poststroke depression: significance of association with neurodegenerative disorders. 2015 , 74, 401-10		9
1530	Rare Variants in PLD3 Do Not Affect Risk for Early-Onset Alzheimer Disease in a European Consortium Cohort. 2015 , 36, 1226-35		20
1529	Differential hippocampal shapes in posterior cortical atrophy patients: A comparison with control and typical AD subjects. 2015 , 36, 5123-36		16
1528	Effects of ketone bodies in Alzheimer's disease in relation to neural hypometabolism, A β amyloid toxicity, and astrocyte function. 2015 , 134, 7-20		67

1527	Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study. 2016 , 49, 633-43	18
1526	Monomeric C-reactive protein--a key molecule driving development of Alzheimer's disease associated with brain ischaemia?. 2015 , 5, 13281	58
1525	Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease. 2016 , 49, 93-100	25
1524	Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. 2015 , 1,	21
1523	Molecular Signaling Mechanisms of Natural and Synthetic Retinoids for Inhibition of Pathogenesis in Alzheimer's Disease. 2016 , 50, 335-52	30
1522	Multiplexed In-cell Immunoassay for Same-sample Protein Expression Profiling. 2015 , 5, 13651	1
1521	Re-examining tau-immunoreactive pathology in the population: granulovacuolar degeneration and neurofibrillary tangles. 2015 , 7, 57	9
1520	Feasibility Study: Comparison of Frontal Cortex Needle Core Versus Open Biopsy for Detection of Characteristic Proteinopathies of Neurodegenerative Diseases. 2015 , 74, 934-42	7
1519	Antemortem Prediction of Braak Stage. 2015 , 74, 1061-70	10
1518	Assessing clinicopathological correlation in chronic traumatic encephalopathy: rationale and methods for the UNITE study. 2015 , 7, 62	71
1517	To Stage Alzheimer's Disease Related Neurodegeneration Using one Section of Hippocampus. 2015 , 48, 597-601	
1516	Restricted disease propagation in multiple system atrophy with prolonged survival. 2015 , 41, 681-5	3
1515	Does Alzheimer Disease Pathologic Change Underlie Subjective Cognitive Complaints?. 2015 , 29, 350-2	4
1514	Corticobasal Syndrome in a Family with Early-Onset Alzheimer's Disease Linked to a Presenilin-1 Gene Mutation. 2015 , 2, 388-394	7
1513	Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. 2015 , 78, 787-800	448
1512	Post-Mortem evaluation of amyloid-dopamine terminal positron emission tomography dementia classifications. 2015 , 78, 824-30	8
1511	Tissue transglutaminase-catalysed cross-linking induces Apolipoprotein E multimers inhibiting Apolipoprotein E's protective effects towards amyloid-beta-induced toxicity. 2015 , 134, 1116-28	11
1510	Multimodality Imaging Approaches in Alzheimer's disease. Part II: 1H MR spectroscopy, FDG PET and Amyloid PET. 2015 , 9, 330-342	3

1509	Metabolic Risk Factors of Sporadic Alzheimer's Disease: Implications in the Pathology, Pathogenesis and Treatment. 2015 , 6, 282-99	75
1508	Unfolded Protein Response and Macroautophagy in Alzheimer's, Parkinson's and Prion Diseases. 2015 , 20, 22718-56	25
1507	Evidence for a neuroprotective microRNA pathway in amnesic mild cognitive impairment. 2015 , 9, 430	46
1506	Neurobiology of Alzheimer's Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. 2015 , 12, 712-22	104
1505	Abnormal Paraplegin Expression in Swollen Neurites, and Synuclein Pathology in a Case of Hereditary Spastic Paraplegia SPG7 with an Ala510Val Mutation. 2015 , 16, 25050-66	11
1504	Turning on the Light Within: Subcortical Nuclei of the Isodentritic Core and their Role in Alzheimer's Disease Pathogenesis. 2015 , 46, 17-34	49
1503	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. 2015 , 10, e0126423	147
1502	Presenilin-1 Dependent Neurogenesis Regulates Hippocampal Learning and Memory. 2015 , 10, e0131266	26
1501	Longitudinal Assessment of Tau Pathology in Patients with Alzheimer's Disease Using [18F]THK-5117 Positron Emission Tomography. 2015 , 10, e0140311	63
1500	Role of Liver X Receptor in AD Pathophysiology. 2015 , 10, e0145467	33
1499	Antiamnesic Effects of a Hydroethanolic Extract of <i>Crinum macowanii</i> on Scopolamine-Induced Memory Impairment in Mice. 2015 , 2015, 242505	10
1498	Prion-Protein-interacting Amyloid- β Oligomers of High Molecular Weight Are Tightly Correlated with Memory Impairment in Multiple Alzheimer Mouse Models. 2015 , 290, 17415-38	79
1497	Neuronal amyloid- β accumulation within cholinergic basal forebrain in ageing and Alzheimer's disease. 2015 , 138, 1722-37	120
1496	Comorbidities in Neurology: Is adenosine the common link?. 2015 , 97, 18-34	62
1495	Loss of endophilin-B1 exacerbates Alzheimer's disease pathology. 2015 , 138, 2005-19	21
1494	Measurement of inter- and intra-observer variability in the routine clinical interpretation of brain 18-FDG PET-CT. 2015 , 29, 233-9	5
1493	CREB expression mediates amyloid β induced basal BDNF downregulation. 2015 , 36, 2406-13	72
1492	Arizona Study of Aging and Neurodegenerative Disorders and Brain and Body Donation Program. 2015 , 35, 354-89	211

1491	Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. 2015 , 138, 2020-33		227
1490	[(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid- β pathology. <i>Alzheimer's and Dementia</i> , 2015 , 11, 975-85	1.2	93
1489	An Assessment of Possible Neuropathology and Clinical Relationships in 46 Sporadic Amyotrophic Lateral Sclerosis Patient Autopsies. 2015 , 15, 301-12		37
1488	Alzheimer's Disease: Current Perspectives [Animal Models, Drugs Under Development, and Potential Nutritional Intervention]. 2015 , 13-28		1
1487	Nicotinic ACh receptors as therapeutic targets in CNS disorders. 2015 , 36, 96-108		299
1486	Alzheimers Association Update. 2015 , 11, 104-105		4
1485	APOE ϵ 2 is associated with milder clinical and pathological Alzheimer disease. 2015 , 77, 917-29		82
1484	Do NIA-AA criteria distinguish Alzheimer's disease from frontotemporal dementia?. <i>Alzheimer's and Dementia</i> , 2015 , 11, 207-15	1.2	18
1483	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. 2015 , 122, 957-72		19
1482	Unusual β synuclein and cerebellar pathologies in a case of hereditary myoclonus-dystonia without SGCE mutation. 2015 , 41, 837-42		1
1481	Frontotemporal lobar degeneration FTLD-tau: preclinical lesions, vascular, and Alzheimer-related co-pathologies. 2015 , 122, 1007-18		41
1480	PART is part of Alzheimer disease. 2015 , 129, 749-56		198
1479	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. 2015 , 129, 729-48		120
1478	Autopsy-confirmed hippocampal-sparing Alzheimer's disease with delusional jealousy as initial manifestation. 2015 , 15, 198-203		1
1477	Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. 2015 , 138, 1370-81		224
1476	Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease. 2015 , 36, 2468-74		52
1475	Cerebral amyloid angiopathy and its co-occurrence with Alzheimer's disease and other cerebrovascular neuropathologic changes. 2015 , 36, 2702-8		73
1474	TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes. 2015 , 138, 3110-22		66

1473	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. 2015 , 138, 2701-15	86
1472	Mutations in ABCA7 in a Belgian cohort of Alzheimer's disease patients: a targeted resequencing study. 2015 , 14, 814-822	95
1471	Age-dependent impairment of glucose tolerance in the 3xTg-AD mouse model of Alzheimer's disease. 2015 , 29, 4273-84	62
1470	The emerging role of microRNAs in Alzheimer's disease. 2015 , 6, 40	148
1469	A critical review of chronic traumatic encephalopathy. 2015 , 56, 276-93	82
1468	Cytokine-producing microglia have an altered beta-amyloid load in aged APP/PS1 Tg mice. 2015 , 48, 86-101	63
1467	Alzheimer's Disease and the Search for Environmental Risk Factors. 2015 , 315-327	
1466	Pretreatment with 5-hydroxymethyl-2-furaldehyde blocks scopolamine-induced learning deficit in contextual and spatial memory in male mice. 2015 , 134, 57-64	8
1465	Pathological features of preclinical or early clinical stages of corticobasal degeneration: a comparison with advanced cases. 2015 , 41, 893-905	16
1464	Intraneuronal APP and extracellular A β independently cause dendritic spine pathology in transgenic mouse models of Alzheimer's disease. 2015 , 129, 909-20	38
1463	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. 2015 , 3, 65-74	6
1462	The biomarker and therapeutic potential of miRNA in Alzheimer's disease. 2015 , 5, 61-74	41
1461	Early neurone loss in Alzheimer's disease: cortical or subcortical?. 2015 , 3, 10	101
1460	Beta-amyloid deposition in chronic traumatic encephalopathy. 2015 , 130, 21-34	185
1459	Nonlinear Association Between Cerebrospinal Fluid and Florbetapir F-18 β Amyloid Measures Across the Spectrum of Alzheimer Disease. 2015 , 72, 571-81	73
1458	2015 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2015 , 11, 332-84	1.2 1212
1457	Precision medicine: Clarity for the clinical and biological complexity of Alzheimer's and Parkinson's diseases. 2015 , 212, 601-5	28
1456	Partial depletion of striatal dopamine enhances penetrance of cognitive deficits in a transgenic mouse model of Alzheimer's disease. 2015 , 93, 1413-22	11

1455	Case records of the Massachusetts General Hospital. Case 9-2015. A 31-year-old man with personality changes and progressive neurologic decline. 2015 , 372, 1151-62	7
1454	Cerebral cortical A β 2 and PHF- τ 325 consecutive brain autopsies stratified by diagnosis, location, and APOE. 2015 , 74, 100-9	19
1453	Combined Alzheimer's disease and cerebrovascular staging explains advanced dementia cognition. <i>Alzheimer's and Dementia</i> , 2015 , 11, 1358-66	1.2 10
1452	Can we influence the epidemiology of dementia? Perspectives from population-based studies. 2015 , 91, 651-4	10
1451	[Late onset dementia: Specific clinical and pathophysiological features]. 2015 , 50, 261-3	1
1450	A novel method for early diagnosis of Alzheimer's disease based on pseudo Zernike moment from structural MRI. 2015 , 305, 361-71	39
1449	Frontotemporal dementia with parkinsonism linked to chromosome 17 with the MAPT R406W mutation presenting with a broad distribution of abundant senile plaques. 2015 , 35, 75-82	8
1448	Assessment of the degree of asymmetry of pathological features in neurodegenerative diseases. What is the significance for brain banks?. 2015 , 122, 1499-508	8
1447	Molecular markers of neuropsychological functioning and Alzheimer's disease. 2015 , 1, 61-6	5
1446	14th Annual Meeting of the Society for Experimental Biology and Medicine: Threading through peripheral and central nervous system presentations. 2015 , 75, 143-57	2
1445	Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. 2015 , 309, 29-50	174
1444	How many biomarkers to discriminate neurodegenerative dementia?. 2015 , 52, 314-26	14
1443	Characterizing Apolipoprotein E ϵ Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β Amyloid Peptide Plaques. 2015 , 72, 1124-31	53
1442	β Secretase processing of APP inhibits neuronal activity in the hippocampus. 2015 , 526, 443-7	257
1441	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. 2015 , 130, 501-10	31
1440	Loss of calbindin-D28K is associated with the full range of tangle pathology within basal forebrain cholinergic neurons in Alzheimer's disease. 2015 , 36, 3163-3170	24
1439	Evidence for human transmission of amyloid- β pathology and cerebral amyloid angiopathy. 2015 , 525, 247-50	311
1438	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. 2015 , 256, 168-83	42

1437	DNA repair factor BRCA1 depletion occurs in Alzheimer brains and impairs cognitive function in mice. 2015 , 6, 8897		104
1436	Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. <i>Alzheimer's and Dementia</i> , 2015 , 11, 964-74	1.2	288
1435	Neuropathology and biochemistry of A β and its aggregates in Alzheimer's disease. 2015 , 129, 167-82		141
1434	Cortical pyroglutamate amyloid- β levels and cognitive decline in Alzheimer's disease. 2015 , 36, 12-9		21
1433	Emerging concepts in Alzheimer's disease. 2015 , 10, 291-319		152
1432	Epigenomics of Alzheimer's disease. 2015 , 165, 200-20		79
1431	Detection of Amyloid β Signature in the Lens and Its Correlation in the Brain to Aid in the Diagnosis of Alzheimer's Disease. 2015 , 30, 738-45		31
1430	Challenges of multimorbidity of the aging brain: a critical update. 2015 , 122, 505-21		91
1429	Bioactive Nutrients for Brain Health. 2015 , 49-56		
1428	Recent Increases in Hippocampal Tau Pathology in the Aging Japanese Population: The Hisayama Study. 2017 , 55, 613-624		6
1427	Microscopic Examination. 2016 , 90-107		3
1426	Dynamics of Human Mitochondrial Complex I Assembly: Implications for Neurodegenerative Diseases. 2016 , 3, 43		57
1425	Visual and Ocular Manifestations of Alzheimer's Disease and Their Use as Biomarkers for Diagnosis and Progression. 2016 , 7, 55		90
1424	Labeling Pathological Tau: An Important Quest for the Unknown. 2016 , 10, 253		
1423	Characteristics of Tau and Its Ligands in PET Imaging. 2016 , 6, 7		71
1422	Subacute Changes in Cleavage Processing of Amyloid Precursor Protein and Tau following Penetrating Traumatic Brain Injury. 2016 , 11, e0158576		14
1421	Drug Development in Alzheimer's Disease: The Contribution of PET and SPECT. 2016 , 7, 88		20
1420	Recursive Subsystems in Aphasia and Alzheimer's Disease: Case Studies in Syntax and Theory of Mind. 2016 , 7, 405		5

1419	Alzheimer's Disease and the Aggregation of Amyloid β 2016 , 31-52	
1418	The blood clotting Factor XIIIa forms unique complexes with amyloid-beta (A β) and colocalizes with deposited A β in cerebral amyloid angiopathy. 2016 , 42, 255-72	13
1417	Applicability of digital analysis and imaging technology in neuropathology assessment. 2016 , 36, 270-82	9
1416	Clinicopathological correlates of depression in early Alzheimer's disease in the NACC. 2016 , 31, 1301-1311	15
1415	Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains. 2016 , 36, 333-45	14
1414	RETRACTED ARTICLE: Complex Effect of RNA Spliceosome Inhibition on Amyloid Precursor Protein Expression. 2016 , 41, 3417	
1413	Alzheimer's disease: A review of its visual system neuropathology. Optical coherence tomography-a potential role as a study tool in vivo. 2016 , 254, 2079-2092	17
1412	Tackling amyloidogenesis in Alzheimer's disease with A2V variants of Amyloid- β 2016 , 6, 20949	18
1411	Comparison of New Tau PET-Tracer Candidates With [18F]T808 and [18F]T807. 2016 , 15,	33
1410	Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer's Disease. 2016 , 53, 1257-70	18
1409	Presence of cerebral amyloid modulates phenotype and pattern of neurodegeneration in early Parkinson's disease. 2016 , 87, 1112-22	28
1408	Tau Platelets Correlate with Regional Brain Atrophy in Patients with Alzheimer's Disease. 2017 , 55, 1595-1603	14
1407	ABCA7 Mediates Phagocytic Clearance of Amyloid- β in the Brain. 2016 , 54, 569-84	50
1406	P3-253: Performance of [18F]Flutemetamol Amyloid Imaging Against the Current (2012) NIA-AA Recommendations for the Neuropathological Diagnosis of Alzheimer's Disease. 2016 , 12, P926-P926	
1405	MicroRNA-146a suppresses ROCK1 allowing hyperphosphorylation of tau in Alzheimer's disease. 2016 , 6, 26697	57
1404	Increased occurrence of protein kinase CK2 in astrocytes in Alzheimer's disease pathology. 2016 , 13, 4	34
1403	Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study. 2016 , 57, 900-6	63
1402	A comprehensive study of the genetic impact of rare variants in SORL1 in European early-onset Alzheimer's disease. 2016 , 132, 213-224	62

1401	PET Imaging of Tau Deposition in the Aging Human Brain. 2016 , 89, 971-982		619
1400	Impaired thermoregulation and beneficial effects of thermoneutrality in the 3Tg-AD model of Alzheimer's disease. 2016 , 43, 47-57		32
1399	Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. 2016 , 42, 80-90		24
1398	Unbiased Stereological Analysis of Reactive Astrogliosis to Estimate Age-Associated Cerebral White Matter Injury. 2016 , 75, 539-54		10
1397	Phenotypic characteristics of Alzheimer patients carrying an ABCA7 mutation. 2016 , 86, 2126-33		19
1396	Multisite assessment of NIA-AA guidelines for the neuropathologic evaluation of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016 , 12, 164-169	1.2	62
1395	Regional profiles of the candidate tau PET ligand 18F-AV-1451 recapitulate key features of Braak histopathological stages. 2016 , 139, 1539-50		275
1394	Neuropathological diagnosis of vascular cognitive impairment and vascular dementia with implications for Alzheimer's disease. 2016 , 131, 659-85		199
1393	Integration of Chinese medicine with Western medicine could lead to future medicine: molecular module medicine. 2016 , 22, 243-50		4
1392	The Science of Vascular Contributions to Cognitive Impairment and Dementia (VCID): A Framework for Advancing Research Priorities in the Cerebrovascular Biology of Cognitive Decline. 2016 , 36, 281-8		109
1391	2016 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2016 , 12, 459-509	1.2	1615
1390	Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. 2016 , 75, 516-26		33
1389	Development of acetophenone ligands as potential neuroimaging agents for cholinesterases. 2016 , 24, 5270-5279		4
1388	Biomarker-guided classification scheme of neurodegenerative diseases. 2016 , 5, 383-387		19
1387	Diagnostic de la maladie d'Alzheimer : apport de l'imagerie au florbÉapir et autres radiopharmaceutiques de la plaque amyloÏde. 2016 , 40, 364-381		2
1386	Sex-related dimorphism in dentate gyrus atrophy and behavioral phenotypes in an inducible tTa:APPsi transgenic model of Alzheimer's disease. 2016 , 96, 171-185		10
1385	Alzheimer's Disease Biomarker Profile in Cerebrospinal Fluid of Individuals with Immune-Mediated Encephalitis. 2016 , 64, e29-31		
1384	Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort. 2016 , 42, 106-16		13

1383	Atypical Alzheimer's disease. 2016 , 17-29	3
1382	Decreased hippocampal metabolism in high-amyloid mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2016 , 12, 1288-1296	1.2 20
1381	Distribution and Load of Amyloid- β Pathology in Parkinson Disease and Dementia with Lewy Bodies. 2016 , 75, 936-945	73
1380	Alzheimer's disease prevention: A way forward. 2016 , 216, 495-503	2
1379	The identification of raft-derived tau-associated vesicles that are incorporated into immature tangles and paired helical filaments. 2016 , 42, 639-653	12
1378	Tau positron emission tomographic imaging in aging and early Alzheimer disease. 2016 , 79, 110-9	591
1377	The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. 2016 , 132, 545-61	29
1376	Aphasic variant of Alzheimer disease: Clinical, anatomic, and genetic features. 2016 , 87, 1337-43	46
1375	Quantification of immunohistochemical findings of neurofibrillary tangles and senile plaques for a diagnosis of dementia in forensic autopsy cases. 2016 , 22, 82-9	1
1374	Chitinase expression in Alzheimer's disease and non-demented brains regions. 2016 , 369, 242-249	22
1373	Clinical Diagnosis of Alzheimer's Disease. 2016 , 27-48	2
1372	An autoradiographic evaluation of AV-1451 Tau PET in dementia. 2016 , 4, 58	305
1371	Amyloid Pathology Affects the Hearts of Patients With Alzheimer's Disease: Mind the Heart. 2016 , 68, 2395-2407	81
1370	Detection of Striatal Amyloid Plaques with [18F]flutemetamol: Validation with Postmortem Histopathology. 2016 , 52, 863-73	40
1369	Neuropathology of supercentenarians - four autopsy case studies. 2016 , 4, 97	16
1368	Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation. 2016 , 10, 24-33	122
1367	Glucose levels during life and neuropathologic findings at autopsy among people never treated for diabetes. 2016 , 48, 72-82	12
1366	Tenascin-C Is Associated with Cored Amyloid- β Plaques in Alzheimer Disease and Pathology Burdened Cognitively Normal Elderly. 2016 , 75, 868-76	21

1365	Reduce vascular risk to prevent dementia?. 2016 , 388, 738-40	12
1364	NEUROLOGÍA DE LAS DEMENCIAS NEURODEGENERATIVAS. 2016 , 27, 297-308	1
1363	In Vivo Tau, Amyloid, and Gray Matter Profiles in the Aging Brain. 2016 , 36, 7364-74	109
1362	Alzheimer's disease and chronic traumatic encephalopathy: Distinct but possibly overlapping disease entities. 2016 , 30, 1279-1292	31
1361	The road to restoring neural circuits for the treatment of Alzheimer's disease. 2016 , 539, 187-196	280
1360	SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0. 2016 , 57, 1316-22	94
1359	Astroglial pathology predominates the earliest stage of corticobasal degeneration pathology. 2016 , 139, 3237-3252	80
1358	Human Central Nervous System (CNS) ApoE Isoforms Are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared with Plasma. 2016 , 291, 27204-27218	27
1357	Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1 β . 2016 , 16, 185	34
1356	Post-mortem assessment in vascular dementia: advances and aspirations. 2016 , 14, 129	73
1355	Post-mortem histopathology underlying β -amyloid PET imaging following flutemetamol F 18 injection. 2016 , 4, 130	57
1354	Expression of A152T human tau causes age-dependent neuronal dysfunction and loss in transgenic mice. 2016 , 17, 530-51	77
1353	Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans. 2016 ,	2
1352	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. 2016 , 8, 17	75
1351	Alzheimer's disease prevention: A way forward. 2016 , 216, 495-503	3
1350	Combined Genome-Wide CSF A β 2's Associations and Simple Network Properties Highlight New Risk Factors for Alzheimer's Disease. 2016 , 58, 120-8	5
1349	Immunolocalization of Tom1 in relation to protein degradation systems in Alzheimer's disease. 2016 , 365, 101-7	8
1348	Loss of ceramide synthase 2 activity, necessary for myelin biosynthesis, precedes tau pathology in the cortical pathogenesis of Alzheimer's disease. 2016 , 43, 89-100	39

1347	Caring for older people living alone with dementia: Healthcare professionals' experiences. 2016 , 15, 221-38		18
1346	Amyloid-Beta Positron Emission Tomography Imaging of Alzheimer's Pathology in Parkinson's Disease Dementia. 2016 , 3, 367-375		22
1345	Analysis of RNA from Alzheimer's Disease Post-mortem Brain Tissues. 2016 , 53, 1322-1328		49
1344	Suspected non-Alzheimer disease pathophysiology--concept and controversy. 2016 , 12, 117-24		174
1343	Relationship of Hippocampal Volume to Amyloid Burden across Diagnostic Stages of Alzheimer's Disease. 2016 , 41, 68-79		10
1342	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. 2016 , 46, 57-87		11
1341	A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments. 2016 , 15, 239-54		6
1340	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016 , 12, 292-323	1.2	832
1339	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. 2016 , 139, 1211-25		135
1338	Altered Proteins in the Aging Brain. 2016 , 75, 316-25		109
1337	Imaging in-vivo tau pathology in Alzheimer's disease with THK5317 PET in a multimodal paradigm. 2016 , 43, 1686-99		98
1336	Molecular genetics of early-onset Alzheimer's disease revisited. <i>Alzheimer's and Dementia</i> , 2016 , 12, 733-48		258
1335	Association of APOE with tau-tangle pathology with and without Amyloid. 2016 , 37, 19-25		66
1334	Symptomatic and preclinical Alzheimer's disease: Neuropathology and imaging. 2016 , 22, 127-131		1
1333	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. 2016 , 37, 663-72		35
1332	Defeating Alzheimer's disease and other dementias: a priority for European science and society. 2016 , 15, 455-532		921
1331	Neuropathology. 2016 , 667-749		
1330	Association between CYP17A1 rs3824755 and rs743572 gene polymorphisms and Alzheimer's disease in the Chinese Han population. 2016 , 618, 77-82		5

1329	Pathological β -synuclein distribution in subjects with coincident Alzheimer's and Lewy body pathology. 2016 , 131, 393-409	93
1328	Precision Medicine: Clarity for the Complexity of Dementia. 2016 , 186, 500-6	32
1327	Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease. 2016 , 186, 375-84	53
1326	Propagation of A β pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. 2016 , 131, 5-25	54
1325	Selective vulnerability in neurodegeneration: insights from clinical variants of Alzheimer's disease. 2016 , 87, 1000-4	50
1324	Alzheimer's as a Systems-Level Disease Involving the Interplay of Multiple Cellular Networks. 2016 , 1303, 3-48	24
1323	CSF β Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease. 2016 , 58, 88-92	63
1322	Dissecting Complex and Multifactorial Nature of Alzheimer's Disease Pathogenesis: a Clinical, Genomic, and Systems Biology Perspective. 2016 , 53, 4833-64	31
1321	Advanced Neuroimaging Methods Towards Characterization of Early Stages of Alzheimer's Disease. 2016 , 1303, 509-19	7
1320	Clinical-pathologic correlations in vascular cognitive impairment and dementia. 2016 , 1862, 945-51	10
1319	The neuropathology and cerebrovascular mechanisms of dementia. 2016 , 36, 172-86	176
1318	Early changes in extracellular matrix in Alzheimer's disease. 2017 , 43, 167-182	85
1317	A quantitative study of tau pathology in 11 cases of chronic traumatic encephalopathy. 2017 , 43, 154-166	16
1316	Monoaminergic neuropathology in Alzheimer's disease. 2017 , 151, 101-138	137
1315	Genome-wide interaction study of brain beta-amyloid burden and cognitive impairment in Alzheimer's disease. 2017 , 22, 287-295	44
1314	REM sleep without atonia in middle-aged and older psychiatric patients and Lewy body disease: a case series. 2017 , 32, 397-406	7
1313	Typical and atypical appearance of early-onset Alzheimer's disease: A clinical, neuroimaging and neuropathological study. 2017 , 37, 150-173	17
1312	Duration and Pathologic Correlates of Lewy Body Disease. 2017 , 74, 310-315	31

1311	Regional correlations between [C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort. 2017 , 13, 130-137	37
1310	Incipient progressive supranuclear palsy is more common than expected and may comprise clinicopathological subtypes: a forensic autopsy series. 2017 , 133, 809-823	39
1309	Performance of a Condensed Protocol That Reduces Effort and Cost of NIA-AA Guidelines for Neuropathologic Assessment of Alzheimer Disease. 2017 , 76, 39-43	5
1308	Ketogenic diets and Alzheimer's disease. 2017 , 6, 1-9	31
1307	Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. 2017 , 44, 825-837	27
1306	Gene-based association study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. 2017 , 53, 193.e17-193.e25	15
1305	Locus coeruleus at asymptomatic early and middle Braak stages of neurofibrillary tangle pathology. 2017 , 43, 373-392	45
1304	Frontotemporal dementia with the V337M mutation: Tau-PET and pathology correlations. 2017 , 88, 758-766	58
1303	Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?. 2017 , 16, 1	29
1302	Human Striatal Dopaminergic and Regional Serotonergic Synaptic Degeneration with Lewy Body Disease and Inheritance of APOE ϵ . 2017 , 187, 884-895	12
1301	Two distinct classes of degenerative change are independently linked to clinical progression in mild cognitive impairment. 2017 , 54, 1-9	16
1300	Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid- β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial. 2017 , 56, 129-143	47
1299	Recent Progress in Alzheimer's Disease Research, Part 1: Pathology. 2017 , 57, 1-28	47
1298	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. 2017 , 7, 69-87	193
1297	Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer's disease and other neurodegenerative diseases. 2017 , 14, 285-299	49
1296	Amyloid plaque structure and cell surface interactions of β amyloid fibrils revealed by electron tomography. 2017 , 7, 43577	43
1295	Fluorodeoxyglucose metabolism associated with tau-amyloid interaction predicts memory decline. 2017 , 81, 583-596	90
1294	Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. 2017 , 53, 83-92	45

1293	Loss of precuneus dendritic spines immunopositive for spinophilin is related to cognitive impairment in early Alzheimer's disease. 2017 , 55, 159-166		21
1292	Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept. <i>Alzheimer's and Dementia</i> , 2017 , 13, 454-467	1.2	49
1291	Laminar degeneration of frontal and temporal cortex in Parkinson disease dementia. 2017 , 38, 667-671		6
1290	Mixed pathologies including chronic traumatic encephalopathy account for dementia in retired association football (soccer) players. 2017 , 133, 337-352		128
1289	Diagnosing the frontal variant of Alzheimer's disease: a clinician's yellow brick road. 2017 , 4, 2		17
1288	The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly. 2017 , 35, 231-262		1
1287	Interactions of pathological proteins in neurodegenerative diseases. 2017 , 134, 187-205		193
1286	Preclinical models of Alzheimer's disease for identification and preclinical validation of therapeutic targets: from fine-tuning strategies for validated targets to new venues for therapy. 2017 , 115-156		1
1285	Tau Antibody Targeting Pathological Species Blocks Neuronal Uptake and Interneuron Propagation of Tau in Vitro. 2017 , 187, 1399-1412		65
1284	Applying fluid biomarkers to Alzheimer's disease. 2017 , 313, C3-C10		35
1283	Altered temporal lobe white matter lipid ion profiles in an experimental model of sporadic Alzheimer's disease. 2017 , 82, 23-34		9
1282	Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review. 2017 , 58, 789-801		72
1281	Resistance to Alzheimer Disease Neuropathologic Changes and Apparent Cognitive Resilience in the Nun and Honolulu-Asia Aging Studies. 2017 , 76, 458-466		44
1280	Higher levels of myelin phospholipids in brains of neuronal β synuclein transgenic mice precede myelin loss. 2017 , 5, 37		12
1279	Pathology of Brain Aging. 2017 , 1-11		
1278	Enhanced Tau Aggregation in the Presence of Amyloid β 2017 , 187, 1601-1612		106
1277	The midbrain-to-pons ratio distinguishes progressive supranuclear palsy from non-fluent primary progressive aphasia. 2017 , 24, 956-965		5
1276	Use of Analgesics (Opioids and Nonsteroidal Anti-Inflammatory Drugs) and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. 2017 , 58, 435-448		6

1275	Hippocampal Sclerosis in Older Patients: Practical Examples and Guidance With a Focus on Cerebral Age-Related TDP-43 With Sclerosis. 2017 , 141, 1113-1126	21
1274	The Exceptional Vulnerability of Humans to Alzheimer's Disease. 2017 , 23, 534-545	50
1273	Fluorescence and autoradiographic evaluation of tau PET ligand PBB3 to β -synuclein pathology. 2017 , 32, 884-892	39
1272	Patterns of Microglial Cell Activation in Alzheimer Disease and Frontotemporal Lobar Degeneration. 2017 , 17, 145-154	22
1271	Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease. 2017 , 134, 475-487	34
1270	SIRT3 and mitochondrial metabolism in neurodegenerative diseases. 2017 , 109, 184-192	56
1269	Longitudinal changes in amyloid positron emission tomography and volumetric magnetic resonance imaging in the nondemented Down syndrome population. 2017 , 9, 1-9	42
1268	Epigenome Editing in the Brain. 2017 , 978, 409-424	6
1267	Diagnostic accuracy of CSF neurofilament light chain protein in the biomarker-guided classification system for Alzheimer's disease. 2017 , 108, 355-360	38
1266	Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue. 2017 , 5, 41	58
1265	Impaired prosaposin lysosomal trafficking in frontotemporal lobar degeneration due to progranulin mutations. 2017 , 8, 15277	53
1264	Hierarchical Organization of Tau and Amyloid Deposits in the Cerebral Cortex. 2017 , 74, 813-820	44
1263	White-matter integrity on DTI and the pathologic staging of Alzheimer's disease. 2017 , 56, 172-179	107
1262	Amyloid positron emission tomography in sporadic cerebral amyloid angiopathy: A systematic critical update. 2017 , 15, 247-263	40
1261	Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. 2017 , 140, 748-763	194
1260	Effective expression of Drebrin in hippocampus improves cognitive function and alleviates lesions of Alzheimer's disease in APP (swe)/PS1 (E9) mice. 2017 , 23, 590-604	14
1259	[F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. 2017 , 134, 619-628	56
1258	Microvascular changes in Down syndrome with Alzheimer's-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 1389-1396	1.2 13

1257	Changes in CD200 and intercellular adhesion molecule-1 (ICAM-1) levels in brains of Lewy body disorder cases are associated with amounts of Alzheimer's pathology not β -synuclein pathology. 2017 , 54, 175-186	24
1256	Hérogène gène de la maladie d'Alzheimer: des mutations causales aux facteurs de risque gènes rares et fréquents. 2017 , 8, 96-105	
1255	Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. 2017 , 133, 923-931	31
1254	Absence of Alzheimer Disease Neuropathologic Changes in Eyes of Subjects With Alzheimer Disease. 2017 , 76, 376-383	36
1253	Genetic Alzheimer Disease and Sporadic Dementia With Lewy Bodies: A Comorbidity Presenting as Primary Progressive Aphasia. 2017 , 30, 23-29	10
1252	Amyloid- β accumulation in the CNS in human growth hormone recipients in the UK. 2017 , 134, 221-240	67
1251	Locus coeruleus cellular and molecular pathology during the progression of Alzheimer's disease. 2017 , 5, 8	126
1250	Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. 2017 , 57, 645-665	76
1249	2017 Alzheimer's disease facts and figures. 2017 , 13, 325-373	795
1248	Metabolomic-guided discovery of Alzheimer's disease biomarkers from body fluid. 2017 , 95, 2005-2024	24
1247	Modulation of linoleic acid-binding properties of human serum albumin by divalent metal cations. 2017 , 30, 341-353	7
1246	Modeling the Relationships Among Late-Life Body Mass Index, Cerebrovascular Disease, and Alzheimer's Disease Neuropathology in an Autopsy Sample of 1,421 Subjects from the National Alzheimer's Coordinating Center Data Set. 2017 , 57, 953-968	15
1245	Clinical validity of presynaptic dopaminergic imaging with ¹ I-ioflupane and noradrenergic imaging with I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. 2017 , 52, 228-242	26
1244	Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. 2017 , 52, 214-227	52
1243	Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis. 2017 , 16, 55-65	273
1242	Risk of incident clinical diagnosis of Alzheimer's disease-type dementia attributable to pathology-confirmed vascular disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 613-623	1.2 19
1241	Alzheimer's disease: experimental models and reality. 2017 , 133, 155-175	274
1240	Pathological correlations of [¹⁸ F]-AV-1451 imaging in non-alzheimer tauopathies. 2017 , 81, 117-128	135

1239	Insulin Resistance and Neurodegeneration: Progress Towards the Development of New Therapeutics for Alzheimer's Disease. 2017 , 77, 47-65	144
1238	Binding Sites for Amyloid- β Oligomers and Synaptic Toxicity. 2017 , 7,	58
1237	F-flortaucipir tau positron emission tomography distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A multicenter study. 2017 , 82, 622-634	106
1236	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. 2017 , 32, 1772-1779	30
1235	β Secretase in microglia - implications for neurodegeneration and neuroinflammation. 2017 , 143, 445-454	12
1234	Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease. 2017 , 140, 3286-3300	273
1233	Clinicopathological correlations in behavioural variant frontotemporal dementia. 2017 , 140, 3329-3345	139
1232	Disease and Region Specificity of Granulin Immunopositivities in Alzheimer Disease and Frontotemporal Lobar Degeneration. 2017 , 76, 957-968	13
1231	Statistical considerations for assessing cognition and neuropathology associations in preclinical Alzheimer's disease. 2017 , 1, 92-104	3
1230	Signs and symptoms preceding the diagnosis of Alzheimer's disease: a systematic scoping review of literature from 1937 to 2016. 2017 , 7, e015746	69
1229	ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. 2017 , 549, 523-527	520
1228	Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18 F]UCB-H. 2017 , 3, 481-486	33
1227	A Cytomic Approach Towards Genomic Individuality of Neurons. 2017 , 81-106	1
1226	DNAJC12 and dopa-responsive nonprogressive parkinsonism. 2017 , 82, 640-646	38
1225	Terahertz Imaging and Electromagnetic Model of Axon Demyelination in Alzheimer's Disease. 2017 , 7, 711-721	12
1224	Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer's Disease. 2017 , 6, 37-56	37
1223	Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes. 2017 , 9, 10-20	29
1222	Genetic Comparison of Symptomatic and Asymptomatic Persons With Alzheimer Disease Neuropathology. 2017 , 31, 232-238	12

1221	Performance of [¹⁸ F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease. 2017 , 9, 25-34	40
1220	Unusual neuropathological features and increased brain aluminium in a resident of Camelford, UK. 2017 , 43, 537-541	6
1219	Pathology of the Superior Colliculus in Chronic Traumatic Encephalopathy. 2017 , 94, 33-42	7
1218	APP mouse models for Alzheimer's disease preclinical studies. 2017 , 36, 2473-2487	341
1217	UPLC-MS/MS method for determination of schisandrin in rat plasma and brain microdialysates: application to a comparative pharmacokinetic and brain distribution study in normal and Alzheimer's disease rats. 2017 , 9, 4740-4746	4
1216	Validation of an electronic image reader training programme for interpretation of [¹⁸ F]flutemetamol amyloid PET brain images. 2017 , 38, 234-241	40
1215	Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau. 2017 , 92, 1291-1303	31
1214	Four Decades of Research in Alzheimer's Disease (1975-2014): A Bibliometric and Scientometric Analysis. 2017 , 59, 763-783	20
1213	¹⁸ F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2017 , 11, CD012216	23
1212	¹⁸ F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2017 , 11, CD012884	20
1211	Why do so many clinical trials of therapies for Alzheimer's disease fail?. 2017 , 390, 2327-2329	111
1210	Cholinesterases in normal and Alzheimer's disease primary olfactory gyrus. 2017 , 43, 571-583	6
1209	Regulator of Cell Cycle (RGCC) Expression During the Progression of Alzheimer's Disease. 2017 , 26, 693-702	22
1208	Quantification of Butyrylcholinesterase Activity as a Sensitive and Specific Biomarker of Alzheimer's Disease. 2017 , 58, 491-505	36
1207	Higher levels of different muscarinic receptors in the cortex and hippocampus from subjects with Alzheimer's disease. 2017 , 124, 273-284	5
1206	Brain imaging evidence of early involvement of subcortical regions in familial and sporadic Alzheimer's disease. 2017 , 1655, 23-32	21
1205	The pertussis hypothesis: Bordetella pertussis colonization in the pathogenesis of Alzheimer's disease. 2017 , 222, 228-240	9
1204	Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic. <i>Alzheimer's and Dementia</i> , 2017 , 13, 45-58 ^{1,2}	163

1203	Mixed neuropathologies and estimated rates of clinical progression in a large autopsy sample. <i>Alzheimer's and Dementia</i> , 2017 , 13, 654-662	1.2	53
1202	Clustering of tau-immunoreactive pathology in chronic traumatic encephalopathy. 2017 , 124, 185-192		6
1201	Clinical anatomy of the most common dementias. 2017 , 30, 53-57		
1200	An investigation of cerebrovascular lesions in dementia with Lewy bodies compared to Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017 , 13, 257-266	1.2	24
1199	TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. 2017 , 27, 472-479		107
1198	Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution?. 2017 , 27, 603-611		9
1197	Pharmacokinetic Evaluation of the Tau PET Radiotracer F-T807 (F-AV-1451) in Human Subjects. 2017 , 58, 484-491		65
1196	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. 2017 , 3, 83-91		57
1195	Molecular Imaging and Precision Medicine in Dementia and Movement Disorders. 2017 , 12, 119-136		1
1194	Widespread tau seeding activity at early Braak stages. 2017 , 133, 91-100		75
1193	The Differential Effects of Alzheimer's Disease and Lewy Body Pathology on Cognitive Performance: a Meta-analysis. 2017 , 27, 1-17		22
1192	Epigenetic dysregulation of brainstem nuclei in the pathogenesis of Alzheimer's disease: looking in the correct place at the right time?. 2017 , 74, 509-523		10
1191	Distinct spatiotemporal accumulation of N-truncated and full-length amyloid- β 2 in Alzheimer's disease. 2017 , 140, 3301-3316		10
1190	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. 2017 , 59, 1139-1152		52
1189	Neuropathology of dementia. 94-122		1
1188	Alzheimer's disease. 123-142		
1187	Transactive DNA Binding Protein 43 Rather Than Other Misfolded Proteins in the Brain is Associated with Islet Amyloid Polypeptide in Pancreas in Aged Subjects with Diabetes Mellitus. 2017 , 59, 43-56		6
1186	Association between Cholesterol Exposure and Neuropathological Findings: The ACT Study. 2017 , 59, 1307-1315		5

1185	Study on synthesis and properties of nanoparticles loaded with amaryllidaceous alkaloids. 2017 , 12, 356-364	1
1184	18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI). 2017 , 11, CD012883	17
1183	The Relationship of Brain Amyloid Load and APOE Status to Regional Cortical Thinning and Cognition in the ADNI Cohort. 2017 , 59, 1269-1282	21
1182	Perspective, Summary, and Directions for Future Research on Alzheimer's Disease. 2017 , 361-386	
1181	Photobiomodulation with Near Infrared Light Helmet in a Pilot, Placebo Controlled Clinical Trial in Dementia Patients Testing Memory and Cognition. 2017 , 8,	63
1180	Epigenomics of Alzheimer's Disease. 2017 , 227-278	
1179	The Neuroanatomy of the Reticular Nucleus Locus Coeruleus in Alzheimer's Disease. 2017 , 11, 80	31
1178	Association between the APOE 4 Allele and Late-Onset Alzheimer's Disease in an Ecuadorian Mestizo Population. 2017 , 2017, 1059678	8
1177	Markers of Alzheimer's Disease in Primary Visual Cortex in Normal Aging in Mice. 2017 , 2017, 3706018	4
1176	Neuropathological and transcriptomic characteristics of the aged brain. 2017 , 6,	50
1175	Alzheimer's disease pathology and shunt surgery outcome in normal pressure hydrocephalus. 2017 , 12, e0182288	17
1174	CCL11 is increased in the CNS in chronic traumatic encephalopathy but not in Alzheimer's disease. 2017 , 12, e0185541	38
1173	Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. 2017 , 14, e1002258	209
1172	Cognitive function in very old men does not correlate to biomarkers of Alzheimer's disease. 2017 , 17, 208	7
1171	Lessons learned about [F-18]-AV-1451 off-target binding from an autopsy-confirmed Parkinson's case. 2017 , 5, 75	60
1170	Cerebrovascular pathology in Down syndrome and Alzheimer disease. 2017 , 5, 93	37
1169	Trajectories of physical function prior to death and brain neuropathology in a community-based cohort: the act study. 2017 , 17, 258	3
1168	Does genetic testing for ERG gene polymorphisms provide new possibilities of treatment for cognitive function disorders in postmenopausal women?. 2017 , 13, 1224-1232	2

1167	Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea. 2017 , 58, 1055-1060		10
1166	Role of circulating factors in cardiac aging. 2017 , 9, S17-S29		11
1165	Memory complaints, dementia, and neuropathology in older blacks and whites. 2018 , 83, 718-729		26
1164	6,7,4'-Trihydroxyisoflavone, a major metabolite of daidzein, improves learning and memory via the cholinergic system and the p-CREB/BDNF signaling pathway in mice. 2018 , 826, 140-147		22
1163	Integrated neurodegenerative disease autopsy diagnosis. 2018 , 135, 643-646		7
1162	Age-Dependent Changes to Sphingolipid Balance in the Human Hippocampus are Gender-Specific and May Sensitize to Neurodegeneration. 2018 , 63, 503-514		23
1161	NIA commentary on the NIA-AA Research Framework: Towards a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 576-578	1.2	39
1160	CXCR4 involvement in neurodegenerative diseases. 2018 , 8, 73		36
1159	Risk score prediction model for dementia in patients with type 2 diabetes. 2018 , 25, 976-983		11
1158	Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease. 2018 , 62, 1815-1826		8
1157	Hippocampal Sclerosis in the Oldest Old: A Finnish Population-Based Study. 2018 , 63, 263-272		13
1156	NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 535-562	1.2	3155
1155	Negative 11C-PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination. 2018 , 63, 79-85		1
1154	Evidence of amyloid- β cerebral amyloid angiopathy transmission through neurosurgery. 2018 , 135, 671-679		59
1153	Elevated medial temporal lobe and pervasive brain tau-PET signal in normal participants. 2018 , 10, 210-216		11
1152	Early vs late age at onset frontotemporal dementia and frontotemporal lobar degeneration. 2018 , 90, e1047-e1056		25
1151	The Mechanisms of Bushen-Yizhi Formula as a Therapeutic Agent against Alzheimer's Disease. 2018 , 8, 3104		27
1150	Molecular subtypes of Alzheimer's disease. 2018 , 8, 3269		44

1149	Altered Expression of Circulating Cdc42 in Frontotemporal Lobar Degeneration. 2018 , 61, 1477-1483	6
1148	Evidence-based Interpretation of Amyloid-IPET Results: A Clinician's Tool. 2018 , 32, 28-34	21
1147	Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease. 2018 , 61, 1323-1332	70
1146	Multimodal Characterization of the Late Effects of Traumatic Brain Injury: A Methodological Overview of the Late Effects of Traumatic Brain Injury Project. 2018 , 35, 1604-1619	23
1145	Neuropathology correlates of cognitive assessments. 2018 , 187, 835-844	
1144	Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease. 2018 , 378, 321-330	512
1143	Clinicopathological and I-FP-CIT SPECT correlations in patients with dementia. 2018 , 5, 376-381	8
1142	Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. 2018 , 39, 1500-1515	13
1141	Biopsy Pathology of Neurodegenerative Disorders in Adults. 2018 , 659-680	2
1140	Accumulation of beta-synuclein in cortical neurons is associated with autophagy attenuation in the brains of dementia with Lewy body patients. 2018 , 1681, 1-13	9
1139	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. 2018 , 32, 35-42	3
1138	Vasodilator dysfunction and oligodendrocyte dysmaturation in aging white matter. 2018 , 83, 142-152	17
1137	[F]AV-1451 clustering of entorhinal and cortical uptake in Alzheimer's disease. 2018 , 83, 248-257	42
1136	Rates of Amyloid Imaging Positivity in Patients With Primary Progressive Aphasia. 2018 , 75, 342-352	59
1135	Alzheimer's disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A β total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. <i>Alzheimer's and Dementia</i> , 2018 , 14, 492-501	1.2 71
1134	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. 2018 , 77, 2-20	40
1133	Selective Vulnerability of Brainstem Nuclei in Distinct Tauopathies: A Postmortem Study. 2018 , 77, 149-161	25
1132	Advances in microstructural diffusion neuroimaging for psychiatric disorders. 2018 , 182, 259-282	50

1131	5-Methoxyindole-2-carboxylic acid (MICA) suppresses A β -mediated pathology in <i>C. elegans</i> . 2018 , 108, 215-225	8
1130	Association between residual teeth number in later life and incidence of dementia: A systematic review and meta-analysis. 2018 , 18, 48	24
1129	Improving the identification of dementia with Lewy bodies in the context of an Alzheimer's-type dementia. 2018 , 10, 27	29
1128	Characterization of 3 Novel Tau Radiopharmaceuticals, C-RO-963, C-RO-643, and F-RO-948, in Healthy Controls and in Alzheimer Subjects. 2018 , 59, 1869-1876	61
1127	Alzheimer disease. 2017 , 145, 325-337	62
1126	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology. 2018 , 136, 363-376	83
1125	An intronic VNTR affects splicing of ABCA7 and increases risk of Alzheimer's disease. 2018 , 135, 827-837	40
1124	2018 Alzheimer's disease facts and figures. 2018 , 14, 367-429	1154
1123	Circular Inference in Dementia Diagnostics. 2018 , 63, 69-73	10
1122	Capillary cerebral amyloid angiopathy in Alzheimer's disease: association with allocortical/hippocampal microinfarcts and cognitive decline. 2018 , 135, 681-694	42
1121	Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnesic mild cognitive impairment patients. 2018 , 10, 269-277	9
1120	Pedunculopontine Nucleus Cholinergic Deficiency in Cervical Dystonia. 2018 , 33, 827-834	10
1119	FDG-PET in tau-negative amnesic dementia resembles that of autopsy-proven hippocampal sclerosis. 2018 , 141, 1201-1217	46
1118	Postmortem Histopathologic Analysis of Neurosyphilis: A Report of 3 Cases With Clinicopathologic Correlations. 2018 ,	6
1117	When Decrease A β -42 in CSF May Not Mean Alzheimer's Disease: Insights From Two Case Reports With Early Onset Dementia. 2018 , 32, 359-363	
1116	Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia. 2018 , 23, 1666-1673	69
1115	Different apathy clinical profile and neural correlates in behavioral variant frontotemporal dementia and Alzheimer's disease. 2018 , 33, 141-150	25
1114	Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease?. 2018 , 26, 182-193	34

1113	Cerebral hypoperfusion is not associated with an increase in amyloid pathology in middle-aged or elderly people. <i>Alzheimer's and Dementia</i> , 2018 , 14, 54-61	1.2	13
1112	Probing the correlation of neuronal loss, neurofibrillary tangles, and cell death markers across the Alzheimer's disease Braak stages: a quantitative study in humans. 2018 , 61, 1-12		50
1111	Inflammatory pathology markers (activated microglia and reactive astrocytes) in early and late onset Alzheimer disease: a post mortem study. 2018 , 44, 298-313		34
1110	Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease. 2018 , 17, 452-464		83
1109	Correlations of F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease. 2018 , 59, 671-674		97
1108	Alzheimer's disease. 2018 , 25, 59-70		846
1107	Peptides isolated from animal venom as a platform for new therapeutics for the treatment of Alzheimer's disease. 2018 , 67, 79-86		10
1106	Eclalbasaponin II Ameliorates the Cognitive Impairment Induced by Cholinergic Blockade in Mice. 2018 , 43, 351-362		8
1105	Sex differences in the association of alcohol with cognitive decline and brain pathology in a cohort of octogenarians. 2018 , 235, 761-770		13
1104	(-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. 2018 , 84, 488-498		39
1103	Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. 2018 , 23, 81-93		59
1102	Treated hypothyroidism is associated with cerebrovascular disease but not Alzheimer's disease pathology in older adults. 2018 , 62, 64-71		11
1101	Von Economo neurons of the anterior cingulate across the lifespan and in Alzheimer's disease. 2018 , 99, 69-77		26
1100	Application of the condensed protocol for the NIA-AA guidelines for the neuropathological assessment of Alzheimer's disease in an academic clinical practice. 2018 , 72, 433-440		4
1099	Amyloid precursor protein-fragments-containing inclusions in cardiomyocytes with basophilic degeneration and its association with cerebral amyloid angiopathy and myocardial fibrosis. 2018 , 8, 16594		7
1098	The Brain Donation Program in South Korea. 2018 , 59, 1197-1204		4
1097	TDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study. 2018 , 66, 1549-1558		8
1096	Deep Profiling of the Aggregated Proteome in Alzheimer's Disease: From Pathology to Disease Mechanisms. 2018 , 6,		13

1095	Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas. 2018 , 6, 147		67
1094	Cerebral Corpora amylacea are dense membranous labyrinths containing structurally preserved cell organelles. 2018 , 8, 18046		13
1093	MR approaches in neurodegenerative disorders. 2018 , 108, 1-16		10
1092	Prediction of Autopsy Verified Neuropathological Change of Alzheimer's Disease Using Machine Learning and MRI. 2018 , 10, 406		10
1091	Prevalence of amyloid- β pathology in distinct variants of primary progressive aphasia. 2018 , 84, 729-740		74
1090	Non-beta-amyloid/tau cerebrospinal fluid markers inform staging and progression in Alzheimer's disease. 2018 , 10, 98		19
1089	Imaging the evolution and pathophysiology of Alzheimer disease. 2018 , 19, 687-700		194
1088	Oxidative Stress Levels in the Brain Are Determined by Post-Mortem Interval and Ante-Mortem Vitamin C State but Not Alzheimer's Disease Status. 2018 , 10,		4
1087	Reinstating plasticity and memory in a tauopathy mouse model with an acetyltransferase activator. 2018 , 10,		33
1086	Al β and the dementia syndrome: Simple versus complex perspectives. 2018 , 48, e13025		8
1085	Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1505-1521	1.2	97
1084	Questions concerning the role of amyloid- β in the definition, aetiology and diagnosis of Alzheimer's disease. 2018 , 136, 663-689		101
1083	Distinct microglia profile in Creutzfeldt-Jakob disease and Alzheimer's disease is independent of disease kinetics. 2018 , 38, 591-600		2
1082	Modeling Alzheimer's disease in progeria mice. An age-related concept. 2018 , 8, 1524815		0
1081	Imaging Protein Misfolding in the Brain Using β Sheet Ligands. 2018 , 12, 585		21
1080	The role of microglia in processing and spreading of bioactive tau seeds in Alzheimer's disease. 2018 , 15, 269		96
1079	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. 2018 , 6, 88		32
1078	Atherosclerosis, Hypertension, and Diabetes in Alzheimer's Disease, Vascular Dementia, and Mixed Dementia: Prevalence and Presentation. 2018 , 65, 1247-1258		24

1077	Soluble TREM2 changes during the clinical course of Alzheimer's disease: A meta-analysis. 2018 , 686, 10-16	41
1076	Clinical Experience with Cerebrospinal Fluid A β 2, Total and Phosphorylated Tau in the Evaluation of 1,016 Individuals for Suspected Dementia. 2018 , 65, 1417-1425	10
1075	Pathological Assessment of Chronic Traumatic Encephalopathy: Review of Concepts and Methodology. 2018 , 8, 555-564	0
1074	Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease. 2018 , 136, 569-587	35
1073	Extracellular Forms of A β and Tau from iPSC Models of Alzheimer's Disease Disrupt Synaptic Plasticity. 2018 , 23, 1932-1938	43
1072	Dementia Research: Populations, Progress, Problems, and Predictions. 2018 , 64, S119-S143	5
1071	Differentiation of Alzheimer's disease based on local and global parameters in personalized Virtual Brain models. 2018 , 19, 240-251	36
1070	Influence of Lewy Pathology on Alzheimer's Disease Phenotype: A Retrospective Clinico-Pathological Study. 2018 , 63, 1317-1323	11
1069	Emergence of exosomal DNA in molecular neuropathology. 2018 , 42, 9-22	1
1068	Completed suicide in an autopsy-confirmed case of early onset Alzheimer's disease. 2018 , 8, 81-88	3
1067	Susceptibility MRI captures nigral pathology in patients with parkinsonian syndromes. 2018 , 33, 1432-1439	29
1066	Dual tracer tau PET imaging reveals different molecular targets for C-THK5351 and C-PBB3 in the Alzheimer brain. 2018 , 45, 1605-1617	27
1065	Structural and Functional Imaging. 2018 , 103-136	1
1064	Mitochondrial dysfunction and altered ribostasis in hippocampal neurons with cytoplasmic inclusions of multiple system atrophy. 2018 , 38, 361	3
1063	A review of brain biorepository management and operations. 2018 , 150, 83-92	3
1062	Minimal neuropathologic diagnosis for brain banking in the normal middle-aged and aged brain and in neurodegenerative disorders. 2018 , 150, 131-141	5
1061	Early stage memory impairment, visual hallucinations, and myoclonus combined with temporal lobe atrophy predict Alzheimer's disease pathology in corticobasal syndrome. 2018 , 24, 145-150	3
1060	The age of onset and evolution of Braak tangle stage and Thal amyloid pathology of Alzheimer's disease in individuals with Down syndrome. 2018 , 6, 56	48

1059	mTOR-Related Brain Dysfunctions in Neuropsychiatric Disorders. 2018 , 19,		54
1058	Association of Lower Spiritual Well-Being, Social Support, Self-Esteem, Subjective Well-Being, Optimism and Hope Scores With Mild Cognitive Impairment and Mild Dementia. 2018 , 9, 371		27
1057	Validity of the QUADAS-2 in Assessing Risk of Bias in Alzheimer's Disease Diagnostic Accuracy Studies. 2018 , 9, 221		6
1056	DNA methylation analysis on purified neurons and glia dissects age and Alzheimer's disease-specific changes in the human cortex. 2018 , 11, 41		96
1055	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. 2018 , 10, 54		19
1054	Association of cerebrospinal fluid β -synuclein with total and phospho-tau protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer's disease biomarkers. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1623-1631	1.2	30
1053	Cognitive and emotional alterations in App knock-in mouse models of $A\beta$ amyloidosis. 2018 , 19, 46		30
1052	Diffuse Amyloid- β Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. 2018 , 64, 1307-1324		19
1051	Histological and Behavioral Phenotypes of a Novel Mutated APP Knock-In Mouse. 2018 , 65, 165-180		4
1050	Instrumental neutron activation analysis, a technique for measurement of Se, Hg, Fe, Zn, K, Mn, Br, and the Hg:Se ratio in brain tissue samples with results from the Memory and Aging Project (MAP). 2018 , 318, 43-48		6
1049	Infrequent false positive [18 F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques. 2018 , 10, 60		19
1048	Differential Phagocytic Properties of CD45 Microglia and CD45 Brain Mononuclear Phagocytes-Activation and Age-Related Effects. 2018 , 9, 405		44
1047	The Role of Genetics in Advancing Precision Medicine for Alzheimer's Disease-A Narrative Review. 2018 , 5, 108		40
1046	Chronic Traumatic Encephalopathy in Professional American Football Players: Where Are We Now?. 2018 , 9, 445		15
1045	Synaptic Tau Seeding Precedes Tau Pathology in Human Alzheimer's Disease Brain. 2018 , 12, 267		115
1044	An Algorithm for Preclinical Diagnosis of Alzheimer's Disease. 2018 , 12, 275		21
1043	Rac1 activation links tau hyperphosphorylation and $A\beta$ dysmetabolism in Alzheimer's disease. 2018 , 6, 61		27
1042	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. 2018 , 64, 889-897		7

1041	Identification and therapeutic modulation of a pro-inflammatory subset of disease-associated-microglia in Alzheimer's disease. 2018 , 13, 24	138
1040	Modelling Alzheimer's disease: Insights from in vivo to in vitro three-dimensional culture platforms. 2018 , 12, 1944-1958	13
1039	Molecular imaging in dementia: Past, present, and future. <i>Alzheimer's and Dementia</i> , 2018 , 14, 1522-1552.2	40
1038	Modified amyloid variants in pathological subgroups of β -amyloidosis. 2018 , 5, 815-831	14
1037	Screening for dementia with the Vienna Visuo-Constructional Test 3.0 screening (VVT 3.0 screening). 2018 , 32, 196-203	2
1036	Spreading of Tau Pathology in Sporadic Alzheimer's Disease Along Cortico-cortical Top-Down Connections. 2018 , 28, 3372-3384	50
1035	How the Brain Is Affected. 2018 , 3-21	
1034	Neuroprotective Effects of Soy Isoflavones on Scopolamine-Induced Amnesia in Mice. 2018 , 10,	31
1033	The spectrum of preclinical Alzheimer's disease pathology and its modulation by ApoE genotype. 2018 , 71, 72-80	21
1032	Tau seeding activity begins in the transentorhinal/entorhinal regions and anticipates phospho-tau pathology in Alzheimer's disease and PART. 2018 , 136, 57-67	105
1031	Molecular biomarkers of Alzheimer's disease: progress and prospects. 2018 , 11,	109
1030	IgM response against amyloid-beta in aging: a potential peripheral protective mechanism. 2018 , 10, 81	12
1029	Exposure to Strong Anticholinergic Medications and Dementia-Related Neuropathology in a Community-Based Autopsy Cohort. 2018 , 65, 607-616	10
1028	How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. 2018 , 91, 395-402	35
1027	Early Impairments of Hippocampal Neurogenesis in 5xFAD Mouse Model of Alzheimer's Disease Are Associated with Altered Expression of SOXB Transcription Factors. 2018 , 65, 963-976	15
1026	Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment. 2018 , 64, 137-148	20
1025	Estimation of amyloid distribution by [18 F]flutemetamol PET predicts the neuropathological phase of amyloid β protein deposition. 2018 , 136, 557-567	29
1024	Alzheimer's genetic risk is reduced in primary age-related tauopathy: a potential model of resistance?. 2018 , 5, 927-934	10

1023	Pretangle pathology within cholinergic nucleus basalis neurons coincides with neurotrophic and neurotransmitter receptor gene dysregulation during the progression of Alzheimer's disease. 2018 , 117, 125-136		26
1022	The Domestic Dog as a Model for Human Brain Aging and Alzheimer's Disease. 2018 , 177-194		3
1021	Sporadic Creutzfeldt-Jakob Disease in a Woman Married Into a Gerstmann-Strüssler-Scheinker Family: An Investigation of Prions Transmission via Microchimerism. 2018 , 77, 673-684		4
1020	Connectome-derived diffusion characteristics of the fornix in Alzheimer's disease. 2018 , 19, 331-342		12
1019	¹⁸ F-FDG Is a Superior Indicator of Cognitive Performance Compared to ¹⁸ F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis. 2019 , 70, 1197-1207		28
1018	The basis of cellular and regional vulnerability in Alzheimer's disease. 2019 , 138, 729-749		31
1017	Alzheimer's disease and other neurodegenerative dementias in comorbidity: A clinical and neuropathological overview. 2019 , 73, 26-31		42
1016	Profound degeneration of wake-promoting neurons in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1253-1263	1.2	41
1015	Accelerated acceleration of Alzheimer-related pathology spreading and its association with prion protein. 2019 , 138, 913-941		48
1014	Neuropathology of dementia in patients with Parkinson's disease: a systematic review of autopsy studies. 2019 , 90, 1234-1243		37
1013	Sleep as a Therapeutic Target in the Aging Brain. 2019 , 16, 554-568		8
1012	The neuropathological diagnosis of Alzheimer's disease. 2019 , 14, 32		554
1011	A standardized autopsy protocol for arthrogyrosis (multiple congenital contractures). 2019 , 181, 474-478		3
1010	Amylin as a potential link between type 2 diabetes and alzheimer disease. 2019 , 86, 539-551		39
1009	FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology. 2019 , 78, 844-853		6
1008	Cognitive function and neuropathological outcomes: a forward-looking approach. 2019 , 266, 2920-2928		2
1007	Enfermedad de Alzheimer. 2019 , 12, 4338-4346		7
1006	The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer's Disease. 2019 , 70, 983-993		9

1005	The Challenge of Defining Alzheimer Disease Based on Biomarkers in the Absence of Symptoms. 2019,	4
1004	Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging-Alzheimer's Association Research Framework. 2019,	106
1003	Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid- β Mouse Model. 2019, 60, 1787-1793	28
1002	Improving diagnostic accuracy of multiple system atrophy: a clinicopathological study. 2019, 142, 2813-2827	60
1001	Traumatic Brain Injury and Risk of Long-Term Brain Changes, Accumulation of Pathological Markers, and Developing Dementia: A Review. 2019, 70, 629-654	34
1000	Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force. 2019, 6, 157-163	39
999	Sex differences in the genetic predictors of Alzheimer's pathology. 2019, 142, 2581-2589	32
998	Integrating Gene and Protein Expression Reveals Perturbed Functional Networks in Alzheimer's Disease. 2019, 28, 1103-1116.e4	34
997	Ozone Inhibits APP/A β Production and Improves Cognition in an APP/PS1 Transgenic Mouse Model. 2019, 418, 110-121	2
996	Tauopathy in basal ganglia involvement is exacerbated in a subset of patients with Alzheimer's disease: The Hisayama study. 2019, 11, 415-423	8
995	Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease. 2019, 93, e476-e484	15
994	Evaluation of Associations of Alzheimer's Disease Risk Variants that Are Highly Expressed in Microglia with Neuropathological Outcome Measures. 2019, 70, 659-666	5
993	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467	1.2 11
992	Lower nucleus accumbens β -synuclein load and D3 receptor levels in Parkinson's disease with impulsive compulsive behaviours. 2019, 142, 3580-3591	6
991	Electroacupuncture Improves Synaptic Function in SAMP8 Mice Probably via Inhibition of the AMPK/eEF2K/eEF2 Signaling Pathway. 2019, 2019, 8260815	8
990	Brain Amyloid- β Deposition and Blood Biomarkers in Patients with Clinically Diagnosed Alzheimer's Disease. 2019, 69, 169-178	15
989	[F]-AV-1451 binding profile in chronic traumatic encephalopathy: a postmortem case series. 2019, 7, 164	13
988	Microglial motility in Alzheimer's disease and after A β 2 immunotherapy: a human post-mortem study. 2019, 7, 174	18

987	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimer's disease. 2019 , 9, 15758		8
986	Association of Genetic Variants With Primary Open-Angle Glaucoma Among Individuals With African Ancestry. 2019 , 322, 1682-1691		31
985	Tau and Amyloid- β Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk. 2019 , 72, 641-652		2
984	A β Seeding as a Tool to Study Cerebral Amyloidosis and Associated Pathology. 2019 , 12, 233		16
983	"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia". <i>Alzheimer's and Dementia</i> , 2019 , 15, 153-157	1.2	15
982	Biomarker-Based Signature of Alzheimer's Disease in Pre-MCI Individuals. 2019 , 9,		8
981	Unique β -synuclein pathology within the amygdala in Lewy body dementia: implications for disease initiation and progression. 2019 , 7, 142		22
980	In vivo measures of tau burden are associated with atrophy in early Braak stage medial temporal lobe regions in amyloid-negative individuals. <i>Alzheimer's and Dementia</i> , 2019 , 15, 1286-1295	1.2	13
979	The bivariate distribution of amyloid- β and tau: relationship with established neurocognitive clinical syndromes. 2019 , 142, 3230-3242		77
978	Cholinergic muscarinic M and M receptors as therapeutic targets for cognitive, behavioural, and psychological symptoms in psychiatric and neurological disorders. 2019 , 24, 2307-2314		24
977	Cross species application of quantitative neuropathology assays developed for clinical Alzheimer's disease samples. 2019 , 9, 1657768		1
976	Perspective: Clinical relevance of the dichotomous classification of Alzheimer's disease biomarkers: Should there be a "gray zone"? <i>Alzheimer's and Dementia</i> , 2019 , 15, 1348-1356	1.2	17
975	Comorbidity of age-related macular degeneration with Alzheimer's disease: A histopathologic case-control study. 2019 , 14, e0223199		2
974	Social Aspects of Dementia Prevention from a Worldwide to National Perspective: A Review on the International Situation and the Example of Italy. 2019 , 2019, 8720904		12
973	Higher CSF Tau Levels Are Related to Hippocampal Hyperactivity and Object Mnemonic Discrimination in Older Adults. 2019 , 39, 8788-8797		29
972	Novel cogrinding of donepezil with neurotransmitters and coumarins: characterization, physical properties and in vitro drug release study. 2019 , 17, 1887-1897		2
971	CH(II), a cerebroprotein hydrolysate, exhibits potential neuro-protective effect on Alzheimer's disease. 2019 , 14, e0222757		3
970	ApoE attenuates unresolvable inflammation by complex formation with activated C1q. 2019 , 25, 496-506		107

969	The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. 2019 , 103, 263-293	120
968	FDG-PET patterns associated with underlying pathology in corticobasal syndrome. 2019 , 92, e1121-e1135	41
967	Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study. 2019 , 11, 11	18
966	Is there a specific memory signature associated with AβPET positivity in patients with amnesic mild cognitive impairment?. 2019 , 77, 94-103	7
965	F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. 2019 , 11, 13	70
964	Amyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer's Disease. 2019 , 8,	133
963	A longitudinal model for tau aggregation in Alzheimer's disease based on structural connectivity. 2019 , 11492, 384-393	5
962	Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease. 2019 , 130, 104511	26
961	Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. 2019 , 321, 2316-2325	115
960	Lewy pathology in Parkinson's disease consists of crowded organelles and lipid membranes. 2019 , 22, 1099-1109	323
959	Brains of rhesus monkeys display Aβ deposits and glial pathology while lacking Aβ dimers and other Alzheimer's pathologies. 2019 , 18, e12978	10
958	Resistance and resilience to Alzheimer's disease pathology are associated with reduced cortical pTau and absence of limbic-predominant age-related TDP-43 encephalopathy in a community-based cohort. 2019 , 7, 91	30
957	Subthreshold amyloid and its biological and clinical meaning: Long way ahead. 2019 , 93, 72-79	27
956	Q Virus-like particle-based vaccine induces robust immunity and protects against tauopathy. 2019 , 4, 26	22
955	Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer's Disease. 2019 , 69, 953-961	16
954	Dysregulation of BDNF in Prefrontal Cortex in Alzheimer's Disease. 2019 , 69, 1089-1097	11
953	Increased Tau Phosphorylation in Motor Neurons From Clinically Pure Sporadic Amyotrophic Lateral Sclerosis Patients. 2019 , 78, 605-614	7
952	Alzheimer's disease neuropathological change and loss of matrix/neuropil in patients with idiopathic Normal Pressure Hydrocephalus, a model of Alzheimer's disease. 2019 , 7, 98	8

951	Associations of regional amyloid- β plaque and phospho-tau pathology with biological factors and neuropsychological functioning among HIV-infected adults. 2019 , 25, 741-753		9
950	Different microvascular alterations underlie microbleeds and microinfarcts. 2019 , 86, 279-292		27
949	Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease: A Longitudinal Study. 2019 , 76, 915-924		277
948	Persistent neuropathological effects 14 years following amyloid- β immunization in Alzheimer's disease. 2019 , 142, 2113-2126		74
947	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 927-939	1.2	30
946	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. 2019 , 138, 389-399		55
945	Apathy and Disinhibition Related to Neuropathology in Amnesic Versus Behavioral Dementias. 2019 , 34, 337-343		4
944	The standardization of cerebrospinal fluid markers and neuropathological diagnoses brings to light the frequent complexity of concomitant pathology in Alzheimer's disease: The next challenge for biochemical markers?. 2019 , 72, 15-23		3
943	Proteomic signatures of brain regions affected by tau pathology in early and late stages of Alzheimer's disease. 2019 , 130, 104509		25
942	The Full Spectrum of Alzheimer's Disease Is Rooted in Metabolic Derangements That Drive Type 3 Diabetes. 2019 , 1128, 45-83		21
941	Factors that predict diagnostic stability in neurodegenerative dementia. 2019 , 266, 1998-2009		7
940	Comparison of F-florbetaben quantification results using the standard Centiloid, MR-based, and MR-less CapAIBL approaches: Validation against histopathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 807-816	1.2	26
939	Early neuronal accumulation of DNA double strand breaks in Alzheimer's disease. 2019 , 7, 77		68
938	Depression in Alzheimer's Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?. 2019 , 69, 651-661		20
937	Biomarker profiles of Alzheimer's disease and dynamic of the association between cerebrospinal fluid levels of β amyloid peptide and tau. 2019 , 14, e0217026		12
936	Interpretable classification of Alzheimer's disease pathologies with a convolutional neural network pipeline. 2019 , 10, 2173		53
935	A novel patch-based procedure for estimating brain age across adulthood. 2019 , 197, 618-624		13
934	Mesenchymal Stromal Cell Therapies for Neurodegenerative Diseases. 2019 , 94, 892-905		53

933	Mild Cognitive Impairment with a High Risk of Progression to Alzheimer's Disease Dementia (MCI-HR-AD): Effect of Souvenaid Treatment on Cognition and F-FDG PET Scans. 2019 , 3, 95-102	5
932	A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia. 2019 , 142, 1723-1735	82
931	An update on the interactions between Alzheimer's disease, autophagy and inflammation. 2019 , 705, 157-166	38
930	Association of Cortical β Amyloid Protein in the Absence of Insoluble Deposits With Alzheimer Disease. 2019 , 76, 818-826	17
929	Longitudinal tau-PET uptake and atrophy in atypical Alzheimer's disease. 2019 , 23, 101823	27
928	A brief history of "Alzheimer disease": Multiple meanings separated by a common name. 2019 , 92, 1053-1059	22
927	Proteomic Profiles of the Early Mitochondrial Changes in APP/PS1 and ApoE4 Transgenic Mice Models of Alzheimer's Disease. 2019 , 18, 2632-2642	11
926	Photo-oxygenation inhibits tau amyloid formation. 2019 , 55, 6165-6168	12
925	Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer's disease. 2019 , 6, 723-738	19
924	Alternative splicing in a presenilin 2 variant associated with Alzheimer disease. 2019 , 6, 762-777	15
923	Deep undepleted human serum proteome profiling toward biomarker discovery for Alzheimer's disease. 2019 , 16, 16	60
922	Ophthalmology-Based Neuropathology Risk Factors: Diabetic Retinopathy is Associated with Deep Microinfarcts in a Community-Based Autopsy Study. 2019 , 68, 647-655	5
921	Neurodegenerative Diseases and Ageing. 2019 , 91, 75-106	5
920	Potential Diagnostic Value of Red Blood Cells β Synuclein Heteroaggregates in Alzheimer's Disease. 2019 , 56, 6451-6459	13
919	Molecular Basis of Alzheimer's Disease: Focus on Mitochondria. 2019 , 72, S95-S116	47
918	Cognitive Resilience to Alzheimer's Disease Pathology in the Human Brain. 2019 , 68, 1071-1083	17
917	The role of gut microbiota in pathogenesis of Alzheimer's disease. 2019 , 127, 954-967	78
916	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. 2019 , 22, 101698	9

915	Loss of DPP6 in neurodegenerative dementia: a genetic player in the dysfunction of neuronal excitability. 2019 , 137, 901-918		21
914	Small molecules as therapeutic drugs for Alzheimer's disease. 2019 , 96, 47-62		67
913	The Neuropathological and Clinical Diagnostic Criteria of Chronic Traumatic Encephalopathy: A Critical Examination in Relation to Other Neurodegenerative Diseases. 2019 , 68, 591-608		6
912	Tobacco Smoking and Dementia in a Kentucky Cohort: A Competing Risk Analysis. 2019 , 68, 625-633		7
911	Multi-site dynamic recording for A β oligomers-induced Alzheimer's disease in vitro based on neuronal network chip. 2019 , 133, 183-191		11
910	Understanding the Amyloid Hypothesis in Alzheimer's Disease. 2019 , 68, 493-510		33
909	A cortical microvascular structure in vascular dementia, Alzheimer's disease, frontotemporal lobar degeneration and nondemented controls: a sign of angiogenesis due to brain ischaemia?. 2019 , 45, 557-569		7
908	Greater Regional Cortical Thickness is Associated with Selective Vulnerability to Atrophy in Alzheimer's Disease, Independent of Amyloid Load and APOE Genotype. 2019 , 69, 145-156		3
907	Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. 2019 , 321, 1258-1260		4
906	Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. 2019 , 321, 1286-1294		223
905	Novel methods for integration and visualization of genomics and genetics data in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 788-798	1.2	13
904	Physical Activity Alleviates Cognitive Dysfunction of Alzheimer's Disease through Regulating the mTOR Signaling Pathway. 2019 , 20,		24
903	The de-Alzheimerization of age-related dementias: implications for drug targets and approaches to effective therapeutics. 2019 , 44, 62-75		6
902	Why Outcomes Vary. 2019 , 285-382		
901	Late Effects. 2019 , 496-554		
900	Assessment of APOE in atypical parkinsonism syndromes. 2019 , 127, 142-146		10
899	Connectome-wide network analysis of white matter connectivity in Alzheimer's disease. 2019 , 22, 101690		9
898	HSP90 and Its Novel Co-Chaperones, SGT1 and CHP-1, in Brain of Patients with Parkinson's Disease and Dementia with Lewy Bodies. 2019 , 9, 97-107		9

897	Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease. 2019 , 11, 18	23
896	Qualitative Comparison of Semantic Memory Impairment in Patients with Amnesic Mild Cognitive Impairment Based on β Amyloid Status. 2019 , 15, 27-37	1
895	Structural signature of sporadic Creutzfeldt-Jakob disease. 2019 , 26, 1037-1043	1
894	The relationship between the morphological subtypes of microglia and Alzheimer's disease neuropathology. 2019 , 29, 726-740	34
893	Neuropathological Diagnoses of Demented Hispanic, Black, and Non-Hispanic White Decedents Seen at an Alzheimer's Disease Center. 2019 , 68, 145-158	29
892	Correlations Between Single Nucleotide Polymorphisms, Cognitive Dysfunction, and Postmortem Brain Pathology in Alzheimer's Disease Among Han Chinese. 2019 , 35, 193-204	5
891	Entorhinal cortex tau, amyloid- β cortical thickness and memory performance in non-demented subjects. 2019 , 142, 1148-1160	49
890	Fact, Fiction, or Evolution: Mechanism Hypothesis of Alzheimer's Disease. 2019 ,	
889	Different aspects of Alzheimer's disease-related amyloid β peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia. 2019 , 7, 178	16
888	Alzheimer's disease. 2019 , 167, 231-255	128
887	Subregional Density of Neurons, Neurofibrillary Tangles and Amyloid Plaques in the Hippocampus of Patients With Alzheimer's Disease. 2019 , 13, 99	16
886	Anticholinesterase and Antioxidant Activities of Spilanthes filicaulis Whole Plant Extracts for the Management of Alzheimer's Disease. 2019 , 15, 103-113	0
885	Selective memory and behavioral alterations after ambient ultrafine particulate matter exposure in aged 3xTgAD Alzheimer's disease mice. 2019 , 16, 45	16
884	Circadian sleep/wake-associated cells show dipeptide repeat protein aggregates in C9orf72-related ALS and FTLT cases. 2019 , 7, 189	14
883	Strengths and Weaknesses of the Gray Mouse Lemur (<i>h</i>) as a Model for the Behavioral and Psychological Symptoms and Neuropsychiatric Symptoms of Dementia. 2019 , 10, 1291	5
882	Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer's disease. 2019 , 11, 111	14
881	Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimer's Disease. 2019 ,	2
880	Alzheimer's disease pathology explains association between dementia with Lewy bodies and APOE- ϵ /TOMM40 long poly-T repeat allele variants. 2019 , 5, 814-824	9

879	Neuropathological Findings of Dementia Associated With Subjective Hearing Loss. 2019 , 40, e883-e893		3
878	The amyloid- β degradation intermediate A β 4 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease. 2019 , 7, 194		9
877	Dreaming of a New World Where Alzheimer's Is a Treatable Disorder. 2019 , 11, 317		5
876	Risk of developing cerebral β amyloid plaques with posttranslational modification among HIV-infected adults. 2019 , 33, 2157-2166		4
875	Magnetic resonance imaging brain atrophy assessment in primary age-related tauopathy (PART). 2019 , 7, 204		17
874	Association of Longitudinal Changes in Cerebrospinal Fluid Total Tau and Phosphorylated Tau 181 and Brain Atrophy With Disease Progression in Patients With Alzheimer Disease. 2019 , 2, e1917126		15
873	Evidence for Decreased Nucleolar PARP-1 as an Early Marker of Cognitive Impairment. 2019 , 2019, 4383258		5
872	Motor deficits in 16-month-old male and female 3xTg-AD mice. 2019 , 356, 305-313		23
871	Spectrum of tau pathologies in Huntington's disease. 2019 , 99, 1068-1077		11
870	Neuroimaging markers of global cognition in early Alzheimer's disease: A magnetic resonance imaging-electroencephalography study. 2019 , 9, e01197		10
869	Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease. 2019 , 97, 3-17		51
868	Neuropathologic, genetic, and longitudinal cognitive profiles in primary age-related tauopathy (PART) and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2019 , 15, 8-16	1.2	46
867	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimer's and Dementia</i> , 2019 , 15, 292-312	1.2	155
866	Dementia with Lewy bodies - from scientific knowledge to clinical insights. 2019 , 15, 103-112		26
865	Tau impairs neural circuits, dominating amyloid- β effects, in Alzheimer models in vivo. 2019 , 22, 57-64		152
864	Increased Hyaluronan and TSG-6 in Association with Neuropathologic Changes of Alzheimer's Disease. 2019 , 67, 91-102		19
863	Neuroprotective effects of a <i>Rhodiola crenulata</i> extract on amyloid- β peptides (A β)-induced cognitive deficits in rat models of Alzheimer's disease. 2019 , 57, 331-338		17
862	Seeding selectivity and ultrasensitive detection of tau aggregate conformers of Alzheimer disease. 2019 , 137, 585-598		54

861	Crosstalk between mitochondrial dysfunction, oxidative stress, and age related neurodegenerative disease: Etiologies and therapeutic strategies. 2019 , 218, 165-184		128
860	Luminex-based quantification of Alzheimer's disease neuropathologic change in formalin-fixed post-mortem human brain tissue. 2019 , 99, 1056-1067		6
859	A nonhuman primate model of early Alzheimer's disease pathologic change: Implications for disease pathogenesis. <i>Alzheimer's and Dementia</i> , 2019 , 15, 93-105	1.2	44
858	Neuropsychological Deficit Profiles, Vascular Risk Factors, and Neuropathological Findings in Hispanic Older Adults with Autopsy-Confirmed Alzheimer's Disease. 2019 , 67, 291-302		7
857	Beyond the neuron-cellular interactions early in Alzheimer disease pathogenesis. 2019 , 20, 94-108		142
856	Multisite study of the relationships between antemortem [C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology. <i>Alzheimer's and Dementia</i> , 2019 , 15, 205-216	1.2	82
855	Neurotheranostics as personalized medicines. 2019 , 148, 252-289		36
854	Comparison of longitudinal Aβ in nondemented elderly and Down syndrome. 2019 , 73, 171-176		12
853	Coexistence of Multiple Sclerosis and Alzheimer's disease: A review. 2019 , 27, 232-238		15
852	Rare variants in the neuronal ceroid lipofuscinosis gene MFSD8 are candidate risk factors for frontotemporal dementia. 2019 , 137, 71-88		20
851	Biomarkers for tau pathology. 2019 , 97, 18-33		96
850	Pro-apoptotic effects of low doses of dimethoate in rat brain. 2019 , 363, 57-63		4
849	Elevated YKL-40 and low sAPPβ/YKL-40 ratio in antemortem cerebrospinal fluid of patients with pathologically confirmed FTLD. 2019 , 90, 180-186		15
848	Fluid-based proteomics targeted on pathophysiological processes and pathologies in neurodegenerative diseases. 2019 , 151, 417-434		10
847	The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer's disease. 2019 , 137, 89-102		47
846	Proteomics of neurodegenerative diseases: analysis of human post-mortem brain. 2019 , 151, 435-445		22
845	PET imaging of tau protein targets: a methodology perspective. 2019 , 13, 333-344		31
844	Prominent microglial activation in cortical white matter is selectively associated with cortical atrophy in primary progressive aphasia. 2019 , 45, 216-229		11

843	Association between contact sports participation and chronic traumatic encephalopathy: a retrospective cohort study. 2020 , 30, 63-74	38
842	Microstructural White Matter Alterations in Mild Cognitive Impairment and Alzheimer's Disease : Study Based on Neurite Orientation Dispersion and Density Imaging (NODDI). 2020 , 30, 569-579	21
841	Association of anxiety with subcortical amyloidosis in cognitively normal older adults. 2020 , 25, 2599-2607	14
840	Evidence of corticofugal tau spreading in patients with frontotemporal dementia. 2020 , 139, 27-43	14
839	Duration of American Football Play and Chronic Traumatic Encephalopathy. 2020 , 87, 116-131	70
838	The Molecular Misreading of APP and UBB Induces a Humoral Immune Response in Alzheimer's Disease Patients with Diagnostic Ability. 2020 , 57, 1009-1020	8
837	Neurofilament Light Chain as a Biomarker, and Correlation with Magnetic Resonance Imaging in Diagnosis of CNS-Related Disorders. 2020 , 57, 469-491	21
836	Advance of sporadic Alzheimer's disease animal models. 2020 , 40, 431-458	31
835	Neuropathologic basis of in vivo cortical atrophy in the aphasic variant of Alzheimer's disease. 2020 , 30, 332-344	5
834	Suboptimal validity of amyloid imaging-based diagnosis and management of Alzheimer's disease: why it is time to abandon the approach. 2020 , 47, 225-230	6
833	Interaction between tissue transglutaminase and amyloid-beta: Protein-protein binding versus enzymatic crosslinking. 2020 , 592, 113578	3
832	From the Entorhinal Region via the Prosubiculum to the Dentate Fascia: Alzheimer Disease-Related Neurofibrillary Changes in the Temporal Allocortex. 2020 , 79, 163-175	10
831	A third of community-dwelling elderly with intermediate and high level of Alzheimer's neuropathologic changes are not demented: A meta-analysis. 2020 , 58, 101002	7
830	Deep Multilayer Brain Proteomics Identifies Molecular Networks in Alzheimer's Disease Progression. 2020 , 105, 975-991.e7	111
829	Every-other-day feeding exacerbates inflammation and neuronal deficits in 5XFAD mouse model of Alzheimer's disease. 2020 , 136, 104745	9
828	Fluselenamyl: Evaluation of radiation dosimetry in mice and pharmacokinetics in brains of non-human primate. 2020 , 82-83, 33-40	
827	To stage, or not to stage. 2020 , 61, 10-22	14
826	Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET. 2020 , 12,	172

825	Binding of [F]AV1451 in post mortem brain slices of semantic variant primary progressive aphasia patients. 2020 , 47, 1949-1960		6
824	Early-Onset Dementia in War Veterans: Brain Polypathology and Clinicopathologic Complexity. 2020 , 79, 144-162		9
823	The search for a unique Raman signature of amyloid-beta plaques in human brain tissue from Alzheimer's disease patients. 2020 , 145, 1724-1736		13
822	Preclinical Alzheimer's disease: a valid concept. 2020 , 19, 31		7
821	Decrease in 18F-Florbetapir Accumulation in the Cerebral Hemisphere With Hypoperfusion and Misery Perfusion Due to Chronic Atherosclerotic Occlusion of the Internal Carotid Artery. 2020 , 45, e115-e116		
820	Brain imaging measurements of fibrillar amyloid- β burden, paired helical filament tau burden, and atrophy in cognitively unimpaired persons with two, one, and no copies of the APOE ϵ allele. <i>Alzheimer's and Dementia</i> , 2020 , 16, 598-609	1.2	10
819	Hyperphosphorylated Tau, Increased Adenylate Cyclase 5 (ADCY5) Immunoreactivity, but No Neuronal Loss in ADCY5-Dyskinesia. 2020 , 7, 70-77		3
818	Tau-positron emission tomography correlates with neuropathology findings. <i>Alzheimer's and Dementia</i> , 2020 , 16, 561-571	1.2	52
817	Necrosome complex detected in granulovacuolar degeneration is associated with neuronal loss in Alzheimer's disease. 2020 , 139, 463-484		38
816	β Amyloid PET and neuropathology in dementia with Lewy bodies. 2020 , 94, e282-e291		31
815	Dementia With Lewy Bodies: A Clinicopathologic Series of False-positive Cases. 2020 , 34, 178-182		2
814	The Potential Role of MicroRNA-124 in Cerebral Ischemia Injury. 2019 , 21,		27
813	Developing robust biomarkers for vascular cognitive disorders: adding 'V' to the AT(N) research framework. 2020 , 33, 148-155		2
812	The microvascular extracellular matrix in brains with Alzheimer's disease neuropathologic change (ADNC) and cerebral amyloid angiopathy (CAA). 2020 , 17, 60		7
811	Circular RNA Encoded Amyloid Beta peptides-A Novel Putative Player in Alzheimer's Disease. 2020 , 9,		11
810	Characterizing Clinical and Neuropathological Traits of APOE Haplotypes in African Americans and Europeans. 2020 , 78, 467-477		3
809	Comparison of Amyloid in Cerebrospinal Fluid, Brain Imaging, and Autopsy in a Case of Progressive Supranuclear Palsy. 2020 , 34, 275-277		0
808	One or more β amyloid(s)? New insights into the prion-like nature of Alzheimer's disease. 2020 , 175, 213-237		1

807	The complex relationship between genotype, pathology and phenotype in familial dementia. 2020 , 145, 105082	1
806	Predicting future rates of tau accumulation on PET. 2020 , 143, 3136-3150	25
805	Mixed Brain Pathology Is the Most Common Cause of Cognitive Impairment in the Elderly. 2020 , 78, 453-465	7
804	Cerebrovascular Senescence Is Associated With Tau Pathology in Alzheimer's Disease. 2020 , 11, 575953	15
803	Amyloid-beta peptide and phosphorylated tau in the frontopolar cerebral cortex and in the cerebellum of toothed whales: aging versus hypoxia. 2020 , 9,	3
802	Interleukin-17A: The Key Cytokine in Neurodegenerative Diseases. 2020 , 12, 566922	23
801	Galantamine-Memantine combination in the treatment of Alzheimer's disease and beyond. 2020 , 293, 113409	18
800	Hypertension and Alzheimer's disease: indirect effects through circle of Willis atherosclerosis. 2020 , 2, fcaa114	2
799	The combined effect of amyloid- β and tau biomarkers on brain atrophy in dementia with Lewy bodies. 2020 , 27, 102333	9
798	Relationship between β amyloid and structural network topology in decedents without dementia. 2020 , 95, e532-e544	3
797	The Function of Transthyretin Complexes with Metallothionein in Alzheimer's Disease. 2020 , 21,	8
796	Sporadic Creutzfeldt-Jakob Disease and Other Proteinopathies in Comorbidity. 2020 , 11, 596108	0
795	Nanobiosensors for Non-Amyloidbeta-Tau Biomarkers as Advanced Reporters of Alzheimer's Disease. 2020 , 10,	
794	Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference?. 2020 , 6, e512	24
793	A/T/(N) Profile in Cerebrospinal Fluid of Parkinson's Disease with/without Cognitive Impairment and Dementia with Lewy Bodies. 2020 , 10,	4
792	Relationship of amyloid beta and neurofibrillary tau deposition in Neurodegeneration in Aging Down Syndrome (NIAD) study at baseline. 2020 , 6, e12096	7
791	Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia. 2020 , 172, 669-677	17
790	Cerebral Amyloid Angiopathy Presenting as Massive Subarachnoid Haemorrhage: A Case Study and Review of Literature. 2020 , 12, 538456	1

789	Defining and predicting transdiagnostic categories of neurodegenerative disease. 2020 , 4, 787-800	8
788	Limbic-predominant age-related TDP-43 encephalopathy, ADNC pathology, and cognitive decline in aging. 2020 , 95, e1951-e1962	6
787	The Alzheimer's Biomarker Consortium-Down Syndrome: Rationale and methodology. 2020 , 12, e12065	21
786	Alzheimer's disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study. 2021 , 15, 1355-1363	2
785	Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. 2020 , 61, 1413-1418	6
784	Does amnesia specifically predict Alzheimer's pathology? A neuropathological study. 2020 , 95, 123-130	9
783	Quantitative immunohistochemical analysis of myeloid cell marker expression in human cortex captures microglia heterogeneity with anatomical context. 2020 , 10, 11693	11
782	3D Mapping of TAU Neurofibrillary Tangle Pathology in the Human Medial Temporal Lobe. 2020 ,	2
781	Cause of death in autopsy-confirmed dementia disorders. 2020 , 27, 2415-2421	6
780	Aging and Progression of Beta-Amyloid Pathology in Alzheimer's Disease Correlates with Microglial Heme-Oxygenase-1 Overexpression. 2020 , 9,	7
779	The Neuropathological Diagnosis of Alzheimer's Disease-The Challenges of Pathological Mimics and Concomitant Pathology. 2020 , 10,	12
778	Hippocampal sclerosis, TDP-43, and the duration of the symptoms of dementia of AD patients. 2020 , 7, 1546-1556	2
777	Microglia facilitate loss of perineuronal nets in the Alzheimer's disease brain. 2020 , 58, 102919	49
776	Neuropathological assessment of the Alzheimer spectrum. 2020 , 127, 1229-1256	13
775	Building an Ex Vivo Atlas of the Earliest Brain Regions Affected by Alzheimer's Disease Pathology. 2020 ,	3
774	Circulating ethanolamine plasmalogen indices in Alzheimer's disease: Relation to diagnosis, cognition, and CSF tau. <i>Alzheimer's and Dementia</i> , 2020 , 16, 1234-1247	1.2 8
773	A novel SNCA E83Q mutation in a case of dementia with Lewy bodies and atypical frontotemporal lobar degeneration. 2020 , 40, 620-626	6
772	Association of tau accumulation and atrophy in mild cognitive impairment: a longitudinal study. 2020 , 34, 815-823	4

771	Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome. 2020 , 12, e12113	9
770	Concomitant LATE-NC in Alzheimer's disease is not associated with increased tau or amyloid- β pathological burden. 2020 , 46, 722-734	2
769	Relationship Between PET-Assessed Amyloid Burden and Visual and Verbal Episodic Memory Performance in Elderly Subjects. 2020 , 78, 229-244	4
768	Small RNA modifications in Alzheimer's disease. 2020 , 145, 105058	16
767	Cerebrospinal fluid sTREM2 in Alzheimer's disease: comparisons between clinical presentation and AT classification. 2020 , 10, 15886	9
766	Neuroimaging in dementias. 2020 , 187-197	
765	Denser brain capillary network with preserved pericytes in Alzheimer's disease. 2020 , 30, 1071-1086	8
764	Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration. 2020 , 88, 1009-1022	9
763	Hippocampal alterations in glutamatergic signaling during amyloid progression in APP/PS1 mice. 2020 , 10, 14503	5
762	Predicting Thioflavin Fluorescence of Retinal Amyloid Deposits Associated With Alzheimer's Disease From Their Polarimetric Properties. 2020 , 9, 47	6
761	Association of TDP-43 proteinopathy, cerebral amyloid angiopathy, and Lewy bodies with cognitive impairment in individuals with or without Alzheimer's disease neuropathology. 2020 , 10, 14579	9
760	Association of probable REM sleep behavior disorder with pathology and years of contact sports play in chronic traumatic encephalopathy. 2020 , 140, 851-862	4
759	Antihypertensive medications ameliorate Alzheimer's disease pathology by slowing its propagation. 2020 , 6, e12060	2
758	Clinician-judged hearing impairment and associations with neuropathologic burden. 2020 , 95, e1640-e1649	7
757	Brain Tau Imaging: Food and Drug Administration Approval of F-Flortaucipir Injection. 2020 , 61, 1411-1412	7
756	Classification and Graphical Analysis of Alzheimer's Disease and Its Prodromal Stage Using Multimodal Features From Structural, Diffusion, and Functional Neuroimaging Data and the APOE Genotype. 2020 , 12, 238	6
755	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. 2020 , 10,	10
754	Neuropathological correlates of cortical superficial siderosis in cerebral amyloid angiopathy. 2020 , 143, 3343-3351	17

753	Amyloid- β cerebrospinal fluid levels and the interpretation of APP, PSEN1 and PSEN2 mutations. 2020 , 12, 108		9
752	Assessment of genetic risk for improved clinical-neuropathological correlations. 2020 , 8, 160		
751	Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid- β plaques in Alzheimer's disease. 2020 , 140, 463-476		17
750	Degeneration of the locus coeruleus is a common feature of tauopathies and distinct from TDP-43 proteinopathies in the frontotemporal lobar degeneration spectrum. 2020 , 140, 675-693		5
749	Tau reduction in aged mice does not impact Microangiopathy. 2020 , 8, 137		1
748	Dementia-related psychosis and the potential role for pimavanserin. 2020 , 1-9		2
747	Glial activation is moderated by sex in response to amyloidosis but not to tau pathology in mouse models of neurodegenerative diseases. 2020 , 17, 374		10
746	Distinct effects of beta-amyloid and tau on cortical thickness in cognitively healthy older adults. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1085-1096	1.2	8
745	The Significance of Tau Aggregates in the Human Brain. 2020 , 10,		6
744	A high cerebrospinal fluid soluble TREM2 level is associated with slow clinical progression of Alzheimer's disease. 2020 , 12, e12128		6
743	Differentiating Mild Cognitive Impairment, Alzheimer's Disease, and Dementia With Lewy Bodies Using Cingulate Island Sign on Perfusion IMP-SPECT. 2020 , 11, 568438		0
742	Neuropsychiatric symptoms in limbic-predominant age-related TDP-43 encephalopathy and Alzheimer's disease. 2020 , 143, 3842-3849		6
741	Chronic Sodium Selenate Treatment Restores Deficits in Cognition and Synaptic Plasticity in a Murine Model of Tauopathy. 2020 , 13, 570223		6
740	Association of Neighborhood-Level Disadvantage With Alzheimer Disease Neuropathology. 2020 , 3, e207559		29
739	Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy. 2020 , 143, 3463-3476		13
738	Cell-to-Cell Transmission of Tau and β Synuclein. 2020 , 26, 936-952		39
737	Evolution of the Research Literature and the Scientific Community of Alzheimer's Disease from 1983-2017: A 35-Year Survey. 2020 , 75, 1105-1134		1
736	Plasma pyroglutamate-modified amyloid beta differentiates amyloid pathology. 2020 , 12, e12029		7

735	Aggregates of RNA Binding Proteins and ER Chaperones Linked to Exosomes in Granulovacuolar Degeneration of the Alzheimer's Disease Brain. 2020 , 75, 139-156	10
734	Change in Expression of 5-HT ₆ Receptor at Different Stages of Alzheimer's Disease: A Postmortem Study with the PET Radiopharmaceutical [¹⁸ F]2FNQ1P. 2020 , 75, 1329-1338	1
733	Network Pharmacology Study of Heat-Clearing and Detoxifying Traditional Chinese Medicine for Alzheimer's Disease. 2020 , 2020, 7831675	1
732	Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer's disease. 2020 , 15, 28	11
731	The Alzheimer Disease-Causing Presenilin-1 L435F Mutation Causes Increased Production of Soluble A β 3 Species in Patient-Derived iPSC-Neurons, Closely Mimicking Matched Patient Brain Tissue. 2020 , 79, 592-604	5
730	Hippocampal β -synuclein pathology correlates with memory impairment in multiple system atrophy. 2020 , 143, 1798-1810	15
729	Extracellular Sortilin Proteopathy Relative to β Amyloid and Tau in Aged and Alzheimer's Disease Human Brains. 2020 , 12, 93	3
728	Positron Emission Tomography Imaging With [¹⁸ F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. 2020 , 77, 829-839	105
727	On the horizon-the value and promise of the global pipeline of Alzheimer's disease therapeutics. 2020 , 6, e12009	8
726	Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. 2020 , 12,	79
725	Looking for a Treatment for the Early Stage of Alzheimer's Disease: Preclinical Evidence with Co-Ultramicronized Palmitoylethanolamide and Luteolin. 2020 , 21,	9
724	A TOMM40/APOE allele encoding APOE-E3 predicts high likelihood of late-onset Alzheimer's disease in autopsy cases. 2020 , 8, e1317	4
723	Progressive dysexecutive syndrome due to Alzheimer's disease: a description of 55 cases and comparison to other phenotypes. 2020 , 2, fcaa068	36
722	Utility of FDG-PET in diagnosis of Alzheimer-related TDP-43 proteinopathy. 2020 , 95, e23-e34	11
721	Tau molecular diversity contributes to clinical heterogeneity in Alzheimer's disease. 2020 , 26, 1256-1263	123
720	Evolution of neuronal and glial tau isoforms in chronic traumatic encephalopathy. 2020 , 30, 913-925	15
719	Blood Biomarkers of Cognitive Health and Neurodegenerative Disease. 2020 , 568-586	
718	The presubiculum links incipient amyloid and tau pathology to memory function in older persons. 2020 , 94, e1916-e1928	8

717	Synaptic Loss, ER Stress and Neuro-Inflammation Emerge Late in the Lateral Temporal Cortex and Associate with Progressive Tau Pathology in Alzheimer's Disease. 2020 , 57, 3258-3272	14
716	Senescence as an Amyloid Cascade: The Amyloid Senescence Hypothesis. 2020 , 14, 129	18
715	Nicotine-induced upregulation of miR-132-5p enhances cell survival in PC12 cells by targeting the anti-apoptotic protein Bcl-2. 2020 , 42, 405-414	5
714	Clinicopathological findings of a long-term survivor of V180I genetic Creutzfeldt-Jakob disease. 2020 , 14, 109-117	8
713	Cognitive deficit, and neuropathological correlates, in the oldest-old. 2020 , 176, 670-676	5
712	Alzheimer-related genes show accelerated evolution. 2020 ,	1
711	The clinical promise of biomarkers of synapse damage or loss in Alzheimer's disease. 2020 , 12, 21	69
710	Epidemiology of neurological diseases in older adults. 2020 , 176, 642-648	15
709	The effect of ApoE ϵ 4 on clinical and structural MRI markers in prodromal Alzheimer's disease. 2020 , 10, 464-474	9
708	Confirmation of I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders. 2020 , 61, 1628-1635	7
707	A Clinicopathological Report of a 93-Year-Old Former Street Boxer With Coexistence of Chronic Traumatic Encephalopathy, Alzheimer's Disease, Dementia With Lewy Bodies, and Hippocampal Sclerosis With TDP-43 Pathology. 2020 , 11, 42	4
706	Diffeomorphic Registration With Intensity Transformation and Missing Data: Application to 3D Digital Pathology of Alzheimer's Disease. 2020 , 14, 52	12
705	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's disease. 2020 , 12, 22	39
704	Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. 2020 , 156, 214-235	98
703	Fyn kinase inhibition reduces protein aggregation, increases synapse density and improves memory in transgenic and traumatic Tauopathy. 2020 , 8, 96	11
702	Evaluation of F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration in rodents and in human tissue. 2020 , 10, 7938-7955	3
701	Invited Review - Understanding cause and effect in Alzheimer's pathophysiology: Implications for clinical trials. 2020 , 46, 623-640	12
700	F-fluorodeoxyglucose positron emission tomography in dementia with Lewy bodies. 2020 , 2, fcaa040	3

699	Identification of Conserved Proteomic Networks in Neurodegenerative Dementia. 2020 , 31, 107807	21
698	The Utility of the National Alzheimer's Coordinating Center's Database for the Rapid Assessment of Evolving Neuropathologic Conditions. 2020 , 34, 105-111	6
697	mutations reduce T-synthase activity in advanced Alzheimer's disease. 2020 , 6, e12040	1
696	Amyloid-beta (1-42) lesion of CA1 rat dorsal hippocampus reduces contextual fear memory and increases expression of microglial genes regulating neuroinflammation. 2020 , 393, 112795	5
695	Chronic traumatic encephalopathy in a former Australian rules football player diagnosed with Alzheimer's disease. 2020 , 8, 23	8
694	Histopathology of diffusion-weighted imaging-positive lesions in cerebral amyloid angiopathy. 2020 , 139, 799-812	10
693	Altered Waste Disposal System in Aging and Alzheimer's Disease: Focus on Astrocytic Aquaporin-4. 2019 , 10, 1656	31
692	is a correlate of phenotypic heterogeneity in Alzheimer disease in a national cohort. 2020 , 94, e607-e612	13
691	Alzheimer's disease pathology in APOE transgenic mouse models: The Who, What, When, Where, Why, and How. 2020 , 139, 104811	21
690	Generation and Characterization of Novel Monoclonal Antibodies Targeting p62/sequestosome-1 Across Human Neurodegenerative Diseases. 2020 , 79, 407-418	4
689	Fabry Disease With Concomitant Lewy Body Disease. 2020 , 79, 378-392	10
688	Risk factors for earlier dementia onset in autopsy-confirmed Alzheimer's disease, mixed Alzheimer's with Lewy bodies, and pure Lewy body disease. <i>Alzheimer's and Dementia</i> , 2020 , 16, 524-530 ^{1,2}	2
687	OCIAD1 contributes to neurodegeneration in Alzheimer's disease by inducing mitochondria dysfunction, neuronal vulnerability and synaptic damages. 2020 , 51, 102569	5
686	Correlative x-ray phase-contrast tomography and histology of human brain tissue affected by Alzheimer's disease. 2020 , 210, 116523	18
685	Microglial autophagy is impaired by prolonged exposure to amyloid peptides: evidence from experimental models and Alzheimer's disease patients. 2020 , 42, 613-632	26
684	Identifying Morphological Patterns of Hippocampal Atrophy in Patients With Mesial Temporal Lobe Epilepsy and Alzheimer Disease. 2020 , 11, 21	8
683	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. 2020 , 139, 717-734	8
682	Effect Modifiers of TDP-43-Associated Hippocampal Atrophy Rates in Patients with Alzheimer's Disease Neuropathological Changes. 2020 , 73, 1511-1523	5

681	TDP-43 is associated with a reduced likelihood of rendering a clinical diagnosis of dementia with Lewy bodies in autopsy-confirmed cases of transitional/diffuse Lewy body disease. 2020 , 267, 1444-1453	1
680	Renin-Angiotensin System and Alzheimer's Disease Pathophysiology: From the Potential Interactions to Therapeutic Perspectives. 2020 , 27, 484-511	10
679	Alzheimer Disease, Biomarkers, and Clinical Symptoms-Quo Vadis?-Reply. 2020 , 77, 394	3
678	Imaging Tau Pathology-The Next Step. 2020 , 77, 796-797	3
677	Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. 2020 , 8, 61	26
676	Clinical and neuropsychological profile of patients with dementia and chronic traumatic encephalopathy. 2020 , 91, 586-592	5
675	MRI and flortaucipir relationships in Alzheimer's phenotypes are heterogeneous. 2020 , 7, 707-721	6
674	Utility of spontaneous animal models of Alzheimer's disease in preclinical efficacy studies. 2020 , 380, 273-286	4
673	Generating Cell Type-Specific Protein Signatures from Non-symptomatic and Diseased Tissues. 2020 , 48, 2218-2232	0
672	Mitochondrial biogenesis as a therapeutic target for traumatic and neurodegenerative CNS diseases. 2020 , 329, 113309	17
671	Association between transactive response DNA-binding protein of 43 kDa type and cognitive resilience to Alzheimer's disease: a case-control study. 2020 , 92, 92-97	4
670	New fluid biomarkers tracking non-amyloid- β and non-tau pathology in Alzheimer's disease. 2020 , 52, 556-568	34
669	Association between retinal thickness and β amyloid brain accumulation in individuals with subjective cognitive decline: FundaciACE Healthy Brain Initiative. 2020 , 12, 37	9
668	Diversity in A β deposit morphology and secondary proteome insolubility across models of Alzheimer-type amyloidosis. 2020 , 8, 43	6
667	A Practical Guide to the Automated Analysis of Vascular Growth, Maturation and Injury in the Brain. 2020 , 14, 244	9
666	Increased glutaminyl cyclase activity in brains of Alzheimer's disease individuals. 2021 , 156, 979-987	2
665	Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging. 2021 , 26, 309-321	19
664	β Amyloid may accumulate in the human brain after focal bacterial infection: An F-flutemetamol positron emission tomography study. 2021 , 28, 877-883	1

663	Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes. 2021 , 62, 855-860	1
662	Accumulation of neurofibrillary tangles and activated microglia is associated with lower neuron densities in the aphasic variant of Alzheimer's disease. 2021 , 31, 189-204	12
661	Contribution of homozygous and compound heterozygous missense mutations in VWA2 to Alzheimer's disease. 2021 , 99, 100.e17-100.e23	1
660	Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. 2021 , 144, 325-339	42
659	Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia Phenotype. 2021 , 89, 520-533	6
658	Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases. 2021 , 76, 121-126	
657	Diagnostic Accuracy of Amyloid versus F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia. 2021 , 89, 389-401	7
656	Dysbiosis is one of the risk factor for stroke and cognitive impairment and potential target for treatment. 2021 , 164, 105277	15
655	Cognitive Impairment in Older Adults and Therapeutic Strategies. 2021 , 73, 152-162	8
654	Alzheimer's Disease Neuropathological Comorbidities are Common in the Younger-Old. 2021 , 79, 389-400	10
653	The value of multimodal imaging with I-FP-CIT SPECT in differential diagnosis of dementia with Lewy bodies and Alzheimer's disease dementia. 2021 , 99, 11-18	1
652	Ascorbate deficiency decreases dopamine release in gulo and APP/PSEN1 mice. 2021 , 157, 656-665	6
651	Alzheimer's disease neuropathology in the hippocampus and brainstem of people with obstructive sleep apnea. 2021 , 44,	10
650	Different Morphology of Neuritic Plaques in the Archicortex of Alzheimer's Disease with Comorbid Synucleinopathy: A Pilot Study. 2020 , 17, 948-958	1
649	Assessing visuo-constructive functions in patients with subjective cognitive decline, mild cognitive impairment and Alzheimer's disease with the Vienna Visuo-Constructional Test 3.0 (VVT 3.0). 2021 , 35, 147-155	1
648	Proposed research criteria for prodromal behavioural variant frontotemporal dementia.. 2022 ,	1
647	Psychological assessment of neurocognitive disorders. 2021 , 251-262	
646	Liraglutide Has Anti-Inflammatory and Anti-Amyloid Properties in Streptozotocin-Induced and 5xFAD Mouse Models of Alzheimer's Disease. 2021 , 22,	7

645	Amyloid-PET-Positive Patient With bvFTD: Wrong Diagnosis, False Positive Scan, or Copathology?. 2021 , 11, e952-e955	1
644	Effect of Shortening the Scan Duration on Quantitative Accuracy of [F]Flortaucipir Studies. 2021 , 23, 604-613	2
643	Dysbiosis and Alzheimer's Disease: Cause or Treatment Opportunity?. 2021 , 1	8
642	Lipidomic Analysis of Postmortem Prefrontal Cortex Phospholipids Reveals Changes in 'Choline Plasmalogen Containing Docosahexaenoic Acid' and Stearic Acid Between Cases With and Without Alzheimer's Disease. 2021 , 23, 161-175	5
641	Tau Pathologies Mediate the Associations of Vascular Risk Burden with Cognitive Impairments in Non-demented Elders: The CABLE Study.. 2022 , 9, 136-143	0
640	Alterations and interactions of subcortical modulatory systems in Alzheimer's disease. 2021 , 261, 379-421	4
639	Tauvid—The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease. 2021 , 14,	8
638	Amyloid in the ageing brain: New frameworks and perspectives. 2021 , 1, 100008	0
637	Molecular characterization of selectively vulnerable neurons in Alzheimer's disease. 2021 , 24, 276-287	64
636	Colorimetric metasurfaces shed light on fibrous biological tissue. 2021 , 9, 11619-11639	0
635	Memory Resilience in Alzheimer Disease With Primary Progressive Aphasia. 2021 , 96, e916-e925	4
634	Reduced [F]flortaucipir retention in white matter hyperintensities compared to normal-appearing white matter. 2021 , 48, 2283-2294	2
633	Modular machine learning for Alzheimer's disease classification from retinal vasculature. 2021 , 11, 238	19
632	Seeding Propensity and Characteristics of Pathogenic β yn Assemblies in Formalin-Fixed Human Tissue from the Enteric Nervous System, Olfactory Bulb, and Brainstem in Cases Staged for Parkinson's Disease. 2021 , 10,	5
631	Allele-specific expression of Parkinson's disease susceptibility genes in human brain. 2021 , 11, 504	4
630	Chinese nutraceuticals and physical activity; their role in neurodegenerative tauopathies. 2021 , 16, 1	9
629	Iron-loading is a prominent feature of activated microglia in Alzheimer's disease patients.	
628	Fine Particulate Matter and Markers of Alzheimer's Disease Neuropathology at Autopsy in a Community-Based Cohort. 2021 , 79, 1761-1773	2

627	Heterogeneity in Synuclein fibril activity correlates to disease phenotypes in Lewy body dementia. 2021 , 141, 547-564	9
626	Neuroigin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. 2021 , 9, 19	8
625	Ecto-GPR37: a potential biomarker for Parkinson's disease. 2021 , 10, 8	3
624	Hippocampal transcriptome-wide association study and neurobiological pathway analysis for Alzheimer's disease. 2021 , 17, e1009363	5
623	Vascular Lesions, APOE ϵ , and Tau Pathology in Alzheimer Disease. 2021 , 80, 240-246	1
622	Evaluation of fluid channels in the human dura and superior sagittal sinus in older patients. 2021 , 746, 135649	0
621	Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. 2021 , 48, 2097-2109	14
620	Alzheimer's disease brain contains tau fractions with differential prion-like activities. 2021 , 9, 28	4
619	Cerebrospinal Fluid Biomarkers of Alzheimer's Disease: Current Evidence and Future Perspectives. 2021 , 11,	13
618	Clinical and Biological Correlates of White Matter Hyperintensities in Patients With Behavioral-Variant Frontotemporal Dementia and Alzheimer Disease. 2021 , 96, e1743-e1754	5
617	What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia. 2021 , 34, 237-245	9
616	Extracellular Protein Aggregates Colocalization and Neuronal Dystrophy in Comorbid Alzheimer's and Creutzfeldt-Jakob Disease: A Micromorphological Pilot Study on 20 Brains. 2021 , 22,	0
615	Contribution of rare homozygous and compound heterozygous VPS13C missense mutations to dementia with Lewy bodies and Parkinson's disease. 2021 , 9, 25	7
614	Mapping of SARS-CoV-2 Brain Invasion and Histopathology in COVID-19 Disease. 2021 ,	25
613	Hippocampal Sclerosis in Frontotemporal Dementia: When Vascular Pathology Meets Neurodegeneration. 2021 , 80, 313-324	1
612	Remodeling Alzheimer-amyloidosis models by seeding. 2021 , 16, 8	0
611	Defective Lysosomal Lipid Catabolism as a Common Pathogenic Mechanism for Dementia. 2021 , 23, 1-24	3
610	Limbic-predominant age-related TDP-43 encephalopathy neuropathologic change and microvascular pathologies in community-dwelling older persons. 2021 , 31, e12939	5

609	Association of Position Played and Career Duration and Chronic Traumatic Encephalopathy at Autopsy in Elite Football and Hockey Players. 2021 , 96, e1835-e1843	7
608	Complex Inclusion Bodies and Defective Proteome Hubs in Neurodegenerative Disease: New Clues, New Challenges. 2021 , 1073858421989582	2
607	Cerebrovascular and Neurodegenerative Pathologies in Long-Term Stable Mild Cognitive Impairment. 2021 , 79, 1269-1283	0
606	Detecting Alzheimer's disease biomarkers with a brief tablet-based cognitive battery: sensitivity to Aβ and tau PET. 2021 , 13, 36	3
605	Protein Expression of Angiotensin-Converting Enzyme 2 (ACE2) is Upregulated in Brains with Alzheimer's Disease. 2021 , 22,	19
604	Iron loading is a prominent feature of activated microglia in Alzheimer's disease patients. 2021 , 9, 27	14
603	Collaborative Neuropathology Network Characterizing Outcomes of TBI (CONNECT-TBI). 2021 , 9, 32	3
602	TAR DNA-Binding Protein 43 Is Associated with Rate of Memory, Functional and Global Cognitive Decline in the Decade Prior to Death. 2021 , 80, 683-693	2
601	First symptom guides diagnosis and prognosis in neurodegenerative diseases-a retrospective study of autopsy proven cases. 2021 , 28, 1801-1811	4
600	Acute Brain Ischemia, Infarction and Hemorrhage in Subjects Dying with or Without Autopsy-Proven Acute Pneumonia. 2021 ,	3
599	Tetramethylpyrazine Improves Cognitive Impairment and Modifies the Hippocampal Proteome in Two Mouse Models of Alzheimer's Disease. 2021 , 9, 632843	5
598	Ground state depletion microscopy as a tool for studying microglia-synapse interactions. 2021 , 99, 1515-1532	2
597	Pontine Arteriosclerosis and Locus Coeruleus Oxidative Stress Differentiate Resilience from Mild Cognitive Impairment in a Clinical Pathologic Cohort. 2021 , 80, 325-335	1
596	Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes. 2021 , 80, 185-195	2
595	Disentangling The Spatio-Temporal Heterogeneity of Alzheimer's Disease Using A Deep Predictive Stratification Network. 2021 ,	
594	Comparison of memory, affective behavior, and neuropathology in APP knock-in mice to 5xFAD and APP/PS1 mice. 2021 , 404, 113192	5
593	Visualization of neurofibrillary tangle maturity in Alzheimer's disease: A clinicopathologic perspective for biomarker research. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1554-1574	1.2 11
592	White matter hyperintensities and patterns of atrophy in early onset Alzheimer's disease with causative gene mutations. 2021 , 203, 106552	0

591	Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	0
590	Microstructural white matter alterations in Alzheimer's disease and amnesic mild cognitive impairment and its diagnostic value based on diffusion kurtosis imaging: a tract-based spatial statistics study. 2021 , 1		1
589	Relationships Between Cognition and Neuropathological Tau in Alzheimer's Disease Assessed by 18F Flortaucipir PET. 2021 , 80, 1091-1104		4
588	AMYQ: An index to standardize quantitative amyloid load across PET tracers. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1499-1508	1.2	4
587	Superior Frontal Gyrus Locus DNA Methylation in Alzheimer's Disease. 2021 , 5, 275-282		2
586	Cognition at Each Stage of Lewy Body Disease with Co-occurring Alzheimer's Disease Pathology. 2021 , 80, 1243-1256		4
585	Editorial: Understanding factors that, beyond plaques and tangles, contribute to the heterogeneity of Alzheimer disease and implications for the development of biomarkers and design of interventions. 2021 , 34, 226-227		
584	Sequence of proteome profiles in preclinical and symptomatic Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021 , 17, 946-958	1.2	4
583	Quantitative endophenotypes as an alternative approach to understanding genetic risk in neurodegenerative diseases. 2021 , 151, 105247		1
582	In vivo Characterization of Biochemical Variants of Amyloid- β in Subjects with Idiopathic Normal Pressure Hydrocephalus and Alzheimer's Disease Neuropathological Change. 2021 , 80, 1003-1012		2
581	Four distinct trajectories of tau deposition identified in Alzheimer's disease. 2021 , 27, 871-881		81
580	Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1709-1724	1.2	10
579	Letter: Recommendation to Create New Neuropathologic Guidelines for the Post-Mortem Diagnosis of Chronic Traumatic Encephalopathy. 2021 , 89, E97-E98		4
578	Identification of multiple system atrophy mimicking Parkinson's disease or progressive supranuclear palsy. 2021 , 144, 1138-1151		7
577	Continuous Monitoring of Tau-Induced Neurotoxicity in Patient-Derived iPSC-Neurons. 2021 , 41, 4335-4348		1
576	Aggregated Tau Measured by Visual Interpretation of Flortaucipir Positron Emission Tomography and the Associated Risk of Clinical Progression of Mild Cognitive Impairment and Alzheimer Disease: Results From 2 Phase III Clinical Trials. 2021 , 78, 445-453		5
575	Alternative Targets to Fight Alzheimer's Disease: Focus on Astrocytes. 2021 , 11,		7
574	Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. 2021 , 78, 396-406		41

573	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. 2021 , 13, 82		3
572	Multiple Neurodegenerative Pathologies in an Alzheimer's Disease Patient Treated with Fornical Deep Brain Stimulation. 2021 , 80, 1383-1387		
571	Bridging Scales in Alzheimer's Disease: Biological Framework for Brain Simulation With The Virtual Brain. 2021 , 15, 630172		1
570	Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia. 2021 , 5, 321-336		6
569	Mixed pathologies in pancreatic β cells from subjects with neurodegenerative diseases and their interaction with prion protein. 2021 , 9, 64		2
568	Complete Evaluation of Dementia: PET and MRI Correlation and Diagnosis for the Neuroradiologist. 2021 , 42, 998-1007		4
567	Visit-to-Visit Blood Pressure Variability, Neuropathology, and Cognitive Decline. 2021 , 96, e2812-e2823		6
566	A Systematic Review of the Association between Amyloid- β and τ Pathology with Functional Connectivity Alterations in the Alzheimer Dementia Spectrum Utilizing PET Scan and rsfMRI. 2021 , 11, 78-90		1
565	Restoring miR-132 expression rescues adult hippocampal neurogenesis and memory deficits in Alzheimer's disease. 2021 , 28, 1805-1821.e8		21
564	The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. <i>Alzheimer's and Dementia</i> , 2021 ,	1.2	5
563	Differential microRNA expression analyses across two brain regions in Alzheimer's disease.		1
562	On Gaps of Clinical Diagnosis of Dementia Subtypes: A Study of Alzheimer's Disease and Lewy Body Disease.		
561	Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1663-1674	1.2	5
560	Karyopherin abnormalities in neurodegenerative proteinopathies. 2021 , 144, 2915-2932		2
559	Comparing PET and MRI Biomarkers Predicting Cognitive Decline in Preclinical Alzheimer Disease. 2021 ,		5
558	Marked Mild Cognitive Deficits in Humanized Mouse Model of Alzheimer's-Type Tau Pathology. 2021 , 15, 634157		1
557	Robust β synuclein pathology in select brainstem neuronal populations is a potential instigator of multiple system atrophy. 2021 , 9, 80		3
556	Reducing acetylated tau is neuroprotective in brain injury. 2021 , 184, 2715-2732.e23		18

555	Rhesus monkeys as a translational model for late-onset Alzheimer's disease. 2021 , 20, e13374	1
554	Identification of retinoblastoma binding protein 7 (Rbbp7) as a mediator against tau acetylation and subsequent neuronal loss in Alzheimer's disease and related tauopathies. 2021 , 142, 279-294	3
553	A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. 2021 , 48, 2295-2305	11
552	Relationship between F-18 florbetapir uptake in occipital lobe and neurocognitive performance in Alzheimer's disease. 2021 , 39, 984-993	1
551	The contact activation system and vascular factors as alternative targets for Alzheimer's disease therapy. 2021 , 5, e12504	3
550	Old age genetically confirmed frontotemporal lobar degeneration with TDP-43 has limbic predominant TDP-43 deposition. 2021 , 47, 1050-1059	3
549	Tau isoforms are differentially expressed across the hippocampus in chronic traumatic encephalopathy and Alzheimer's disease. 2021 , 9, 86	8
548	Ganoderic Acid A Promotes Amyloid- β Clearance (In Vitro) and Ameliorates Cognitive Deficiency in Alzheimer's Disease (Mouse Model) through Autophagy Induced by Activating Axl. 2021 , 22,	4
547	Semantic memory impairment in dementia: A cross-cultural adaptation study. 2021 , 1	0
546	Early Detection of Tau Pathology.	1
545	Single-synapse analyses of Alzheimer's disease implicate pathologic tau, DJ1, CD47, and ApoE.	1
544	R1441G but not G2019S mutation enhances LRRK2 mediated Rab10 phosphorylation in human peripheral blood neutrophils. 2021 , 142, 475-494	5
543	Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. 2021 , 20, 484-496	86
542	Emerging insights into the role of albumin with plasma exchange in Alzheimer's disease management. 2021 , 60, 103164	1
541	Aggregated Tau-PHF6 (VQIVYK) Potentiates NLRP3 Inflammasome Expression and Autophagy in Human Microglial Cells. 2021 , 10,	7
540	Clinical, Imaging, and Pathologic Characteristics of Patients With Right vs Left Hemisphere-Predominant Logopenic Progressive Aphasia. 2021 , 97, e523-e534	1
539	"Don't Phos Over Tau": recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer's disease and other tauopathies. 2021 , 16, 37	17
538	ARCAM-1 Facilitates Fluorescence Detection of Amyloid-Containing Deposits in the Retina. 2021 , 10, 5	3

537	Acute systemic inflammation exacerbates neuroinflammation in Alzheimer's disease: IL-1 β drives amplified responses in primed astrocytes and neuronal network dysfunction. <i>Alzheimer's and Dementia</i> , 2021 , 17, 1735-1755	1.2	15
536	CSF1R inhibition rescues tau pathology and neurodegeneration in an A/T/N model with combined AD pathologies, while preserving plaque associated microglia. 2021 , 9, 108		7
535	Synapsin-caveolin-1 gene therapy preserves neuronal and synaptic morphology and prevents neurodegeneration in a mouse model of AD. 2021 , 21, 434-450		1
534	The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer's Disease Pathology. 2021 , 9, 684874		5
533	The informed road map to prevention of Alzheimer Disease: A call to arms. 2021 , 16, 49		7
532	Downstream effects of polypathology on neurodegeneration of medial temporal lobe subregions. 2021 , 9, 128		3
531	Comparing amyloid- β plaque burden with antemortem PiB PET in autosomal dominant and late-onset Alzheimer disease. 2021 , 142, 689-706		8
530	Dysregulated protein phosphorylation: A determining condition in the continuum of brain aging and Alzheimer's disease. 2021 , 31, e12996		4
529	Near-Infrared Optical Spectroscopy In Vivo Distinguishes Subjects with Alzheimer's Disease from Age-Matched Controls. 2021 , 82, 791-802		0
528	Erythrocyte sphingolipid species as biomarkers of Alzheimer's disease.. 2022 , 12, 178-185		1
527	A Concise Overview of Biosensing Technologies for the Detection of Alzheimer's Disease Biomarkers. 2021 ,		2
526	Entorhinal cortex EWAS meta-analysis highlights four novel loci showing differential methylation in Alzheimer's disease.		1
525	Dynamic theta/beta ratio of clinical EEG in Alzheimer's disease. 2021 , 359, 109219		1
524	The complexity of Alzheimer's disease: an evolving puzzle. 2021 , 101, 1047-1081		7
523	White matter hyperintensities in autopsy-confirmed frontotemporal lobar degeneration and Alzheimer's disease. 2021 , 13, 129		4
522	Three-dimensional mapping of neurofibrillary tangle burden in the human medial temporal lobe. 2021 , 144, 2784-2797		9
521	Superiority of Formalin-Fixed Paraffin-Embedded Brain Tissue for Assessment of Progressive Supranuclear Palsy Tau Pathology With [F]PI-2620. 2021 , 12, 684523		1
520	Hippocampal neurobiology and function in an aged mouse model of TDP-43 proteinopathy in an APP/PSEN1 background. 2021 , 758, 136010		

519	Variability in the type and layer distribution of cortical A β pathology in familial Alzheimer's disease. 2021 , e13009	1
518	Deep learning-based identification of genetic variants: Application to Alzheimer's disease classification.	0
517	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. 2021 , 158, 1394-1411	2
516	Blood-Brain Barrier Breakdown: An Emerging Biomarker of Cognitive Impairment in Normal Aging and Dementia. 2021 , 15, 688090	22
515	Role of Mitochondria in Neurodegenerative Diseases: From an Epigenetic Perspective. 2021 , 9, 688789	2
514	Multi-scale neural decoding and analysis. 2021 , 18,	2
513	Proteomic landscape of Alzheimer's Disease: novel insights into pathogenesis and biomarker discovery. 2021 , 16, 55	10
512	Canine Cognitive Dysfunction (CCD) scores correlate with amyloid beta 42 levels in dog brain tissue. 2021 , 43, 2379-2386	3
511	Metabolic Profiling of Neocortical Tissue Discriminates Alzheimer's Disease from Mild Cognitive Impairment, High Pathology Controls, and Normal Controls. 2021 , 20, 4303-4317	8
510	Blood-Based Biomarkers of Neuroinflammation in Alzheimer's Disease: A Central Role for Periphery?. 2021 , 11,	4
509	Disease-, region- and cell type specific diversity of β synuclein carboxy terminal truncations in synucleinopathies. 2021 , 9, 146	1
508	Early white matter pathology in the fornix of the limbic system in Huntington disease. 2021 , 142, 791-806	1
507	Planar cell polarity signaling components are a direct target of β amyloid-associated degeneration of glutamatergic synapses. 2021 , 7,	4
506	Differential interaction with TREM2 modulates microglial uptake of modified A β species. 2021 , 69, 2917-2932	2
505	ZCWPW1 loss-of-function variants in Alzheimer's Disease.	1
504	Microglial morphology in Alzheimer's disease and after A β immunotherapy. 2021 , 11, 15955	7
503	The deletion causes early onset autosomal dominant Alzheimer's disease by altering APP processing and increasing amyloid β fibril formation. 2021 , 13,	7
502	Interaction of Exogenous Butyrylcholinesterase with β Amyloid Plaques in 5XFAD/Butyrylcholinesterase-Knockout Mouse Brain. 2021 , 18, 470-481	

501	Concurrent cardiac transthyretin and brain β amyloid accumulation among the older adults: The Hisayama study. 2021 , e13014	3
500	Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer's Disease. 2021 , 9,	1
499	Investigation of the role of matrix metalloproteinases in the genetic etiology of Alzheimer's disease. 2021 , 104, 105.e1-105.e6	3
498	Leveraging Neuroimaging Tools to Assess Precision and Accuracy in an Alzheimer's Disease Neuropathologic Sampling Protocol. 2021 , 15, 693242	
497	Deep learning assisted quantitative assessment of histopathological markers of Alzheimer's disease and cerebral amyloid angiopathy. 2021 , 9, 141	3
496	Integrative brain transcriptome analysis links complement component 4 and HSPA2 to the APOE ϵ protective effect in Alzheimer disease. 2021 ,	1
495	Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer's disease. 2021 , e13016	1
494	ApoE4 attenuates autophagy via FoxO3a repression in the brain. 2021 , 11, 17604	3
493	Can we learn lessons from the FDA's approval of aducanumab?. 2021 , 17, 715-722	17
492	Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease. 2021 , 10, 37	0
491	Network activity changes in the pathophysiology of Alzheimer's disease: the role of aging and early entorhinal cortex dysfunction. 2021 , 1	
490	Seizure prevalence in neurodegenerative diseases-a study of autopsy proven cases. 2022 , 29, 12-18	2
489	Differential Involvement of the Locus Coeruleus in Early- and Late-Onset Alzheimer's Disease: A Potential Mechanism of Clinical Differences?. 2021 , 8919887211044755	1
488	Exogenous A β seeds induce A β depositions in the blood vessels rather than the brain parenchyma, independently of A β brain-specific information. 2021 , 9, 151	0
487	The transcriptional landscape of Alzheimer's disease and its association with Wnt signaling pathway. 2021 , 128, 454-466	2
486	Amyloid pathology and synaptic loss in pathological aging. 2021 , 159, 258-272	0
485	Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases. 2022 , 2389, 209-220	
484	Spatial organization of protein aggregates on red blood cells as physical biomarkers of Alzheimer's disease pathology. 2021 , 7, eabj2137	3

483	The association of Lewy bodies with limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes and their role in cognition and Alzheimer's dementia in older persons. 2021 , 9, 156	3
482	Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in the Era of Disease-Modifying Treatments. 2021 , 11,	0
481	Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. 2021 ,	6
480	Inflammatory Cascade in Alzheimer's Disease Pathogenesis: A Review of Experimental Findings. 2021 , 10,	9
479	Collusion of β -Synuclein and A β Aggravating co-morbidities in a novel prion-type mouse model. 2021 , 16, 63	3
478	Impact of Sterilization Methods on the Seeding Ability of Human Tau Proteopathic Seeds. 2021 , 80, 912-921	
477	Estimation of Discrete Survival Function through Modeling Diagnostic Accuracy for Mismeasured Outcome Data. 1	
476	Alzheimer's Disease-Related Neuropathology Among Patients with Medication Treated Type 2 Diabetes in a Community-Based Autopsy Cohort. 2021 , 83, 1303-1312	1
475	F-florbetapir PET as a marker of myelin integrity across the Alzheimer's disease spectrum. 2021 , 1	2
474	MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. 2021 , 9, 154	2
473	Staging tau pathology with tau PET in Alzheimer's disease: a longitudinal study. 2021 , 11, 483	3
472	Premature termination codon mutations in ABCA7 contribute to Alzheimer's disease risk in Belgian patients. 2021 , 106, 307.e1-307.e7	3
471	Two autopsy cases with injuries to the stomach following cardiopulmonary resuscitation. 2021 , 53, 101916	0
470	Diagnostic biomarkers in Alzheimer's disease. 2021 , 5, 100041	2
469	Gut Dysbiosis and Neurological Disorders: An Eclectic Perspective. 2022 , 489-489	
468	Changes in cognitive function and related brain regions in chronic benzene poisoning: a case report. 2021 , 9, 81	1
467	Case Report of a pathologically confirmed vascular parkinsonism with early cognitive impairment and Behavioral disturbance. 2021 , 21, 15	1
466	Microglial Hyperreactivity Evolved to Immunosuppression in the Hippocampus of a Mouse Model of Accelerated Aging and Alzheimer's Disease Traits. 2020 , 12, 622360	1

465	Unfolding the Medial Temporal Lobe Cortex to Characterize Neurodegeneration Due to Alzheimer's Disease Pathology Using Ex vivo Imaging. 2021 , 3-12	
464	Defective Autophagy and Mitophagy in Aging and Alzheimer's Disease. 2020 , 14, 612757	37
463	Specific pattern of melanin-concentrating hormone (MCH) neuron degeneration in Alzheimer's disease and possible clinical implications.	
462	Maturation of neuronal AD-tau pathology involves site-specific phosphorylation of cytoplasmic and synaptic tau preceding conformational change and fibril formation. 2021 , 141, 173-192	8
461	Longitudinal brain atrophy and CSF biomarkers in early-onset Alzheimer's disease. 2021 , 32, 102804	3
460	The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography. 2021 , 13,	32
459	Tripchlorolide attenuates A β generation by inducing NEP activity in N2a/APP695 cells. 2021 , 12, 301-308	
458	Amyloid-Beta, BDNF, and the Mechanism of Neurodegeneration in Alzheimer's Disease. 2014 , 1597-1620	2
457	Dementia: Genes, Environments, Interactions. 2014 , 201-231	2
456	The APP Proteolytic System and Its Interactions with Dynamic Networks in Alzheimer's Disease. 2016 , 1303, 71-99	6
455	Blood-Based Biomarker Screening with Agnostic Biological Definitions for an Accurate Diagnosis Within the Dimensional Spectrum of Neurodegenerative Diseases. 2018 , 1750, 139-155	10
454	Alzheimer's Disease and Speech Background. 2020 , 107-135	1
453	Neurodegenerative Diseases: Alzheimer Disease (AD). 2019 , 897-931	1
452	Top-Down Projections Direct the Gradual Progression of Alzheimer-Related Tau Pathology Throughout the Neocortex. 2019 , 1184, 291-303	3
451	Identification of early pericyte loss and vascular amyloidosis in Alzheimer's disease retina. 2020 , 139, 813-836	49
450	Altered lipid metabolic homeostasis in the pathogenesis of Alzheimer's disease. 2020 , 469-504	3
449	Topography of cortical thinning in the Lewy body diseases. 2020 , 26, 102196	7
448	Alzheimer's disease. 80-108	1

447	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. 2016 , 139, 2528-39	45
446	Subtypes of functional brain connectivity as early markers of neurodegeneration in Alzheimer's disease.	1
445	Alzheimer's Disease Neuropathological Comorbidities Are Common in the Younger-Old.	1
444	Single-cell epigenomic identification of inherited risk loci in Alzheimer's and Parkinson's disease.	9
443	Molecular characterization of selectively vulnerable neurons in Alzheimer's Disease.	4
442	Single-soma transcriptomics of tangle-bearing neurons in Alzheimer's disease reveals the signatures of tau-associated synaptic dysfunction.	12
441	Time course of phosphorylated tau181 in blood across the Alzheimer's disease spectrum.	2
440	Angiotensin-converting enzyme 2 (ACE2) is upregulated in Alzheimer's disease brain. 2020 ,	13
439	p-tau/A β 2 Ratio Associates with Cognitive Decline in Alzheimer's disease, Mild Cognitive Impairment, and Cognitively Unimpaired Older Adults.	1
438	The role of A β circRNA in Alzheimer's disease: alternative mechanism of A β biogenesis from A β circRNA translation.	3
437	Tauopathy in the APP ^{swe} /PS1 ^{E9} mouse model of familial Alzheimer's disease.	2
436	Multiscale causal network models of Alzheimer's disease identify VGF as a key regulator of disease.	4
435	A Modification of the Bielschowsky Silver Stain for Alzheimer Neuritic Plaques: Suppression of Artifactual Staining by Pretreatment with Oxidizing Agents.	1
434	Flow-cytometric microglial sorting coupled with quantitative proteomics identifies moesin as a highly-abundant microglial protein with relevance to Alzheimer's disease.	1
433	Identification of conserved proteomic networks in neurodegenerative dementia.	2
432	Automatic classification of cortical thickness patterns in Alzheimer's disease patients using the Louvain modularity clustering method. 2018 ,	3
431	Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer's disease pathology: a clinicopathological study. 2020 , 10, 65	13
430	Late-onset Alzheimer Disease. 2019 , 25, 14-33	21

429	Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. 2021 , 96, e671-e683	21
428	Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, β , and Cognitive Impairment. 2021 , 96, e975-e985	7
427	A depressive endophenotype of mild cognitive impairment and Alzheimer's disease. 2013 , 8, e68848	14
426	BIN1 is decreased in sporadic but not familial Alzheimer's disease or in aging. 2013 , 8, e78806	49
425	Molecular markers for granulovacuolar degeneration are present in rimmed vacuoles. 2013 , 8, e80995	4
424	Self-Reported Memory Complaints: A Comparison of Demented and Unimpaired Outcomes. 2016 , 3, 13-19	22
423	APO ϵ and education in cognitively normal older subjects with high levels of AD pathology at autopsy: findings from the Nun Study. 2015 , 6, 14082-91	10
422	Assessment of Basic Knowledge About Alzheimer's Disease Among Older Rural Residents: A Pilot Test of a New Measure. 2017 , 25, 519-548	6
421	The structural MRI markers and cognitive decline in prodromal Alzheimer's disease: a 2-year longitudinal study. 2018 , 8, 1004-1019	15
420	Structure and mechanism of action of tau aggregation inhibitors. 2014 , 11, 918-27	58
419	Cerebrospinal Fluid proNGF: A Putative Biomarker for Early Alzheimer's Disease. 2016 , 13, 800-8	29
418	Characterization of Serum Exosomes from a Transgenic Mouse Model of Alzheimer's Disease. 2019 , 16, 388-395	10
417	Exploring the Potential of Neuroproteomics in Alzheimer's Disease. 2020 , 20, 2263-2278	7
416	Primary age-related tauopathy and the amyloid cascade hypothesis: the exception that proves the rule?. 2016 , 1, 53-57	31
415	Memory loss in Alzheimer's disease. 2013 , 15, 445-54	242
414	a Strong Risk Factor for Alzheimer's Disease. 2020 , 4, 501-511	15
413	Epigenetic Regulation of BMAL1 with Sleep Disturbances and Alzheimer's Disease. 2020 , 77, 1783-1792	2
412	Extracellular Amyloid Deposits in Alzheimer's and Creutzfeldt-Jakob Disease: Similar Behavior of Different Proteins?. 2020 , 22,	6

411	Targeting Metal Homeostasis as a Therapeutic Strategy for Alzheimer's Disease. 83-98	2
410	Association between Alzheimer's disease pathogenesis and early demyelination and oligodendrocyte dysfunction. 2018 , 13, 908-914	30
409	Primary Age-Related Tauopathy: An Elderly Brain Pathology Frequently Encountered during Autopsy. 2019 , 53, 159-163	12
408	Huge Intracranial Meningioma Mimicking Alzheimer Dementia. 2017 , 21, 86-89	1
407	Recent progress and concerns in dementia: Distinguishing Alzheimer's disease and dementia with Lewy bodies via biochemical markers in the cerebrospinal fluid. 2012 , 02, 176-190	5
406	Clinical neuropathology practice news 3-2012: the "ABC" in AD-revised and updated guideline for the neuropathologic assessment of Alzheimer's disease. 2012 , 31, 116-8	4
405	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. 2019 , 8,	27
404	Hippocampus- and Thalamus-Related Fiber-Specific White Matter Reductions in Mild Cognitive Impairment. 2021 ,	0
403	VGF as a biomarker and therapeutic target in neurodegenerative and psychiatric diseases. 2021 , 3, fcab261	2
402	Platelet Behavior Contributes to Neuropathologies: A Focus on Alzheimer's and Parkinson's Disease. 2021 ,	1
401	Role of SIRT3 and Mitochondrial Dysfunction in Neurodegeneration. 2022 , 99-120	
400	Reducing Your Risk of Alzheimer's Dementia: Building a Better Brain as We Age. 2021 , 36, 1257-1265	1
399	Periodontitis and Dementia: A Bidirectional Relationship?. 2021 , 220345211043461	0
398	Ex vivo MRI atlas of the human medial temporal lobe: characterizing neurodegeneration due to tau pathology. 2021 , 9, 173	0
397	TREM2 modulates differential deposition of modified and non-modified A β species in extracellular plaques and intraneuronal deposits. 2021 , 9, 168	2
396	From Cerebrospinal Fluid Neurochemistry to Clinical Diagnosis of Alzheimer's Disease in the Era of Anti-Amyloid Treatments. Report of Four Patients. 2021 , 9,	0
395	Anatomic survey of seeding in Alzheimer's disease brains reveals unexpected patterns. 2021 , 9, 164	1
394	A tale of 2 amyloid positron emission tomography scans in patients with mild cognitive impairment. 2012 , 14,	

393 Correlati neurobiologici nell'anziano con malattia di alzheimer e altre demenze. **2013**, 389-406

392 Chapitre 8. La maladie d'Alzheimer et les syndromes apparentés. **2014**, 215

391 Neurodegenerative Disorders. **2015**, 183-205

390 An Autopsy Confirmed Case of Behavioral Variant Frontotemporal Dementia with Corticobasal Degeneration Pathology. **2015**, 33, 178-182

389 Alzheimer Disease. **2016**, 38-43

388 Encyclopedia of Geropsychology. **2016**, 1-13

387 Cell-Based Therapy in Alzheimer's Disease: Current Knowledge and Perspective. **2016**, 2, 50-58

386 Biomarkers of Alzheimer's Disease. **2017**, 1-35

385 Biomarkers of Alzheimer's Disease. **2017**, 105-139

384 Encyclopedia of Geropsychology. **2017**, 256-268

383 Plasma amyloid β levels are driven by genetic variants near APOE, BACE1, APP, PSEN2: A genome-wide association study in over 12,000 non-demented participants.

382 3D Fractal Analysis of Optical Images of Retinal Amyloid for Staging in Alzheimer's Disease. **2018**,

381 Alzheimer Disease. **2018**, 316-321

380 An Autopsy Confirmed Case of Semantic Variant Primary Progressive Aphasia with Frontotemporal Lobar Degeneration-TDP type C. **2018**, 36, 35-39

379 Methods for Pathological Classification of Alzheimer's Disease. **2018**, 71-89

378 Perturbed functional networks in Alzheimer's Disease reveal opposing roles for TGIF and EGR3.

377 Differentiation of Alzheimer's disease based on local and global parameters in personalized Virtual Brain models. 2

376 A human embryonic stem cell model of A β -dependent chronic progressive neurodegeneration. 0

- 375 Interpretable classification of Alzheimer's disease pathologies with a convolutional neural network pipeline.
- 374 SIMILAR RETINAL FINDINGS IN TRAUMATIC BRAIN INJURY AND ALZHEIMER'S. **2018**, 6, 330-336
- 373 Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer's Disease. **2019**, 307-341
- 372 3D Mapping of Serial Histology Sections with Anomalies Using a Novel Robust Deformable Registration Algorithm. **2019**, 162-173 3
- 371 SNIPE score can capture prodromal Alzheimer's in cognitively normal subjects. 2
- 370 A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. **2019**, 37, 1-7 1
- 369 Defining and predicting transdiagnostic categories of neurodegenerative disease.
- 368 Small RNA modifications in Alzheimer's disease.
- 367 Public knowledge about Alzheimer disease in Mecca Region, Kingdom of Saudi Arabia: a cross-sectional study. **2020**, 56,
- 366 A non-human primate model of familial Alzheimer's disease. 5
- 365 Phenotyping Neuropsychiatric Symptoms Profiles of Alzheimer's Disease Using Cluster Analysis on EEG Power.
- 364 Re: The Second NINDS/NIBIB Consensus Meeting to Define Neuropathological Criteria for the Diagnosis of Chronic Traumatic Encephalopathy. *J Neuropathol Exp Neurol* 2021;80(3):210-9. **2021**, 80, 1007-1008 1
- 363 Identification of the function and mechanism of m6A reader IGF2BP2 in Alzheimer's disease. **2021**, 13, 24086-24100 5
- 362 Dysregulated Protein Phosphorylation as Main Contributor of Granulovacuolar Degeneration at the First Stages of Neurofibrillary Tangles Pathology. **2021**, 0
- 361 (Un)Ethical Early Interventions in the Alzheimer's "Marketplace of Memory". **2021**, 12, 245-247 0
- 360 P-tau235: a novel biomarker for staging preclinical Alzheimer's disease. **2021**, 13, e15098 4
- 359 Increased VLCFA-lipids and ELOVL4 underlie neurodegeneration in frontotemporal dementia. **2021**, 11, 21348 1
- 358 A Simplified Brain Blocking Protocol Optimized for the Diagnosis of Neurodegenerative Disease Saves Time and Money While Preserving Anatomic Relationships. **2021**, 145, 960-968 0

357	PM2.5 exposure in association with AD-related neuropathology and cognitive outcomes. 2022 , 292, 118320	6
356	Neuropathological fingerprints of survival, atrophy and language in primary progressive aphasia.. 2022 ,	0
355	CCCDT5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. 2020 , 6, e12098	0
354	The Limbic System. 2020 , 745-830	0
353	The Cerebral Cortex and Complex Cerebral Functions. 2020 , 831-952	
352	Comparison of amyloid PET measured in Centiloid units with neuropathological findings in Alzheimer's Disease.	
351	Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid- β Positron Emission Tomography. 2020 , 74, 101-112	
350	Neuropathology of Alzheimer's Disease. 2021 ,	11
349	DNA Methylation in Genetic and Sporadic Forms of Neurodegeneration: Lessons from Alzheimer's, Related Tauopathies and Genetic Tauopathies. 2021 , 10,	3
348	State-of-the-Art Machine Learning Techniques for Diagnosis of Alzheimer's Disease from MR-Images: A Systematic Review. 1	0
347	Synapsin-caveolin-1 mitigates cognitive deficits and neurodegeneration in Alzheimer's disease mice.	
346	Genetic risk for Alzheimer's disease influences neuropathology and cognition via multiple biological pathways.	
345	Protecting synapses from amyloid β -associated degeneration by manipulations of Wnt/planar cell polarity signaling.	0
344	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. 2021 , 427-451	
343	Integrative Brain Transcriptome Analysis Links Complement Component 4 and HSPA2 to the APOE ϵ 2 Protective Effect in Alzheimer Disease.	1
342	Retinal involvement in Alzheimer's disease (AD): evidence and current progress on the non-invasive diagnosis and monitoring of AD-related pathology using the eye. 2020 ,	2
341	^{18}F -AV-1451 positron emission tomography in neuropathological substrates of corticobasal syndrome. 2021 , 144, 266-277	1
340	Clinical implications of the new diagnostic guidelines for dementia. 2013 , 10, 32-8	2

339	Revealing MicroRNA Biomarkers for Alzheimer’s Disease Using Next Generation Sequencing Data. 2021,		
338	Parkinson’s disease and parkinsonism: Clinicopathological discrepancies on diagnosis in three patients. 2021, 41, 450		0
337	Is There Any Evidence of Monocytes Involvement in Alzheimer’s Disease? A Pilot Study on Human Postmortem Brain.. 2021, 5, 887-897		0
336	Association of Neurofibrillary Tangle Distribution With Age at Onset-Related Clinical Heterogeneity in Alzheimer Disease: An Autopsy Study. 2021,		0
335	Machine Learning to Predict Brain Amyloid Pathology in Pre-dementia Alzheimer’s Disease Using QEEG Features and Genetic Algorithm Heuristic. 2021, 15, 755499		0
334	Spatial Pattern Separation Testing Differentiates Alzheimer’s Disease Biomarker-Positive and Biomarker-Negative Older Adults With Amnesic Mild Cognitive Impairment.. 2021, 13, 774600		0
333	Common pathways in dementia and diabetic retinopathy: understanding the mechanisms of diabetes-related cognitive decline. 2021,		5
332	Dysfunction of the blood-brain barrier in Alzheimer’s disease: evidence from human studies. 2021,		9
331	Insights Into the Role of CSF1R in the Central Nervous System and Neurological Disorders. 2021, 13, 789834		1
330	Tau Biomarkers in Dementia: Positron Emission Tomography Radiopharmaceuticals in Tauopathy Assessment and Future Perspective. 2021, 22,		0
329	Different rates of cognitive decline in autosomal dominant and late-onset Alzheimer disease. <i>Alzheimer’s and Dementia</i> , 2021,	1.2	0
328	Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease.. 2022, 14, eabg0253		4
327	Automated detection, selection and classification of hippocampal landmark points for the diagnosis of Alzheimer’s disease.. 2021, 214, 106581		2
326	Association of Subjective Hearing Loss and Apolipoprotein E ϵ Allele on Alzheimer’s Disease Neurodegeneration. 2021, 42, e15-e21		0
325	Synapses, Microglia, and Lipids in Alzheimer’s Disease.. 2021, 15, 778822		2
324	Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimer’s disease. 2022, 100030		0
323	Proteomic analysis of human hippocampal subfields provides new insights into the pathogenesis of Alzheimer’s disease and the role of glial cells.. 2022, e13047		1
322	Co-expression Network Analysis of Frontal Cortex during the Progression of Alzheimer’s Disease.. 2022,		0

321	Primary Age-Related Tauopathy (PART) in a Finnish Population-Based Study of the Oldest Old (Vantaa 85+).. 2021 ,			1
320	Amyloid-associated increases in soluble tau is a key driver in accumulation of tau aggregates and cognitive decline in early Alzheimer.			0
319	Validation and test-retest repeatability performance of parametric methods for [C]UCB-J PET.. 2022 , 12, 3			
318	Advances in Deep Neuropathological Phenotyping of Alzheimer Disease: Past, Present, and Future.. 2022 ,			1
317	Long-term associations between amyloid positron emission tomography, sex, apolipoprotein E and incident dementia and mortality among individuals without dementia: hazard ratios and absolute risk.. 2022 , 4, fca017			2
316	Common signatures of differential microRNA expression in Parkinson's and Alzheimer's disease brains.			
315	Mild behavioral impairment is associated with progression to Alzheimer's disease: A clinicopathological study.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2		5
314	Cyclic multiplex fluorescent immunohistochemistry and machine learning reveal distinct states of astrocytes and microglia in normal aging and Alzheimer's disease.. 2022 , 19, 30			1
313	Deep learning-based identification of genetic variants: application to Alzheimer's disease classification.. 2022 ,			1
312	TDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration.. 2022 , 34, 102954			0
311	Longitudinal atrophy in prodromal dementia with Lewy bodies points to cholinergic degeneration.. 2022 , 4, fca013			1
310	Peripheral Transport Proteins Were Associated with 4-Year Cognitive Decline in APOE e4 Non-Carriers: A Longitudinal, Population-Based Study.. 2022 ,			
309	Cortical microstructure in primary progressive aphasia: a multicenter study.. 2022 , 14, 27			0
308	Diabetes: Risk Factor and Translational Therapeutic Implications for Alzheimer's Disease.. 2022 ,			0
307	Anti-HK antibody reveals critical roles of a 20-residue HK region for A β -induced plasma contact system activation.. 2022 ,			2
306	Fluid markers of synapse degeneration in synucleinopathies.. 2022 , 129, 187			0
305	Blood and brain transcriptome analysis reveals APOE genotype-mediated and immune-related pathways involved in Alzheimer disease.. 2022 , 14, 30			0
304	A deep ensemble hippocampal CNN model for brain age estimation applied to Alzheimer's diagnosis. 2022 , 195, 116622			2

303	Recent update on the heterogeneity of the Alzheimer's disease spectrum.. 2021 , 129, 1		5
302	DNA vaccines for cancer treatment. 2022 , 259-278		
301	Cerebrospinal Fluid Biomarkers in Autopsy-Confirmed Alzheimer Disease and Frontotemporal Lobar Degeneration.. 2022 ,		1
300	Aging, Cellular Senescence, and Alzheimer's Disease.. 2022 , 23,		7
299	TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic <i>C. elegans</i> .. 2022 ,		2
298	Phenotypic subtypes of progressive dysexecutive syndrome due to Alzheimer's disease: a series of clinical cases.. 2022 , 1		0
297	CSF biomarkers and plasma p-tau181 as predictors of longitudinal tau accumulation: Implications for clinical trial design.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	3
296	Droplet Degeneration of Hippocampal and Cortical Neurons Signifies the Beginning of Neuritic Plaque Formation.. 2021 ,		2
295	Hemispheric Asymmetry and Atypical Lobar Progression of Alzheimer-Type Tauopathy.. 2022 ,		0
294	Associations of Stages of Objective Memory Impairment (SOMI) with Amyloid PET and Structural MRI: The A4 Study.. 2022 ,		3
293	Association between amyloid-beta deposition and cortical thickness in dementia with Lewy bodies.. 2022 , 48674221081773		
292	Biomarkers Analysis and Clinical Manifestations in Comorbid Creutzfeldt-Jakob Disease: A Retrospective Study in 215 Autopsy Cases.. 2022 , 10,		
291	Characterizing Amyloid Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.. 2022 ,		1
290	Translational approaches to understanding resilience to Alzheimer's disease.. 2022 ,		3
289	Gastrointestinal involvement in Parkinson's disease: pathophysiology, diagnosis, and management.. 2022 , 8, 31		4
288	Quantitative and histologically validated measures of the entorhinal subfields in ex vivo MRI.		1
287	Repeated recurrent intracerebral hemorrhage may be involved in cerebral amyloid angiopathy-related inflammation: An autopsy case.. 2022 ,		0
286	APOE ϵ_4 , Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.. 2022 , 14, 47		2

285	Projective LDDMM: Spatially Reconstructing a Story of Rostrally-Dominant Tau in Alzheimer's Disease.		
284	Lesions without symptoms: understanding resilience to Alzheimer disease neuropathological changes.. 2022 ,		2
283	A Novel Variant (Lys694del) Presenting With Corticobasal Syndrome in a Family With FTD-ALS Spectrum Diseases: Case Report.. 2022 , 13, 826676		0
282	Examining the association between blood-based biomarkers and human post mortem neuropathology in the University of Kentucky Alzheimer's Disease Research Center autopsy cohort.. <i>Alzheimer's and Dementia</i> , 2022 ,	1.2	0
281	Aging the Brain: Multi-Region Methylation Principal Component Based Clock in the Context of Alzheimer's Disease.		0
280	Alzheimer's disease - the journey of a healthy brain into organ failure.. 2022 , 17, 18		3
279	Multicenter F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer's Disease.. 2022 , 12,		0
278	Single-cell Spatial Proteomic Imaging for Human Neuropathology.		1
277	Geropathology. An inside view of biological aging.. 2022 , 4, 23-24		0
276	AI-enabled immunohistochemical characterization for Alzheimer's disease.. 2022 , 2, 100191		1
275	Subcortical Neuronal Correlates of Sleep in Neurodegenerative Diseases.. 2022 ,		0
274	Cerebrospinal fluid catecholamines in Alzheimer's disease patients with and without biological disease.. 2022 , 12, 151		1
273	Multimarker synaptic protein cerebrospinal fluid panels reflect TDP-43 pathology and cognitive performance in a pathological cohort of frontotemporal lobar degeneration.. 2022 , 17, 29		1
272	Phases of volume loss in patients with known frontotemporal lobar degeneration spectrum pathology.. 2022 , 113, 95-107		0
271	Categorical predictive and disease progression modeling in the early stage of Alzheimer's disease.. 2022 , 109581		0
270	White Matter β Amyloid Precursor Protein Immunoreactivity in Autopsied Subjects With and Without COVID-19.		1
269	Current Understanding of the Physiopathology, Diagnosis and Therapeutic Approach to Alzheimer's Disease.. 2021 , 9,		6
268	¹¹ C-PiB PET can underestimate brain amyloid-burden when cotton wool plaques are numerous.. 2021 ,		2

267	Pathological manifestation of human endogenous retrovirus K in frontotemporal dementia.. 2021 , 1,	1
266	Single-synapse analyses of Alzheimer’s disease implicate pathologic tau, DJ1, CD47, and ApoE.. 2021 , 7, eabk0473	1
265	Deafferentation of Olfactory Bulb in Subjects Dying with COVID-19.	
264	Randomized two-stage optimal design for interval-censored data. 2021 , 1-10	2
263	Neuropathologic Correlates of Human Cortical Proteins in Alzheimer Disease and Related Dementias.. 2021 ,	0
262	The severity of neuropsychiatric symptoms is higher in early-onset than late-onset Alzheimer’s Disease. 2021 ,	0
261	Clonal hematopoiesis is associated with protection from Alzheimer’s disease.	0
260	Genomics and Functional Genomics of Alzheimer’s Disease.. 2021 , 1	1
259	Frontotemporal lobar degeneration with TAR DNA-binding protein 43 (TDP-43): its journey of more than 100 years.. 2022 , 1	0
258	Diagnostic Performance of Generative Adversarial Network-Based Deep Learning Methods for Alzheimer’s Disease: A Systematic Review and Meta-Analysis.. 2022 , 14, 841696	0
257	Detection of astrocytic tau pathology facilitates recognition of chronic traumatic encephalopathy neuropathologic change.. 2022 , 10, 50	0
256	Tau polygenic risk scoring: a cost-effective aid for prognostic counseling in Alzheimer’s disease.. 2022 , 143, 571	0
255	Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease.. 2022 ,	1
254	Somatic genomic changes in single Alzheimer’s disease neurons.. 2022 ,	5
253	Synucleinopathies. 149-175	
252	Neurodegenerative disease. 146-168	
251	data_sheet_1.XLSX. 2018 ,	
250	data_sheet_2.DOCX. 2018 ,	

249 Table_1.doc. **2019**,

248 Data_Sheet_1.pdf. **2020**,

247 Table_1.XLSX. **2020**,

246 Table_1.docx. **2020**,

245 Table_2.docx. **2020**,

244 Table_3.docx. **2020**,

243 Table_4.docx. **2020**,

242 Table_5.docx. **2020**,

241 Table_6.docx. **2020**,

240 Image_1.JPEG. **2018**,

239 Image_2.JPEG. **2018**,

238 Data_Sheet_1.pdf. **2020**,

237 Data_Sheet_1.docx. **2020**,

236 Table_1.DOCX. **2020**,

235 Data_Sheet_1.pdf. **2020**,

234 Image_1.JPEG. **2020**,

233 Data_Sheet_1.zip. **2020**,

232 Table_1.docx. **2020**,

231	Macroscopic findings of brain with dementia.. 2022,	2
230	Neuropathology Studies of Dementia in US Persons other than Non-Hispanic Whites.. 2022, 3,	0
229	Amyloid-β In Brain Aging and Alzheimer's Disease. 2022, 335-354	
228	Entorhinal Subfield Vulnerability to Neurofibrillary Tangles in Aging and the Preclinical Stage of Alzheimer's Disease.. 2022,	0
227	Projective LDDMM: Mapping Molecular Digital Pathology with Tissue MRI.	0
226	Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human βsynuclein transgenic mice.. 2022,	0
225	Oxysterols and Oxysterol Sulfates in Alzheimer's Disease Brain and Cerebrospinal Fluid.. 2022,	0
224	Biomarker modeling of Alzheimer's disease using PET-based Braak staging.	2
223	Hyperactive somatostatin interneurons near amyloid plaque and cell-type-specific firing deficits in a mouse model of Alzheimer's disease.	0
222	Neuropathological associations of limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) differ between the oldest-old and younger-old.. 2022,	0
221	Divergent magnetic resonance imaging atrophy patterns in Alzheimer's disease and primary age-related tauopathy. 2022,	1
220	Changes in glial cell phenotypes precede overt neurofibrillary tangle formation, correlate with markers of cortical cell damage, and predict cognitive status of individuals at Braak III-IV stages.. 2022, 10, 72	1
219	Classification of F-Flutemetamol scans in cognitively normal older adults using machine learning trained with neuropathology as ground truth.. 2022, 1	0
218	Biomarker A+T-: is this Alzheimer's disease or not? A combined CSF and pathology study.. 2022,	0
217	Multimodal Biomarkers of Repetitive Head Impacts and Traumatic Encephalopathy Syndrome: A Clinico-Pathological Case Series.. 2022,	0
216	Association of Neighborhood-Level Disadvantage With Neurofibrillary Tangles on Neuropathological Tissue Assessment.. 2022, 5, e228966	
215	Evolution of Clinical-Pathological Correlations in Early-Onset Alzheimer's Disease Over a 25-Year Period in an Academic Brain Bank. 2020, 1-11	0
214	Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology.. 2022,	1

213	Platelet Activating Factor Receptor Exaggerates Microglia-Mediated Microenvironment by IL10-STAT3 Signaling: A Novel Potential Biomarker and Target for Diagnosis and Treatment of Alzheimer's Disease.. 2022 , 14, 856628	
212	Periodontitis as a Risk Factor for Alzheimer's Disease: The Experimental Journey So Far, with Hope of Therapy. 2022 , 241-260	0
211	PERFORMANCE OF SYNNUCLEIN RT-QUIC IN RELATION TO NEUROPATHOLOGICAL STAGING OF LEWY BODY DISEASE.	
210	Astrocyte Dysregulation and Calcium Ion Imbalance May Link the Development of Osteoporosis and Alzheimer's Disease. 2022 , 1-7	0
209	Mouse models of Alzheimer's disease for preclinical research. 2022 , 158, 105361	1
208	Non-standard pipeline without MRI has replicability in computation of Centiloid scale values for PiB and 18F-labeled amyloid PET tracers. 2022 , 2, 100101	
207	Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) is associated with lower R2 relaxation rate: An ex-vivo MRI and pathology investigation. 2022 ,	0
206	Association of cerebral microvascular dysfunction and white matter injury in Alzheimer's disease.	0
205	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. 2022 , 81, 387-413	0
204	Lower Posterior Cingulate N-acetylaspartate to Creatine Level in Early Detection of Biologically Defined Alzheimer's Disease. 2022 , 12, 722	1
203	Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging. 10.1212/WNL.0000000000200735	1
202	N-terminally truncated A β -x proteoforms and their relevance for Alzheimer's pathophysiology. 2022 , 11,	0
201	Different Profiles of Spatial Navigation Deficits In Alzheimer's Disease Biomarker-Positive Versus Biomarker-Negative Older Adults With Amnesic Mild Cognitive Impairment. 14,	2
200	Coupling analysis between functional and structural brain networks in Alzheimer's disease. 2022 , 19, 8963-8974	0
199	Chronic Traumatic Encephalopathy in the Brains of Military Personnel. 2022 , 386, 2169-2177	1
198	Multimodal deep learning for Alzheimer's disease dementia assessment. 2022 , 13,	2
197	Modeling the Competition between Misfolded A β Conformers That Produce Distinct Types of Amyloid Pathology in Alzheimer's Disease. 2022 , 12, 886	
196	Cholesterol and matrisome pathways dysregulated in astrocytes and microglia. 2022 , 185, 2213-2233.e25	8

195	Alzheimer's Disease Cerebrospinal Fluid Biomarkers Differentiate Patients with Creutzfeldt-Jakob Disease and Autoimmune Encephalitis.	1
194	Amygdalar and ERC Rostral Atrophy and Tau Pathology Reconstruction in Preclinical Alzheimer's Disease.	
193	Imaging Alzheimer's pathology stage by stage. 2022 , 2, 465-467	
192	Carer burden and psychological distress in young-onset dementia: An Australian perspective. 2022 , 37,	1
191	Automated Classification of Mild Cognitive Impairment by Machine Learning With Hippocampus-Related White Matter Network. 14,	0
190	Association of Cognition and Dementia With Neuropathologic Changes of Alzheimer Disease and Other Conditions in the Oldest-Old. 10.1212/WNL.000000000200832	1
189	Neuropathology of Dementia Disorders. 2022 , 28, 834-851	0
188	Old age amyotrophic lateral sclerosis and limbic TDP-43 pathology.	0
187	Establishing In-House Cutoffs of CSF Alzheimer's Disease Biomarkers for the AT(N) Stratification of the Alzheimer Center Barcelona Cohort. 2022 , 23, 6891	0
186	Molecular PET Imaging in Alzheimer's Disease.	0
185	Staging of Alzheimer's disease: past, present, and future perspectives. 2022 ,	1
184	Diagnosis of coexistent neurodegenerative dementias in multiple sclerosis.	
183	Performance of Synuclein RT-QuIC in relation to neuropathological staging of Lewy body disease. 2022 , 10,	2
182	Autopsy Human Brain Dissection Protocol for Common Age-Related Neurodegenerative Disorders. 2022 , 255-279	
181	Promising Blood Biomarkers for Clinical Use in Alzheimer's Disease: A Focused Update. 2022 , 18, 401	2
180	Olfactory Bulb Amyloid- β Correlates With Brain Thal Amyloid Phase and Severity of Cognitive Impairment.	0
179	ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer's disease. 1-13	0
178	Cerebral amyloid angiopathy interacts with neuritic amyloid plaques to promote tau and cognitive decline.	1

177	Differentially Aquaporin 5 Expression in Submandibular Glands and Cerebral Cortex in Alzheimer's Disease. 2022 , 10, 1645	0
176	Functionalized Allopurinols Targeting Amyloid-Binding Alcohol Dehydrogenase Rescue A β -Induced Mitochondrial Dysfunction.	1
175	Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia.	1
174	Alzheimer's Disease Blood Biomarkers Associated With Neuroinflammation as Therapeutic Targets for Early Personalized Intervention. 4,	
173	Spatial decrease of synaptic density in amnesic mild cognitive impairment follows the tau build-up pattern.	1
172	SARS-CoV-2 Brain Regional Detection, Histopathology, Gene Expression, and Immunomodulatory Changes in Decedents with COVID-19.	3
171	Parkinson's Progression Markers Initiative brain autopsy program. 2022 , 101, 62-65	
170	Allantoin ameliorates amyloid β -peptide-induced memory impairment by regulating the PI3K/Akt/GSK-3 β signaling pathway in rats. 2022 , 153, 113389	0
169	Update on the Cognitive Presentations of iNPH for Clinicians. 13,	
168	Assessment of Current Practices Across Alzheimer's Disease Research Centers Biorepositories.	
167	Promising Role of Oral Cavity Mesenchymal Stem Cell-Derived Extracellular Vesicles in Neurodegenerative Diseases.	0
166	Regional distribution and maturation of tau pathology among phenotypic variants of Alzheimer's disease.	0
165	Molecular signatures underlying neurofibrillary tangle susceptibility in Alzheimer's disease. 2022 ,	1
164	Preclinical Alzheimer's disease biomarkers accurately predict cognitive and neuropathological outcomes.	0
163	Are we ready to use anti-amyloid therapy in Alzheimer's disease?. 2022 , 80, 15-23	0
162	Neuropathology and emerging biomarkers in corticobasal syndrome. 2022 , 93, 919-929	1
161	The Mechanistic Pathways of Periodontal Pathogens Entering the Brain: The Potential Role of Treponema denticola in Tracing Alzheimer's Disease Pathology. 2022 , 19, 9386	1
160	Heterozygous expression of the Alzheimer's disease-protective PLC γ P522R variant enhances A β clearance while preserving synapses. 2022 , 79,	0

159	Prevalence of chronic traumatic encephalopathy in the Sydney Brain Bank. 2022 , 4,	0
158	Aging the brain: multi-region methylation principal component based clock in the context of Alzheimer's disease. 2022 , 14, 5641-5668	0
157	Selective Detection of Misfolded Tau From Postmortem Alzheimer's Disease Brains. 14,	1
156	Forsythiasides: A review of the pharmacological effects. 9,	
155	GPCR kinases generate an APH1A phosphorylation barcode to regulate amyloid-β generation. 2022 , 40, 111110	
154	Inhibition of NLRP1-Dependent Pyroptosis Prevents Glycogen Synthase Kinase-3β Overactivation-Induced Hyperphosphorylated Tau in Rats.	0
153	Rainwater Charitable Foundation criteria for the neuropathologic diagnosis of progressive supranuclear palsy.	2
152	Antimicrobial, Polarizing Light, and Paired Helical Filament Properties of Fragmented Tau Peptides of Selected Putative Gingipains. 2022 , 1-13	0
151	circRNA drives the formation and deposition of β-amyloid plaques in the sporadic Alzheimer's disease.	
150	Focal amyloid and asymmetric tau in an imaging-to-autopsy case of clinical primary progressive aphasia with Alzheimer disease neuropathology. 2022 , 10,	0
149	Association between depression, gender and Alzheimer's neuropathology in older adults without dementia..	0
148	Semi-quantitative Assessment of Alzheimer's-like Pathology in Two Aged Polar Bears (Ursus maritimus). 2022 , 72, 267-272	
147	FDG-PET combined with learning vector quantization allows classification of neurodegenerative diseases and reveals the trajectory of idiopathic REM sleep behavior disorder. 2022 , 225, 107042	1
146	Association of plasma biomarkers of amyloid and neurodegeneration with cerebrovascular disease and Alzheimer's disease. 2022 , 119, 1-7	
145	Optimal Stimulation Sites and Networks for Deep Brain Stimulation of the Fornix in Alzheimer's Disease.	0
144	Advances in Alzheimer's disease research over the past two decades. 2022 , 21, 866-869	0
143	Acupuncture and Alzheimer's Disease. 2022 , 635-665	0
142	Impaired autophagy in amyloid-beta pathology: A traditional review of recent Alzheimer's research. 2022 , 37, 1	0

- 141 Resilience and resistance to Alzheimer's disease-associated neuropathological substrates in centenarians: an age-continuous perspective. 0
- 140 Spatiotemporal characterization of cellular tau pathology in the human locus coeruleus/pericoerulear complex by three-dimensional imaging. **2022**, 144, 651-676 0
- 139 Differential microRNA expression analyses across two brain regions in Alzheimer's disease. **2022**, 12, 0
- 138 Circulating Amyloid- β and Methionine-Related Metabolites to Predict the Risk of Mild Cognitive Impairment: A Nested Case-Control Study. **2022**, 1-16 0
- 137 LATE-NC aggravates GVD-mediated necroptosis in Alzheimer's disease. **2022**, 10, 1
- 136 In vivo tau staging in Alzheimer's disease. **2022**, 14, 6842-6843 0
- 135 Death induced by survival gene elimination (DISE) contributes to neurotoxicity in Alzheimer's disease. 1
- 134 Diagnosis of Alzheimer's Disease and In Situ Biological Imaging via an Activatable Near-Infrared Fluorescence Probe. **2022**, 94, 13498-13506 0
- 133 White matter integrity and key structures affected in Alzheimer's disease characterized by diffusion tensor imaging. 0
- 132 Differential expression of m5C RNA methyltransferase genes NSUN6 and NSUN7 in Alzheimer's disease and Traumatic Brain Injury. 0
- 131 Synthesizing Images of Tau Pathology from Cross-modal Neuroimaging using Deep Learning. 0
- 130 Effects of Simvastatin on Plasma Amyloid- β Transport in Patients with Hyperlipidemia: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial. **2022**, 1-14 0
- 129 Tau seeding activity in various regions of down syndrome brain assessed by two novel assays. **2022**, 10, 0
- 128 Neuronal loss of the nucleus basalis of Meynert in primary progressive aphasia is associated with Alzheimer's disease neuropathological changes. 0
- 127 Phosphorylation of Tau at Threonine 231 in Patients With Multiple System Atrophy and in a Mouse Model. 0
- 126 Spatial proteomics and iPSC modeling uncover mechanisms of axonal pathology in Alzheimer's disease. 0
- 125 Racial and Ethnic Differences in Amyloid PET Positivity in Individuals With Mild Cognitive Impairment or Dementia. 1
- 124 Müller cell degeneration and microglial dysfunction in the Alzheimer's retina. **2022**, 10, 1

123	Prenatal alcohol exposure causes persistent microglial activation and age- and sex- specific effects on cognition and metabolic outcomes in an Alzheimer’s Disease mouse model. 1-19	0
122	Impact and Risk Factors of Limbic Predominant Age-Related TDP-43 Encephalopathy Neuropathologic Change in an Oldest Old Cohort. 10.1212/WNL.000000000201345	0
121	The VTA dopaminergic system as diagnostic and therapeutical target for Alzheimer’s disease. 13,	0
120	Case Study 3: A 58-Year-Old Woman Referred for Evaluation of Suspected Alzheimer Dementia. 2022, 34, 307-315	0
119	Clinical, radiologic, and pathologic features of the globular glial tauopathy subtype of frontotemporal lobar degeneration in right temporal variant frontotemporal dementia with salient features of Geschwind syndrome. 1-7	0
118	Albumin: A Multi-talented Clinical and Pharmaceutical Player.	0
117	Proteomics of resilience to Alzheimer’s disease identifies brain regional soluble A β levels, actin filament processes, and response to injury.	0
116	Hypothesis review: Alzheimer’s overture guidelines.	1
115	Biosensors toward behavior detection in diagnosis of alzheimer’s disease. 10,	0
114	Alzheimer’s disease-associated U1 snRNP splicing dysfunction causes neuronal hyperexcitability and cognitive impairment. 2022, 2, 923-940	0
113	Retinal Pathological Features and Proteome Signatures of Alzheimer’s.	0
112	Common signatures of differential microRNA expression in Parkinson’s and Alzheimer’s disease brains.	0
111	Neuropathology of the Common Forms of Dementia. 2022,	0
110	ATP-binding cassette transporter expression is widely dysregulated in frontotemporal dementia with TDP-43 inclusions. 15,	0
109	The central role of tau in Alzheimer’s disease: From neurofibrillary tangle maturation to the induction of cell death. 2022, 190, 204-217	2
108	Severe cerebrovascular pathology of the first supercentenarian to be autopsied in the world.	0
107	Linking the Amyloid, Tau, and Mitochondrial Hypotheses of Alzheimer’s Disease and Identifying Promising Drug Targets. 2022, 12, 1676	3
106	Single-cell spatial proteomic imaging for human neuropathology. 2022, 10,	0

105	A Peptide-Centric Quantitative Proteomics Dataset for the Phenotypic Assessment of Alzheimer's Disease.	0
104	Individual regional associations between A β tau- and neurodegeneration (ATN) with microglial activation in patients with primary and secondary tauopathies.	0
103	Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease. 2022 , 13,	2
102	Postmortem 7T MRI for guided histopathology and evaluation of cerebrovascular disease. 2022 , Publish Ahead of Print,	0
101	Site-Specific Phospho-Tau Aggregation-Based Biomarker Discovery for AD Diagnosis and Differentiation.	0
100	All the Tau We Cannot See. 2023 , 74,	2
99	Neuropathology of classic myotonic dystrophy type 1 is characterized by both early initiation of primary age-related tauopathy of the hippocampus and unique 3-repeat tauopathy of the brainstem.	1
98	The application of nanotechnology in treatment of Alzheimer's disease. 10,	0
97	Depression-related phenotypes at early stages of A β and tau accumulation in inducible Alzheimer's disease mouse model: task-oriented and concept-driven interpretations. 2022 , 114187	0
96	Protocol for the Systematic Fixation, Circuit-Based Sampling, and Qualitative and Quantitative Neuropathological Analysis of Human Brain Tissue. 2023 , 3-30	0
95	Event-based modeling of T1-weighted MRI is related to pathology in frontotemporal lobar degeneration due to tau and TDP. 2023 , 37, 103285	0
94	A Review of the Recent Advances in Alzheimer's Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics. 2022 , 12, 2975	1
93	The Spectrum of Alzheimer-Type Pathology in Cognitively Normal Individuals. 2022 , 1-13	1
92	Methylation differences in Alzheimer's disease neuropathologic change in the aged human brain. 2022 , 10,	0
91	Swollen axons impair neuronal circuits in Alzheimer's disease. 2022 , 612, 218-220	0
90	Efficacy and safety of blood derivatives therapy in Alzheimer's disease: a systematic review and meta-analysis. 2022 , 11,	1
89	Cognitive resistance to and resilience against multiple comorbid neurodegenerative pathologies and the impact of APOE status.	1
88	Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer's disease. 14,	0

87	Reduced excitatory neuron activity and interneuron-type-specific deficits in a mouse model of Alzheimer's disease. 2022 , 5,	0
86	Abundant co-pathologies of polyglucosan bodies, frontotemporal lobar degeneration with TDP-43 inclusions, and ageing-related tau astrogliaopathy in a family with a GBE1 mutation.	0
85	Volume atrophy in medial temporal cortex and verbal memory scores in American Indians: Data from the Strong Heart Study.	0
84	Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies.	0
83	Evaluation of an Adoptive Cellular Therapy-Based Vaccine in a Transgenic Mouse Model of Synucleinopathy.	0
82	Associations of phosphorylated tau pathology with whole-hemisphere ex vivo morphometry in 7 tesla MRI.	0
81	Tau PET Visual Reads: Research and Clinical Applications and Future Directions. jnumed.122.265017	0
80	Gray to White Matter Signal Ratio as a novel biomarker of neurodegeneration in Alzheimer's disease. 2022 , 103303	0
79	Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.	1
78	Brain autopsies of critically ill COVID-19 patients demonstrate heterogeneous profile of acute vascular injury, inflammation and age-linked chronic brain diseases. 2022 , 10,	0
77	The PSEN1 E280G mutation leads to increased amyloid- β 3 production in induced pluripotent stem cell neurons and deposition in brain tissue.	0
76	What every neuropathologist needs to know: condensed protocol work-up for clinical dementia syndromes.	0
75	TDP-43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease.	1
74	Brain and spinal cord arteriolosclerosis and its associations with cerebrovascular disease risk factors in community-dwelling older adults.	0
73	Pyroptosis in Alzheimer's disease: cell type-specific activation in microglia, astrocytes and neurons.	0
72	Projective diffeomorphic mapping of molecular digital pathology with tissue MRI. 2022 , 1,	0
71	Recognizing novel drugs against Keap1 in Alzheimer's disease using machine learning grounded computational studies. 15,	4
70	Left-handedness, learning disability, autoimmune disease, and seizure history influence age at onset and phenotypical targeting of Alzheimer's disease.	0

- 69 LATE and potential estrogen-related risk factors collected 30 years earlier: The 90+ Study. ○
- 68 APOE Genotype-specific Methylation Patterns are Linked to Alzheimer Disease Pathology and Estrogen Response. ○
- 67 Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. **2022**, 13, ○
- 66 Sports Concussion and Chronic Traumatic Encephalopathy: Finding a Path Forward. ○
- 65 Disease-associated patterns of acetylation stabilize tau fibril formation. ○
- 64 TDP-43 Pathology in the Setting of Intermediate and High Alzheimer's Disease Neuropathologic Changes: A Preliminary Evaluation Across Ethnoracial Groups. **2023**, 1-11 ○
- 63 Vascular injury is associated with repetitive head impacts and tau pathology in chronic traumatic encephalopathy. **2023**, Publish Ahead of Print, ○
- 62 Locus Coeruleus Dysfunction and Trigeminal Mesencephalic Nucleus Degeneration: A Cue for Periodontal Infection Mediated Damage in Alzheimer's Disease?. **2023**, 20, 1007 1
- 61 Efficacy of Souvenaid[®] Combined with Acetylcholinesterase Inhibitors in the Treatment of Mild Alzheimer's Disease. **2023**, 1-11 ○
- 60 Optical coherence tomography and angiography in Alzheimer's disease and other cognitive disorders. 112067212211489 ○
- 59 The major TMEM106B dementia risk allele affects TMEM106B protein levels and myelin lipid homeostasis in the ageing human hippocampus. ○
- 58 Differential vulnerability of the dentate gyrus to tauopathies in dementias. **2023**, 11, ○
- 57 Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta. ○
- 56 Differential expression of m5C RNA methyltransferase genes NSUN6 and NSUN7 in Alzheimer's disease and traumatic brain injury. ○
- 55 Resilience and resistance to the accumulation of amyloid plaques and neurofibrillary tangles in centenarians: An age-continuous perspective. ○
- 54 Meal Planning for Alzheimer's Disease Using an Ontology-Assisted Multiple Criteria Decision-Making Approach. **2022**, 13, 1-14 ○
- 53 The status of digital pathology and associated infrastructure within Alzheimer's Disease Centers. **2023**, Publish Ahead of Print, ○
- 52 A proteomics analysis of 5xFAD mouse brain regions reveals the lysosome-associated protein Arl8b as a candidate biomarker for Alzheimer's disease. ○

51	Mitochondrial calcium cycling in neuronal function and neurodegeneration. 11,	0
50	The Vascular-Immune Hypothesis of Alzheimer’s Disease. 2023 , 11, 408	1
49	Deciphering the clinico-radiological heterogeneity of dysexecutive Alzheimer’s disease.	0
48	Accumulation of pTau231 at the Postsynaptic Density in Early Alzheimer’s Disease. 2023 , 1-20	0
47	Efficacy of Kami Guibi-tang as an Add-On Therapy to Acetylcholinesterase Inhibitor for Cognitive Function in Mild Alzheimer’s Disease: A Pilot Study. 2023 , 2023, 1-15	0
46	Alzheimer’s Disease Neuropathologic Change and Vitamin Supplement Use Decades Earlier. 2023 , 37, 1-6	0
45	Predicting amyloid PET and tau PET stages with plasma biomarkers.	0
44	Argyrophilic grain disease is common in older adults and may be a risk factor for suicide: a study of Japanese forensic autopsy cases. 2023 , 12,	0
43	TDP -43 and tau concurrence in the entorhinal subfields in primary age-related tauopathy and preclinical Alzheimer’s disease.	0
42	Inflammaging, cellular senescence, and cognitive aging after traumatic brain injury. 2023 , 180, 106090	0
41	The unique neuropathological vulnerability of the human brain to aging. 2023 , 87, 101916	0
40	Multimodal comparisons of QSM and PET in neurodegeneration and aging. 2023 , 273, 120068	0
39	Application of Novel Degradable Employing Autophagy for Expediting Medicinal Research. 2023 , 66, 1700-1711	0
38	Alzheimer’s disease phenotypes show different sleep architecture.	0
37	Carer burden and behavioral disturbance is similar between younger-onset Alzheimer’s disease and behavioral variant frontotemporal dementia. 1-8	0
36	Retinal pathological features and proteome signatures of Alzheimer’s disease. 2023 , 145, 409-438	1
35	The remarkable complexity of the brain microbiome in health and disease.	0
34	Development, initial validation, and application of a visual read method for [¹⁸ F]MK-6240 tau PET. 2023 , 9,	1

- 33 The Alzheimer's Disease Mitochondrial Cascade Hypothesis: A Current Overview. **2023**, 92, 751-768 ○
- 32 Study of neuropathological changes and dementia in 100 centenarians in The 90+ Study. ○
- 31 Endothelial Cells are Heterogeneous in Different Brain Regions and are Dramatically Altered in Alzheimer's Disease. ○
- 30 Clinical and biological significance of RNA N6-methyladenosine regulators in Alzheimer disease. **2023**, 102, e32945 ○
- 29 Cognitive and Neuropsychological Profiles in Alzheimer's Disease and Primary Age-Related Tauopathy and the Influence of Comorbid Neuropathologies. **2023**, 92, 1037-1049 ○
- 28 Advanced Overview of Biomarkers and Techniques for Early Diagnosis of Alzheimer's Disease. ○
- 27 Effectiveness of non-pharmacological therapies on cognitive function in patients with dementia: A network meta-analysis of randomized controlled trials. 15, ○
- 26 Early tau detection in flortaucipir images: validation in autopsy-confirmed data and implications for disease progression. **2023**, 15, ○
- 25 Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease with attenuation after rapamycin treatment in 5XFAD mice. ○
- 24 Utility of Amyloid Positron Emission Tomography Imaging in Older Adults With Epilepsy and Cognitive Decline. **2023**, 38, 153331752311600 ○
- 23 Early amygdala and ERC atrophy linked to 3D reconstruction of rostral neurofibrillary tau tangle pathology in Alzheimer's disease. **2023**, 38, 103374 ○
- 22 Exploring Whether Iron Sequestration within the CNS of Patients with Alzheimer's Disease Causes a Functional Iron Deficiency That Advances Neurodegeneration. **2023**, 13, 511 ○
- 21 On gaps of clinical diagnosis of dementia subtypes: A study of Alzheimer's disease and Lewy body disease. 15, ○
- 20 Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies. ○
- 19 Distinct Transcriptomic Responses to A β plaques, Neurofibrillary Tangles, and APOE in Alzheimer's Disease. ○
- 18 Dementias. **2013**, 609-658 ○
- 17 Anterograde and Retrograde Propagation of Inoculated Human Tau Fibrils and Tau Oligomers in a Non-Transgenic Rat Tauopathy Model. **2023**, 11, 1004 ○
- 16 The presymptomatic treatment with 3HFWC nanosubstance decreased plaque load in 5XFAD mouse model of Alzheimer's disease. ○

- 15 Epigenetic regulons in Alzheimer's disease. **2023**, ○
- 14 Telomerase reverse transcriptase and neurodegenerative diseases. 14, ○
- 13 Microglia directly associate with pericytes in the central nervous system. ○
- 12 T cell aging and Alzheimer's disease. 14, ○
- 11 Mediation of Reduced Hippocampal Volume by Cerebral Amyloid Angiopathy in Pathologically Confirmed Patients with Alzheimer's Disease. **2023**, 1-13 ○
- 10 Guidelines on the Use of Therapeutic Apheresis in Clinical Practice [Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue. **2023**, 38, 77-278 ○
- 9 Association between ATN profiles and mortality in a clinical cohort of patients with cognitive disorders. **2023**, 15, ○
- 8 Stereology neuron counts correlate with deep learning estimates in the human hippocampal subregions. **2023**, 13, ○
- 7 Superior Global Cognition in Oldest-Old Is Associated with Resistance to Neurodegenerative Pathologies: Results from The 90+ Study. **2023**, 1-15 ○
- 6 A peptide-centric quantitative proteomics dataset for the phenotypic assessment of Alzheimer's disease. **2023**, 10, ○
- 5 Multi-regional alterations in glucose and purine metabolic pathways in the Parkinson's disease dementia brain. **2023**, 9, ○
- 4 Large multi-ethnic genetic analyses of amyloid imaging identify new genes for Alzheimer disease. **2023**, 11, ○
- 3 Progranulin deficiency results in sex-dependent alterations in microglia in response to demyelination. ○
- 2 Entorhinal cortex epigenome-wide association study highlights four novel loci showing differential methylation in Alzheimer's disease. **2023**, 15, ○
- 1 Dimensional clinical phenotyping using post-mortem brain donor medical records: Association with neuropathology. ○